8-11-2014 12:00 AM

Functional Imaging of Malignant Gliomas with CT Perfusion

Timothy Pok Chi Yeung, The University of Western Ontario

Supervisor: Drs. Glenn Bauman, The University of Western Ontario
Joint Supervisor: Slav Yartsev, The University of Western Ontario
A thesis submitted in partial fulfillment of the requirements for the Doctor of Philosophy degree in Medical Biophysics
© Timothy Pok Chi Yeung 2014

Follow this and additional works at: https://ir.lib.uwo.ca/etd

Recommended Citation
https://ir.lib.uwo.ca/etd/2252

This Dissertation/Thesis is brought to you for free and open access by Scholarship@Western. It has been accepted for inclusion in Electronic Thesis and Dissertation Repository by an authorized administrator of Scholarship@Western. For more information, please contact wlsadmin@uwo.ca.
Functional Imaging of Malignant Gliomas with CT Perfusion

(Thesis format: Integrated Article)

by

Timothy Pok Chi Yeung

Graduate Program in Medical Biophysics

A thesis submitted in partial fulfillment
of the requirements for the degree of
Doctor of Philosophy

The School of Graduate and Postdoctoral Studies
The University of Western Ontario
London, Ontario, Canada

© Timothy Pok Chi Yeung 2014
Abstract

The overall survival of patients with malignant gliomas remains dismal despite multimodality treatments. Computed tomography (CT) perfusion is a functional imaging tool for assessing tumour hemodynamics. The goals of this thesis are to 1) improve measurements of various CT perfusion parameters and 2) assess treatment outcomes in a rat glioma model and in patients with malignant gliomas.

Chapter 2 addressed the effect of scan duration on the measurements of blood flow (BF), blood volume (BV), and permeability-surface area product (PS). Measurement errors of these parameters increased with shorter scan duration. A minimum scan duration of 90 s is recommended.

Chapter 3 evaluated the improvement in the measurements of these parameters by filtering the CT perfusion images with principal component analysis (PCA). From computer simulation, measurement errors of BF, BV, and PS were found to be reduced. Experiments showed that CT perfusion image contrast-to-noise ratio was improved.

Chapter 4 investigated the efficacy of CT perfusion as a potential early imaging biomarker of response to stereotactic radiosurgery (SRS). Using the C6 glioma model, we showed that responders to SRS (surviving > 15 days) had lower relative BV and PS on day 7 post-SRS when compared to controls and non-responders ($P < 0.05$). Relative BV and PS on day 7 post-SRS were predictive of survival with 92% accuracy.

Chapter 5 examined the use of multiparametric imaging with CT perfusion and 18F-Fluorodeoxyglucose positron emission tomography (FDG-PET) to identify tumour sites that are likely to correlate with the eventual location of tumour progression. We developed a method to generate probability maps of tumour progression based on these imaging data.

Chapter 6 investigated serial changes in tumour volumetric and CT perfusion parameters and their predictive ability in stratifying patients by overall survival. Pre-surgery BF in the non-enhancing lesion and BV in the contrast-enhancing lesion three months after radiotherapy had the highest combination of sensitivities and specificities of $\geq 80\%$ in predicting 24 months overall survival.
Optimization and standardization of CT perfusion scans were proposed. This thesis also provided corroborating evidence to support the use of CT perfusion as a biomarker of outcomes in patients with malignant gliomas.

Keywords

Blood flow, blood volume, brain tumour, permeability-surface area product, dynamic contrast-enhanced computed tomography, CT perfusion, image noise, principal component analysis, radiotherapy, stereotactic radiosurgery
Co-Authorship Statement

This thesis contains material from manuscripts that were previously published. The copyright(s) agreement for these publications are provided in the Appendix D: Permission to Reproduce Previously Published Materials.

The literature review from Chapter 1 will be submitted to the Journal of Neuro-Oncology as a review article entitled “MR and CT perfusion imaging for malignant gliomas: A review of clinical evidence”. The authors are Yeung TPC, Yartsev S, Macdonald D, Fainardi E, Lee TY, and Bauman G. I was responsible for conducting a systematic review, analyzing and interpreting the published data, and writing the manuscript. The other authors helped with the interpretation of the literature and editing the manuscript.

Chapter 2, “The effect of scan duration on the measurement of perfusion parameters in CT perfusion studies of brain tumours” was published in Academic Radiology, 2013; 20(1):59-65 by Yeung TPC, Yartsev S, Bauman G, He W, Fainardi E, Lee TY. I was responsible for the design of the study, analysis and interpretation of the data, and wrote the manuscript. All authors contributed to the interpretation of the data and helped with editing the manuscript. Drs. Bauman and Fainardi were also responsible for recruiting patients. Dr. He helped with statistical analysis of the data.

Chapter 3, “Improving quantitative CT perfusion parameter measurements using principal component analysis” was published in Academic Radiology, 2014; 21(5):624-632 by Yeung TPC, Dekaban M, De Haan N, Morrison L, Hoffman L, Bureau Y, Chen X, Yartsev S, Bauman G, and Lee TY. I was responsible for designing the study, collecting and analyzing the data, and writing the manuscript. Mr. Mark Dekaban and Dr. Xiaogang Chen helped with the computer programming while Mr. Nathan De Haan helped with some of the data collection. Dr. Yves Bureau provided statistical consultations. Miss Laura Morrison and Dr. Lisa Hoffman helped with the in vivo experiments. Drs Bauman, Yartsev, and Lee edited the manuscript and provided supervision and mentorship. Dr. Lee was also instrumental in the design of the simulation study.

Chapter 4 is based on the paper entitled “CT perfusion imaging as an early biomarker of differential response to stereotactic radiosurgery”. This manuscript will be submitted to
the journal *PLOS ONE* in July 2014 to be considered for publication. The authors of this manuscript are Yeung TPC, Kurdi M, Wang Y, Al-Khazraji B, Morrison L, Hoffman L, Jackson D, Crukley C, Lee TY, Bauman G, Yartsev S. I was responsible for designing the study, collecting the data, analyzing and interpreting the results, and writing the manuscript. Drs. Maher Kurdi and Yong Wang helped with the analysis of the histology data. Baraa Al-Khazraji, Cathie Crukley, and Dr. Dwayne Jackson helped with the histology and immunohistochemistry. Dr. Lisa Hoffman and Laura Morrison helped with the *in vivo* experiments. Drs Bauman, Yartsev, and Lee helped design the study, provided supervision, and edited the manuscript. Dr. Yartsev also helped with animal irradiation.

Chapter 5, “Relationship of computed tomography perfusion and positron emission tomography to tumour progression in malignant glioma” was published in the *Journal of Medical Radiation Sciences*, 2014; 61(1):4-13 by Yeung TPC, Yartsev S, Lee TY, Wong E, He W, Fisher B, VanderSpek LL, Macdonald D, and Bauman G. I was responsible for the analysis and interpretation of the data, and I also wrote the manuscript. Dr. Bauman was the principal investigator, and Drs VanderSpek, Fisher, Macdonald, Lee, and Wong were the co-investigators of this study. Dr. He and Wong provided statistical consultations regarding the analysis of the data and edited the manuscript. Drs Bauman, Yartsev, and Lee provided supervision, mentorship, and also edited the manuscript.

Chapter 6 is based on the paper entitled “Treatment monitoring in high-grade gliomas: A longitudinal CT perfusion and MR study”, which will be submitted to the *Journal of Neuro-Oncology* in July 2014 by Yeung TPC, Wang Y, Urbini B, Yartsev S, Bauman G, Lee TY, Fainardi E, and The Project of Emilia-Romagna region on Neuro-Oncology (PERNO) study group. I was responsible for analyzing and interpreting the results of this clinical study. Drs Fainardi and Urbini collected all the radiological, clinical, and therapeutic data. The PERNO group provided financial support for this longitudinal study. Dr. Yong Wang read and interpreted all the radiologic images and delineated all the lesions so the data can be collected. Drs Bauman, Yartsev, and Lee provided supervision, mentorship, and also edited the manuscript.
Acknowledgments

This Ph.D. dissertation is truly a collaborative effort from a village of people. I would like to express my sincere gratitude to many people whom I have worked with during the past 5 years. I have been fortunate enough to receive mentorship from a number of individuals who navigated through the uncharted waters of science with me. I was also very blessed to have worked with a number of individuals whom without their assistance this Ph.D. dissertation would have been impossible.

First and foremost, I would like to thank my three supervisors Drs. Glenn Bauman, Slav Yartsev, and Ting-Yim Lee. Your mentorship have been invaluable during my PhD training and everything you taught me will benefit me for years to come. Dr. Bauman: thank you for your guidance, support, and encouragement over the course of my Ph.D. training. The speed at which you return emails and review drafts of my papers and abstracts still fascinates me. Your attitude towards collaboration and research, which comes across daily in your dedication to your work, staff, and trainees are important lessons you taught me. Dr. Yartsev: your efficiency, attention to detail, and ability to foster independent thinking are important skills that you taught me and they will stay with me for a lifetime. Thank you very much for doing the afterhours experiments with me and thank you for never hesitating to help me in any possible way. Dr. Lee: you are truly a model scientist and philosopher. Although I cannot be your “student” on administrative paperwork, you have treated me as one of your own students. For that I am forever grateful! Your dedication to research, our thought-provoking conversations, and your emphasis on scientific inquiry have pushed me to excel.

I also want to thank my advisors: Drs. Eugene Wong and Dwayne Jackson. Dr. Wong: you are undoubtedly the best and most enthusiastic physics professor I know. I truly enjoyed all the classes you taught, particularly statistical mechanics. Thank you for the insightful conversations and your enthusiasm towards my research. Dr. Jackson: thank you for your guidance in immunohistochemistry. You provided me with great learning opportunities in your lab and helped me bridge medical imaging with biology.

I would also like to express my gratitude to a number of collaborators, staff, and
many others at Western, Robarts, Lawson, and the London Regional Cancer Program (LRCP). To Laura Morrison – thank you very much for always making sure that the experiments went smoothly. I also want to thank you for doing the experiments with me on the countless Friday nights and weekends. Jennifer Hadway, the superwoman of Ting’s Lab, thank you for making sure I could do my experiments amid all the crazy things that happened simultaneously in the lab. I also want to thank you for making sure that our protocols and the numerous modifications were approved in a timely manner. Lise Desjardins, thank you very much for stepping in and helping out with various aspects of the experiments when Laura and Jenn were not available. Dr. Lisa Hoffman – thank you very much for providing us with the C6 glioma cells and helping out with our in vitro experiments. Drs. Wenqing He and Yves Bureau – you have been very supportive, knowledgeable, and willing to provide assistance regarding the statistical analyses of the results presented in this thesis. To Dr. Enrico Fainardi from Ferrara, Italy – thank you for generously sharing your unique malignant glioma imaging datasets with us. Your data has opened up new directions for my Ph.D. thesis, and thank you for “skyping” with me half way around the world to discuss our results. To Dr. Maher Kurdi – thank you for stepping up and helping us with the interpretation of our histology data. To Baraa Al-Khazraji – thank you for teaching me and helping me with immunohistochemistry. I had a lot of fun working with you. To Dr. Yong Wang – thank you very much for going through all MR and CT images from Enrico’s study and all the help that you have provided. To Cathie Crukley – you came to rescue when I was running out of time with my immunohistochemistry work. For that I want to give you a big thank you! I would also like to thank Dr. Trevor Shepard for allowing me to use his ScanScope. To Carol Johnson, Jeff Kempe, and Jeff Craig – all of you saved me a lot of precious time with your computer and technical support. I would also like to thank Barb Barons, Jen Foxcroft, Wendy Hough, Anne Leaist, and Kimberly Trudgeon, administrative staff across the City of London, you’ve always been extremely helpful.

To my lab mates and friends at Robarts and LRCP; you’ve made the past five years fun and enjoyable. I would like to thank the lab mates and friends of Ting’s group who have helped me with various aspects my work over the years. In particular, I would like to thank Dr. Errol Stewart for many insightful (and often controversial) discussions. I also thank Dr.
Xiaogang Chen for his assistance in programming. At LRCP, I would like to thank all the
graduate students and friends for your support and insightful discussions pertaining to
radiotherapy. I also want to express my sincere gratitude to a number of brilliant young
undergraduate and high schools students for their contributions to my PhD thesis. To Nathan
De Haan, Mikhaila Dykstra, Max Li, Qi Qi, Michal Stankiewicz, Michael Roes, and
Katelynn Toms – I wish you all the best in your future endeavours!

To “The Crew” – Sally Chan, Amanda Chew, Jenny Cheung, Amy Chow, Ann
Fu, Candy Fung, Fiona Leong, Jonathan Tang, and Maggie Wong – my life is filled with
joy because of all of you! Thank you for reminding me that I can always count on all of you
for support!

Most importantly, I must thank my Mom for her endless support and unconditional
love throughout my life.

My final thanks goes out to all the institutions that provided financial support for the
work performed at Western and also for stipend funding that I received during my PhD
training. They include the Brain Tumour Foundation of Canada, Canadian Institutes of
Health Research (CIHR), CIHR Strategic Training Program in Cancer Research and
Technology Transfer (CaRTT), LRCP Small Grants for Cancer Research and Training,
Ontario Institute for Cancer Research, Rapid AstraZeneca & Canadian Association of
Radiation Oncology (CARO) Evaluation of Radiomodifiers (RAZCER) Research Award,
and Western University, and The Project of Emilia-Romagna region on Neuro-Oncology
(PERNO) study group.
# Table of Contents

Abstract ........................................................................................................................................ ii

Co-Authorship Statement............................................................................................................ iv

Acknowledgments......................................................................................................................... vi

Table of Contents ....................................................................................................................... ix

List of Tables ................................................................................................................................. xv

List of Figures ............................................................................................................................... xvii

List of Abbreviations ................................................................................................................... xxiii

List of Appendices ......................................................................................................................... xxvi

Epigraph ....................................................................................................................................... xxvii

Dedication ..................................................................................................................................... xxviii

Chapter 1 ..................................................................................................................................... 1

1 Introduction ................................................................................................................................. 1

1.1 Overview ................................................................................................................................ 1

1.2 Malignant Glioma .................................................................................................................. 2

1.3 Current Treatment Strategy for Malignant Glioma ................................................................. 2

1.4 Prognostic Factors and Recurrence Patterns ........................................................................... 3

1.5 The Blood Brain Barrier and Tumour Angiogenesis ............................................................. 5

1.5.1 The Blood Brain Barrier in Brain Tumours ....................................................................... 7

1.5.2 Tumour Hypoxia ............................................................................................................... 7

1.5.3 Formation of Tumour Blood Vessels ............................................................................... 8

1.6 Conventional Imaging of Malignant Gliomas ..................................................................... 10

1.7 Criteria for Assessing Treatment Response .......................................................................... 10

1.8 Perfusion Imaging of Malignant Gliomas ............................................................................. 13

1.8.1 Dynamic Susceptibility-Contrast Magnetic Resonance (DSC-MR) ....................... 16
1.8.2 Dynamic Contrast-Enhanced Magnetic Resonance (DCE-MR) .......... 17
1.8.3 Dynamic Contrast-Enhanced Computed Tomography (DCE-CT) ....... 17
1.8.4 Other Important Perfusion Imaging Techniques .................................. 20
1.9 Literature Review of Perfusion Imaging .................................................. 21
  1.9.1 Correlation with Molecular and Histopathologic Markers .............. 22
  1.9.2 Differentiation of Tumour Grade ...................................................... 25
  1.9.3 Differentiation of Malignant Brain Lesions ...................................... 28
  1.9.4 Differentiation of Progression from Post-treatment Effects ........ 30
  1.9.5 Survival after Radiotherapy and Chemotherapy ............................... 32
  1.9.6 Survival After Anti-angiogenic Therapies ........................................ 34
  1.9.7 Future of Perfusion Imaging ............................................................. 35
1.10 Animal Models of Malignant Glioma ................................................... 36
1.11 Research Goals and Objectives ............................................................. 38
1.12 Thesis Outline ...................................................................................... 39
  1.12.1 The Effect of Scan Duration on the Measurement of DCE-CT Parameters (Chapter 2) ................................................................. 39
  1.12.2 Improving Quantitative DCE-CT Measurements Using Principal Component Analysis (Chapter 3) ......................................................... 39
  1.12.3 DCE-CT Imaging as an Early Biomarker of Differential Response to Stereotactic Radiosurgery (Chapter 4) ........................................ 40
  1.12.4 Relationship of DCE-CT and PET to Tumour Progression in Malignant Glioma (Chapter 5) .............................................................. 40
  1.12.5 Treatment Monitoring of Malignant gliomas in using DCE-CT and MR (Chapter 6) ............................................................................ 41
  1.12.6 Conclusion and Future Work (Chapter 7) ........................................ 41
1.13 References .......................................................................................... 41

Chapter 2 .................................................................................................. 68
2 The Effect of Scan Duration on the Measurement of Perfusion Parameters in CT Perfusion Studies of Brain Tumours ...................................................... 68
Chapter 2

2.1 Introduction

2.2 Materials and Methods

2.2.1 CT Perfusion Imaging

2.2.2 Image Analysis

2.2.3 Measurement Errors of Perfusion Parameters Due to Truncation

2.2.4 Statistical Analysis

2.3 Results

2.4 Discussion

2.5 Conclusions

2.6 References

Chapter 3

3 Improving Quantitative CT Perfusion Parameter Measurements Using Principal Component Analysis

3.1 Introduction

3.2 Materials and Methods

3.2.1 Validation of PCA by Simulation

3.2.2 Principal Component Analysis

3.2.3 In Vivo Experiments

3.2.4 Assessment of Image Quality and Information Loss after PCA Filtering

3.2.5 Calculation of BF, BV, and PS

3.2.6 Statistical Analysis

3.3 Results

3.4 Discussion

3.5 Conclusions

3.6 References

Chapter 4
CT Perfusion Imaging as an Early Biomarker of Differential Response to Stereotactic Radiosurgery ........................................................................................................... 103

4.1 Introduction ........................................................................................................ 103

4.2 Materials and Methods ..................................................................................... 104

4.2.1 C6 Glioma Model .......................................................................................... 104

4.2.2 Baseline CT Perfusion Imaging ..................................................................... 105

4.2.3 Stereotactic Radiosurgery ............................................................................. 106

4.2.4 Follow-up CT Perfusion Imaging ................................................................. 106

4.2.5 Image Analysis ............................................................................................... 107

4.2.6 Histopathologic Examination ....................................................................... 107

4.2.7 Statistical Analysis ........................................................................................ 108

4.3 Results ................................................................................................................ 109

4.3.1 Acute Vascular Changes and Histopathologic Features .............................. 109

4.3.2 Treatment Response, Longitudinal Changes, and Late Histopathologic Features .......................................................................................................................... 114

4.3.3 Early Prediction of Survival after Stereotactic Radiosurgery ...................... 117

4.4 Discussion ......................................................................................................... 119

4.5 Conclusions ....................................................................................................... 121

4.6 References ........................................................................................................ 122

Chapter 5 .................................................................................................................. 127

5 Relationship of Computed Tomography Perfusion and Positron Emission Tomography to Tumour Progression in Malignant Glioma ............................................. 127

5.1 Introduction ....................................................................................................... 127

5.2 Methods ............................................................................................................ 129

5.2.1 Patients ........................................................................................................ 129

5.2.2 Multi-modality Imaging Schedule .................................................................. 129

5.2.3 Image Processing .......................................................................................... 130
7.1 Summary of Findings ........................................................................................................ 167
  7.1.1 Mitigating Uncertainties in CT Perfusion .............................................................. 167
  7.1.2 CT Perfusion as a Biomarker of Treatment Outcomes ......................................... 168
7.2 Clinical Translational Potential .................................................................................. 169
7.3 Future Work .................................................................................................................. 171
  7.3.1 A Framework for Quality Assurance (QA) in CT Perfusion Imaging .... 172
  7.3.2 Delineating a Biologic Target Volume (BTV) in Radiotherapy ......................... 173
  7.3.3 CT Perfusion Imaging to Monitor Response to Combined Anti-angiogenic Therapy, Radiotherapy, and Chemotherapy ................................................................. 174
  7.3.4 References ............................................................................................................ 175
Appendix ................................................................................................................................ 178
  Appendix A: Animal Ethics Approval for the Work Contained Within Chapter 4 ...... 178
  Appendix B: Human Ethics Approval for the Work Contained within Chapter 5 ....... 179
  Appendix C: Human Ethics Approval for the Work Contained Within Chapter 6 ....... 180
  Appendix D: Permission to Reproduce Previously Published Materials ..................... 186
  Appendix E: Membership of the PERNO Study Group .................................................. 202
Curriculum Vitae of Timothy Pok Chi Yeung ................................................................. 204
List of Tables

Table 1-1: The Macdonald criteria for assessing treatment response of malignant gliomas.* 11
Table 1-2: Glossary of perfusion imaging parameters................................................. 14
Table 1-3: Comparison of typical brain perfusion imaging techniques......................... 19
Table 1-4: Correlation of perfusion imaging parameters with histopathologic markers. .... 22
Table 1-5: Summary of sensitivities and specificities of perfusion imaging in differentiating high grade versus low grade gliomas................................................................. 26
Table 1-6: Differentiation between treatment-induced necrosis and true progression.......... 31
Table 2-1: Median (interquartile range) percentage errors associated with scan durations of < 150 seconds....................................................................................................................... 73
Table 2-2: Spearman’s rank correlation of systematic and random errors with scan duration. ........................................................................................................................................ 74
Table 3-1: Intraclass correlation coefficient of different CT perfusion parameters with the true values........................................................................................................................... 91
Table 3-2: Evaluation of quality of computed tomography perfusion image filtering........ 96
Table 3-3: P values of repeated-measures ANOVA for measurements of BF, BV, and PS. 96
Table 4-1: Acute changes (± standard error) in CT perfusion parameters....................... 110
Table 4-2: Summary of histological finding on Hematoxylin and Eosin (H&E) specimens. ....................................................................................................................................... 112
Table 5-1: Summary of images acquired in this study..................................................... 131
Table 5-2: Patient Characteristics.................................................................................. 134
Table 5-3: Multivariate logistic regression....................................................................... 136
Table 5-4: Statistical differences in area under the receiver operating characteristics curve.
........................................................................................................................................ 137

Table 6-1: Patient characteristics, percentages of patients alive 12, 18, and 24 months, and median OS estimates. ..................................................................................................................................................... 150

Table 6-2: Cox proportional hazards regression and Kaplan-Meier analysis results. .......... 156

Table 6-3: Receiver operating characteristic analysis of imaging parameters with sensitivities and specificities ≥ 70%. ........................................................................................................................................ 158
List of Figures

Figure 1-1: Schematic diagram of a brain capillary. The capillary lumen is surrounded by an endothelial cell, which is connected at both ends by tight junctions. Pericytes are attached to the outer surface of the endothelial cell. The endothelial cell and pericyte are ensheathed by a layer of basal lamina. This capillary is then enveloped by astrocytes. Figure adapted from Hawkins and Davis. Pharmacol Rev. 2005;57(2):173-185. Reprinted with permission. ....... 6

Figure 1-2: Contrast-enhanced T1-weighted magnetic resonance (MR) and T2-weighted MR of a patient with glioblastoma multiforme (GBM). .......................................................... 10

Figure 1-3: Blood flow (BF), blood volume (BV), and permeability-surface area (PS) product maps calculated from dynamic contrast-enhanced computed tomography (DCE-CT) images of the same patient as Figure 1-2. .......................................................... 19

Figure 1-4: Article selection flowchart according to the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) guidelines. ................................................. 22

Figure 2-1: Box plots of (a) blood flow (BF), (b) blood volume (BV), and (c) permeability-surface area product (PS) values measured from different scan durations. Outliers (circles) are defined as data that are 1.5 box lengths away from the 25th or 75th quartile. *Significantly different from the 150-second scan (P < .01). .......................................................... 72

Figure 2-2: Box plots of (a) blood flow (BF), (b) blood volume (BV), and (c) permeability-surface area product (PS) systematic errors associated with different scan durations. Outliers (circles) are defined as data that are 1.5 box lengths away from the 25th or 75th quartile. Extreme outliers that are three box lengths away from the quartiles are not displayed. ....... 73

Figure 2-3: Box plots of (a) blood flow (BF), (b) blood volume (BV), and (c) permeability-surface area product (PS) random errors associated with different scan durations. Outliers (circles) are defined as data that are 1.5 box lengths away from the 25th or 75th quartile. Extreme outliers that are three box lengths away from the quartiles are not displayed. ....... 73
Figure 2-4: Differences between perfusion maps obtained from a 150-second scan versus a 60-second scan. The 15-mm² regions of interest in the contrast-enhancing rim (1) and nonenhancing core (2) are displayed. Maps of blood flow (BF), blood volume (BV), and permeability–surface area (PS) are enlarged and centered at the tumour. White arrows point to regions with PS values that appeared to be higher at 60 seconds relative to 150 seconds. The window and level used for computed tomography, BF, BV, and PS were 20 to 100 Hounsfield units, 0 to 180 mL/min/100 g, 0 to 12 mL/100 g, and 0 to 25 mL/min/100 g, respectively.

Figure 3-1: Graphical illustration showing how a tissue time-attenuation curve (TAC), \( Q(t) \), is simulated from a population-averaged arterial TAC, \( C_a(t) \), and a blood flow–scaled impulse residue function, \( H(t) \), with known values of blood flow (BF), blood volume (BV), permeability–surface area product (PS), extraction fraction (E), and mean transit time (MTT).

Figure 3-2: An example of one slice (out of 16 slices) of the digital computed tomography (CT) perfusion phantom with image noise. Each tile contains tissue-enhancement curves reflecting a combination of extraction fraction (E), mean transit time (MTT), blood volume (BV), blood flow (BF), and permeability–surface area product (PS).

Figure 3-3: Maps of blood flow (BF), blood volume (BV), and permeability–surface area product (PS) of the digital phantom without noise (ie, truth), with noise, and after principal component analysis (PCA) filtering with four principal components. Some values of BF, BV, and PS are labeled.

Figure 3-4: Mean error and 95% limits of agreement (ie, mean ± 2 standard deviation from Bland–Altman analysis) without and with principal component analysis (PCA) filtering for (a) blood flow (BF), (b) blood volume (BV), and (c) permeability–surface area product (PS). Solid line is the mean and dashed lines are the upper and lower limits of agreement.

Figure 3-5: Mean map noise and 95% limits of agreement (ie, mean ± 2 standard deviation from a Bland–Altman analysis) without and with principal component analysis (PCA) filtering for (a) blood flow (BF), (b) blood volume (BV), and (c) permeability–surface area.
product (PS). Solid line is the mean and dashed lines are the upper and lower limits of agreement. ................................................................. 93

Figure 3-6: Examples of tumour time-enhancement curves obtained without and with principal component analysis (PCA) filtering. Filtering with two principal components can lead to loss of information as represented by the reduced height in the time-enhancement curve. .................................................................................................................. 94

Figure 3-7: (A) Examples of source computed tomography (CT) images and maps of blood flow (BF), blood volume (BV), and permeability–surface area product (PS) without and with filtering using four principal components (PCs). (B) The first four PCs as a function of time. ........................................................................................................................................................................ 95

Figure 3-8: Brain and tumour blood flow (BF), blood volume (BV), and permeability–surface area product (PS) before and after filtering with different number of principal components. Asterisk (*) indicates a marginal significance of $P = .06$. Dagger (†) indicates $0.01 \leq P < .03$. Double dagger (‡) indicates $P < .01$. .......................................................................................................................... 97

Figure 4-1: Acute CT perfusion changes on the fourth day after stereotactic radiosurgery (SRS). Tumour relative blood flow (rBF) decreased from 1.48 to 0.68, relative blood volume (rBV) decreased from 1.70 to 0.78, while permeability surface-area (PS) decreased from 4.67 to 3.87 ml/min/100g. On the contrary, peritumoural rBF increased from 0.96 to 1.49, rBV increased from 1.06 to 1.52, and PS increased from 2.13 to 3.81 ml/min/100g........................... 110

Figure 4-2: Histological examples of stereotactic radiosurgery (SRS) effects. Representative Hematoxylin & Eosin images of an untreated control, acute histological change at 4 days post-SRS, and late histological change at 59 days post-SRS. Hypercellularity (four point star) and pseudopalisading necrosis (five point star) are classic signs of grade IV glioma, and these were observed in the control animals. Hyalinized blood vessels (arrow) and hypocellularity can be observed shortly after SRS. Regression of tumour and hyalinization of tissue were observed at a later stage after SRS. .................................................................................................................. 111

Figure 4-3: $\alpha$-smooth muscle actin ($\alpha$-SMA) positive vessels in the normal brain, peritumoural region, and tumour of a control and a treated animal after stereotactic
radiosurgery (SRS). Intact α-SMA positive vessels were observed in control animals, but fragmented coverage of vessels by α-SMA is mostly seen in treated animals (red arrow)...

Figure 4-4: Boxplots of intact and fragmented α-smooth muscle actin (α-SMA) positive vessels in the control and SRS groups. Pairs with $P < 0.01$ are connected by black lines.

Figure 4-5: Changes in (i) tumour volume, (ii) relative blood flow (rBF), (iii) relative blood volume (rBV), and (iv) permeability-surface area (PS) in the tumour for controls, responders, and non-responders. *Significantly different from baseline (Friedman test and Wilcoxon-signed rank test). †Significantly different from controls and #significantly different from non-responders (Kruskal-Wallis followed by Mann-Whitney U test).

Figure 4-6: Changes in (i) rBF, (ii) rBV, and (iii) PS in the peritumoural region for controls, responders, and non-responders. *Significantly different from baseline (Friedman test and Wilcoxon-signed rank test). †Significantly different from controls (Kruskal-Wallis followed by Mann-Whitney U test).

Figure 4-7: Kaplan-Meier plots of response to treatment categorized by (A) tumour volume, (B) relative blood flow (rBF), (C) relative blood volume (rBV), and (D) permeability-surface area product (PS). For each imaging parameter, two response groups were identified based on whether the measured value was less than the lower 50% confidence interval of variations across all treated animals derived from the between-subject variation on day 7 post-SRS. Those that met this criteria were ranked as “low” by applying this threshold, and the others were ranked as “high”. Animals with low rBF, rBV, and PS on day 7 post-SRS showed significantly longer survival than the rest of the treated animals (i.e. high rBF, rBV, and PS) and control animals. *Significantly different from control group. †Significantly different from the other treated animals with a “high” value. Significant at $P \leq 0.02$ level (log-rank test).

Figure 5-1: Pre-radiotherapy gross tumour (T1-weighted MR), near-end-of-radiotherapy enhancing lesion (averaged CT) and progressive tumour (T1-weighted MR); and the corresponding parametric maps of blood flow (BF), blood volume (BV), permeability-surface area (PS) product, standard uptake value (SUV) and SUV:BF acquired using CT perfusion and FDG-PET. Blue outlines show the contrast-enhancing lesions delineated by a
radiation oncologist. Yellow outline is the 2-cm bounding box that was set for performing logistic regression. MR, magnetic resonance; CT, computed tomography; FDG-PET, 18-Fluorodeoxyglucose positron emission tomography.

Figure 5-2: Area under the operating characteristic curve (AUC) (top), sensitivities (middle) and specificities (bottom) for the selected logistic regression models. Models with an AUC that is significantly higher than the pre-radiotherapy gross tumour and the end-of-radiotherapy enhancing lesion are indicated with an asterisk (*). 1, Pre-radiotherapy gross tumour; 2, End-of-radiotherapy enhancing lesion; 3, BF; 4, BV; 5, PS; 6, SUV; 7, SUV:BF; 8, BF, PS, SUV:BF; 9, BF, BV, PS, SUV.

Figure 5-3: Probability of tumour progression (patient 3) within the 2-cm bounding box generated using the different logistic regression models. Black line outlines the boundary of the progressive tumour. Based on cross-validation, the magenta line delineates the region with the probability threshold that maximizes the sum of sensitivity and specificity in predicting progression.

Figure 6-1: Serial changes in mean volumes (top row), blood flow (BF, second row), blood volume (BV, third row), and permeability-surface area product (PS, bottom row) in the contrast-enhancing lesions (CEL) of patients stratified by 12 (left column), 18 (middle column), and 24 months (mo) overall survival (OS, right column). Horizontal line represents significant changes between two highlighted time points of the same group. Dotted box represents a significant difference between the groups. Error bar represents one standard deviation.

Figure 6-2: Serial changes in mean volumes (top row), blood flow (BF, second row), blood volume (BV, third row), and permeability-surface area product (PS, bottom row) in the non-enhancing lesions (NEL) of patients stratified by 12 (left column), 18 (middle column), and 24 months (mo) overall survival (OS, right column). Horizontal line represents significant changes between two highlighted time points of the same group. Dotted box represents a significant difference between the groups. Error bar represents one standard deviation.

Figure 6-3: Kaplan-Meier survival plots of blood flow in the non-enhancing lesion (BF_{NEL}), volume of the contrast-enhancing lesion (VOL_{CEL}), volume in the NEL (VOL_{NEL}).
permeability-surface area product in the NEL (PS$_{\text{NEL}}$), blood volume in the CEL (BV$_{\text{CEL}}$), and BV in the NEL (BV$_{\text{NEL}}$) measured at different time points. Higher values in these parameters were associated with worse overall survival (log-rank $P < 0.05$ for all comparisons).

Figure 6-4: Illustrative pre-surgery CT perfusion and MR images of patients with WHO grade IV gliomas. Both patients presented with a contrast-enhancing lesion on post-gadolinium T1-weighted MR images, which also had elevated blood flow (BF), blood volume (BV), and permeability-surface area product (PS). Patient A presented with low BF, BV, and PS in the non-enhancing lesion (NEL, asterisk). However, Patient B presented with regions of elevated BF, BV, and PS in the NEL (red arrows). The survival for patient A was 41.6 months and Patient B was 16.7 months. Identical window and level were used for the color maps.

Figure 7-1: Quality assurance (QA) framework in CT perfusion imaging.
List of Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACRIN</td>
<td>American College of Radiology Imaging Network</td>
</tr>
<tr>
<td>Ang</td>
<td>Angiopoietin</td>
</tr>
<tr>
<td>α-SMA</td>
<td>Alpha-smooth muscle actin</td>
</tr>
<tr>
<td>ANOVA</td>
<td>Analysis of variance</td>
</tr>
<tr>
<td>ASIR</td>
<td>Adaptive statistical iterative reconstruction</td>
</tr>
<tr>
<td>ASL</td>
<td>Arterial Spin labeling</td>
</tr>
<tr>
<td>AUC</td>
<td>Area under the curve</td>
</tr>
<tr>
<td>BBB</td>
<td>Blood-brain barrier</td>
</tr>
<tr>
<td>BF</td>
<td>Blood flow</td>
</tr>
<tr>
<td>BTV</td>
<td>Biologic target volume</td>
</tr>
<tr>
<td>BV</td>
<td>Blood volume</td>
</tr>
<tr>
<td>CEL</td>
<td>Contrast-enhancing lesion</td>
</tr>
<tr>
<td>CI</td>
<td>Confidence interval</td>
</tr>
<tr>
<td>CNR</td>
<td>Contrast-to-noise ratio</td>
</tr>
<tr>
<td>CT</td>
<td>Computed tomography</td>
</tr>
<tr>
<td>DCE-CT</td>
<td>Dynamic contrast-enhanced computed tomography</td>
</tr>
<tr>
<td>DCE-MR</td>
<td>Dynamic contrast-enhanced magnetic resonance</td>
</tr>
<tr>
<td>DNA</td>
<td>Deoxyribonucleic acid</td>
</tr>
<tr>
<td>DSC-MR</td>
<td>Dynamic susceptibility-contrast magnetic resonance</td>
</tr>
<tr>
<td>E</td>
<td>Extraction fraction</td>
</tr>
<tr>
<td>EES</td>
<td>Extravascular extracellular space</td>
</tr>
<tr>
<td>FDG</td>
<td>Fluorodeoxyglucose</td>
</tr>
<tr>
<td>FOV</td>
<td>Field of view</td>
</tr>
<tr>
<td>FLAIR</td>
<td>Fluid attenuated inversion recovery</td>
</tr>
<tr>
<td>FRI</td>
<td>Fractional residual information</td>
</tr>
<tr>
<td>GBM</td>
<td>Glioblastoma multiforme</td>
</tr>
<tr>
<td>H&amp;E</td>
<td>Hematoxylin and eosin</td>
</tr>
<tr>
<td>HIF-1</td>
<td>Hypoxia-inducible factor 1</td>
</tr>
</tbody>
</table>
HIF-1α  Hypoxia-inducible factor 1-alpha
HR         Hazard ratio
IDH1       Isocitrate dehydrogenase 1
iAUC       Initial area under the curve
$k_{ep}$   Efflux rate constant
KDR        Kinase insert domain receptor
$K^{trans}$ Transfer constant
mAUCR_H    The ratio between the iAUC and the final AUC from a DCE-MR scan gives the
            AUCR. The histogram of AUCR of a region is bimodal or skewed, the mean for
            the higher peak of this distribution is calculated to give the mAUCR_H.
MGMT       O(6)-methylguanine-DNA methyltransferase
MMP-9      Matrix metalloproteinase-9
MR         Magnetic resonance
MTT        Mean transit time
MVA        Microvessel area
MVCP       Microvascular cellular proliferation
MVD        Microvessel density
nBF        Normalized blood flow
nBV        Normalized blood volume
nMTT       Normalized mean transit time
NEL        Non-enhancing lesion
OS         Overall survival
PCA        Principal Component Analysis
PET        Positron emission tomography
PFS        Progression-free survival
PO$_2$     Partial pressure of oxygen
PRISMA     Preferred Reporting Items for Systematic Reviews and Meta-analysis
PS         Permeability-surface area product
QA         Quality assurance
RANO       Response Assessment in Neuro-Oncology
rBF        Relative blood flow
rBV        Relative blood volume
<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>ROC</td>
<td>Receiver operating characteristic</td>
</tr>
<tr>
<td>ROI</td>
<td>Region of interest</td>
</tr>
<tr>
<td>RTOG</td>
<td>Radiation Therapy Oncology Group</td>
</tr>
<tr>
<td>SD</td>
<td>Standard deviation</td>
</tr>
<tr>
<td>SE</td>
<td>Standard error of the mean</td>
</tr>
<tr>
<td>SPECT</td>
<td>Single-photon emission computed tomography</td>
</tr>
<tr>
<td>SRS</td>
<td>Stereotactic radiosurgery</td>
</tr>
<tr>
<td>SUV</td>
<td>Standard uptake value corrected for body surface area</td>
</tr>
<tr>
<td>TAC</td>
<td>Time attenuation curve</td>
</tr>
<tr>
<td>TIN</td>
<td>Treatment-induced necrosis</td>
</tr>
<tr>
<td>$v_e$</td>
<td>Volume of extravascular extracellular space per unit volume of tissue</td>
</tr>
<tr>
<td>VEGF</td>
<td>Vascular endothelial growth factor</td>
</tr>
<tr>
<td>VEGFR-2</td>
<td>Vascular endothelial growth factor receptor-2</td>
</tr>
<tr>
<td>$V_p$</td>
<td>Volume of ‘flowing’ blood within the vasculature per unit mass</td>
</tr>
<tr>
<td>WHO</td>
<td>World Health Organization</td>
</tr>
</tbody>
</table>
List of Appendices

Appendix .............................................................................................................................................. 178

Appendix A: Animal Ethics Approval for the Work Contained Within Chapter 4 ........ 178
Appendix B: Human Ethics Approval for the Work Contained within chapter 5 ........ 179
Appendix C: Human Ethics Approval for the Work Contained Within Chapter 6 ........ 180
Appendix D: Permission to Reproduce Previously Published Materials...................... 186
Appendix E: Membership of the PERNO Study Group .................................................. 202
“The brick walls are there for a reason. The brick walls are not there to keep us out. The brick walls are there to give us a chance to show how badly we want something. Because the brick walls are there to stop the people who don’t want it badly enough. They’re there to stop the other people.

Dr. Randy Pausch, *The Last Lecture*
Dedication

To my Mom,

You continue to exemplify courage, endurance, and resilience.

I could not have done it without you.
Chapter 1

1 Introduction

1.1 Overview

Until recently, clinical imaging of brain tumours has been limited largely to magnetic resonance (MR) and computed tomography (CT). MR is used routinely for diagnosis, surgical and radiotherapy guidance, and assessment of treatment response. CT is the workhorse for radiotherapy planning. Both imaging modalities are used for depicting the anatomy, size, and location of brain tumours. However, they have limited capabilities in providing functional information that relate to tumour pathophysiology. There is mounting evidence that functional imaging techniques, such as tumour perfusion imaging, are promising tools in this regard. Perfusion imaging, using CT or MR, can evaluate brain tumour hemodynamics. At present, perfusion imaging is not incorporated into the routine clinical care of patients because the uncertainties in the acquisition and analysis of these images make optimization and standardization difficult. Moreover, perfusion changes in response to different treatments are complex and not yet well understood. These problems make clinical interpretation of perfusion imaging information difficult. Optimization and standardization of image acquisition and analysis can help facilitate the implementation of perfusion imaging in clinical practice. Serial imaging of perfusion changes can improve the interpretation of the perfusion imaging data for evaluating response and prognosis in patients. This thesis focuses on optimizing the use and interpretation of CT perfusion imaging data based on computer simulation, pre-clinical experiments, and clinical studies. This introductory chapter provides an overview of the basic biology and treatment of malignant glioma, angiogenesis, a review of clinical perfusion imaging studies, and an outline of this thesis.
1.2 Malignant Glioma

More than 22,200 North Americans are diagnosed with cancers of the brain and central nervous system each year (1,2). Glial cells are non-neuronal cells that maintain homeostasis, and support and protect neurons in the central nervous system. Gliomas are brain tumours derived from glial cells with astrocytomas being the most common type of glioma. The World Health Organization (WHO) classifies astrocytomas into four grades based on histological features (3). Both pilocytic (WHO grade I) and diffuse (WHO grade II) gliomas are considered low-grade gliomas and typically behave in an indolent fashion. WHO grade III and IV gliomas are high-grade or malignant gliomas, and they account for approximately 70% of all malignant brain tumours (1,4). Anaplastic astrocytomas (WHO grade III) are diffusely infiltrating, demonstrate a high degree of anaplasia, and tend to progress to glioblastoma multiformes (GBMs). Nuclear atypia and mitotic activity are the criteria for diagnosing anaplastic astrocytomas. GBM (WHO grade IV) is the most malignant form of astrocytoma. It is composed of differentiated neoplastic astrocytes. It shows increased mitotic activity, proliferation of microvasculature, and necrosis. Neovascularization and necrosis are histologic hallmarks of GBM reflecting the dysregulated blood supply of these tumours. Despite aggressive treatment with combinations of surgery, radiation and chemotherapy, the median survival of patients with GBM is approximately 12 to 15 months, while it is two to five years for those with anaplastic gliomas (4).

1.3 Current Treatment Strategy for Malignant Glioma

The standard of care for patients with malignant gliomas involves maximal surgical resection when feasible, followed by radiotherapy and concurrent and adjuvant Temozolomide chemotherapy (4,5). Patients usually undergo at least a biopsy to determine tumour grade and often undergo surgical resection to debulk the tumour mass to palliate symptoms and improve function. Within six weeks after surgery, patients will receive 40 to 60 Gy of external beam radiotherapy. The target for radiotherapy is defined
using MR and CT. The gross tumour volume includes the contrast-enhancing lesion (CEL) depicted on pre-surgical MR/CT. The clinical target volume includes a margin (2 – 3 cm) to encompass microscopic spread of cancer (6). The planning target volume is created by an additional 0.3 cm margin to encompass treatment uncertainties (6). External beam radiotherapy is delivered in 2 Gy per fraction, given once daily for five days a week over a period of four to six weeks. Patients also receive concurrent Temozolomide at a dose of 75 mg/m² per day, given 7 days per week until the last day of radiotherapy. Six cycles of adjuvant Temozolomide start at four weeks after the end of radiotherapy based on a five day schedule every 28 days (5).

1.4 Prognostic Factors and Recurrence Patterns

Advanced age (≥ 50 years old), WHO grade IV, poor Karnofsky performance status, and unresectable tumours are the most important pretreatment prognostic factors that predict poor survival (7). The extent of resection, radiation dose, and O6-methylguanine-DNA methyltransferase (MGMT) promoter status are predictors of survival and recurrence patterns after treatment of GBM.

Malignant gliomas often cannot be completely resected due to its infiltrative nature and its proximity to adjacent brain tissues that serve important neurologic functions. In a retrospective study that involved 1215 patients with malignant gliomas, the median survival times after gross-total resection, near-total resection, and subtotal resection were 13, 11, and 8 months, respectively. Survival benefits were significant for gross-total resection versus near-total resection (P < 0.05), and near-total resection versus subtotal resection (P < 0.05) (8). Therefore, maximal surgical resection is favorable because survival is influenced by the extent of resection (8–10).

Radiotherapy plays an important role in prolonging the survival of these patients. It has long been established that a dose-survival relationship exist below 60 Gy (11). However, radiotherapy does not eliminate the risk of recurrence, and most patients will recur despite adjuvant radiotherapy. Over 80% of recurrence occurs within 2 cm of the
irradiated volume (12–17). For this reason, treatment volume is limited to the nearby surrounding region of the brain in order to reduce the toxicity associated with large field radiotherapy. The adoption of partial brain radiotherapy and new radiation technologies including three-dimensional conformal radiotherapy (18–20), intensity-modulated radiotherapy (21–23), stereotactic radiosurgery (SRS) (24–29), and interstitial brachytherapy have attempted to escalate the dose to beyond 60 Gy (30–34). Despite the use of high dose radiotherapy (90-120 Gy), dose escalation alone has not resulted in survival benefit. The target for dose escalation in these studies was typically defined as the CEL on CT or MR after contrast injection, but a few reports showed such procedure may not represent the entire tumour. Using $^{123}$I-$\alpha$-methyl-tyrosine single-photon emission computed tomography (SPECT) and $^{11}$C-methionine positron emission tomography (PET) studies have detected areas of increased metabolic activity that were not visible on contrast-enhanced CT or MR (35–38). In a group of patients with recurrent malignant gliomas, reirradiation of gross tumour volumes based on PET/SPECT + CT/MRI resulted in improved survival compared to reirradiation of gross tumour volumes based on CT/MR alone (9 vs. 5 months, log-rank $P = 0.03$) (35). This result suggests that functional imaging can provide complimentary information to that of CT/MR, and may define a biologic target for dose escalation that is distinct from that delineated by typical contrast-enhanced imaging.

Gliomas are known to be infiltrative neoplasms with the ability to migrate large distances in the brain. It is postulated that as treatment of the local tumour improves, distant failures beyond the typical 2 cm boundary around the irradiated brain volume may become more common. As of yet, however, even in the most favorable instances (completely resected tumours + receiving adjuvant radiotherapy and chemotherapy), the majority of failures are still in close proximity to the original tumour. The O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation is a prognostic factor of survival and recurrence patterns after radiotherapy and Temozolomide chemotherapy. One mechanism of DNA injury induced by Temozolomide is the methylation of DNA (39). The DNA-repair protein $O^6$-alkylguanine-DNA-alkyltransferase is encoded by the gene MGMT, which repairs Temozolomide-induced DNA damage by removing the alkylating lesions at the $O^6$ position of guanine. The
MGMT gene promoter is often methylated in malignant gliomas leading to the silencing of the MGMT gene and rendering tumour cells unable to repair Temozolomide-induced DNA damage (40). Patients with methylated MGMT promoter (i.e. silenced) had significantly longer survival than patients with unmethylated MGMT promoter (21.7 vs. 12.7 months, respectively; log-rank $P < 0.001$) (41). MGMT promoter gene status is also associated with different patterns of recurrence. Recurrences within or at the margin of the irradiated volume were more frequent amongst patients with unmethylated MGMT status than those with methylated MGMT status ($P = 0.01$) although local recurrences still predominated (42).

1.5 The Blood Brain Barrier and Tumour Angiogenesis

A solid tumour cannot grow beyond 1 to 2 mm$^3$ unless new vasculatures are formed to supply oxygen and nutrients to the growing tumour (43–45). Blood flow and the exchange of materials between the brain and systemic circulation are tightly regulated by the blood brain barrier (BBB). The BBB has important implications in tumour development and the growth of new blood vessels.

Brain vasculature is highly specialized and is unlike those found in other organs. The passage of molecules between the systemic circulation and the cerebral parenchyma is regulated physically (via tight junctions) and metabolically (via enzymes and transport systems) by the BBB. It maintains a constant supply of oxygen, glucose and other nutrients for neurons, and excludes exogenous molecules from entering the brain. This regulation is primarily established by three types of cells: endothelial cells, pericytes, and astrocytes (Figure 1-1). Endothelial cells form the lumen of blood vessels, which is the interface for material exchange between the blood and the brain. Pericytes are undifferentiated perivascular cells that envelope the outer surface of arterioles, venules, and capillaries (46). They play important roles in regulating blood flow (47) and maintaining the integrity of the BBB (48). Astrocytes are glial cells that cover more than 99% of the BBB endothelium (46).
Figure 1-1: Schematic diagram of a brain capillary. The capillary lumen is surrounded by an endothelial cell, which is connected at both ends by tight junctions. Pericytes are attached to the outer surface of the endothelial cell. The endothelial cell and pericyte are ensheathed by a layer of basal lamina. This capillary is then enveloped by astrocytes. Figure adapted from Hawkins and Davis. Pharmacol Rev. 2005;57(2):173-185. Reprinted with permission.

Tight junctions between adjacent endothelial cells are responsible for the unique impermeability of the BBB. They are regions where adjacent endothelial cell membranes are tightly associated with each other through the interactions of various tight junction proteins (46). This arrangement is continuous and lacks fenestration. The outer leaflets of adjacent endothelial cell membranes appear to be fused. The BBB physically prevents plasma proteins and hydrophilic molecules (> 500 kDa) from passively diffusing into the brain parenchyma (49). For exogenous molecules that can cross the BBB, there are several active, receptor-mediated transport proteins that function to export these molecules from the brain back into the systemic circulation (50,51). The brain is considered a “sanctuary” site for cancer cells because the BBB contributes to drug-
resistance by excluding many exogenous molecules (e.g. drugs) from entering the brain (49).

1.5.1 The Blood Brain Barrier in Brain Tumours

The integrity of the blood brain barrier is compromised in malignant brain tumours. The expressions of tight junction proteins are decreased or completely lost in primary and metastatic brain tumours (52–54). This leads to increased vascular permeability and may clinically manifest as vasogenic edema. The reduced number of pericytes (55) and astrocytes (56,57) in an aggressive brain tumour further contributes to a dysfunctional BBB. Tumour cells further increase BBB permeability by secreting a variety of factors that down regulate the expression of tight junction proteins (58,59). One such factor is the vascular endothelial growth factor (VEGF), which was originally discovered as the vascular permeability factor (49,58). VEGF is also a driver of tumour vessel formation. The resulting vessels are structurally and functionally compromised and lack the BBB of normal vasculature.

1.5.2 Tumour Hypoxia

Mammalian cells are usually located within 100 to 200 μm of nearby blood vessels, which is the oxygen diffusion limit (60,61). The partial pressure of oxygen (PO₂) in normal tissue ranges between 10 to 80 mm Hg, but PO₂ within certain tumour regions are often less than 5 mm Hg (62). Hypoxia occurs when the tumour grows beyond the oxygen diffusion limit because the vascular supply cannot meet its metabolic demand. This type of hypoxia is called chronic hypoxia, which can lead to tumour necrosis. Cycling hypoxia, sometimes known as acute or intermittent hypoxia, occurs in tumour regions that are poorly perfused due to chaotic and sluggish tumour vasculature (63). Hypoxia is associated with treatment resistance (64,65) and promotes the formation of new tumour blood vessels (66,67). The growth of a solid tumour is dependent on the growth of new blood vessels (44). There are four mechanisms for brain tumours to form new blood vessels, they are co-option, angiogenesis, vasculogenesis, and intussusception.
1.5.3 Formation of Tumour Blood Vessels

1.5.3.1 Co-option

Initial brain tumour vessel formation (< 1 mm in diameter) is believed to occur by the co-option of pre-existing blood vessels (68,69). Early reports demonstrated that pre-existing vessels that were co-opted by tumour cells were not influenced by the tumour as these vessels were not leaky (68,70). This also suggests that this type of vessel formation might not be detected by contrast-enhanced CT or MR since these imaging techniques detect tumour based on the extravasation of contrast agents (68).

1.5.3.2 Angiogenesis

Angiogenesis is a common mechanism for gliomas to grow and progress. Tumour angiogenesis in the brain involves three major steps: 1) regression of pre-existing blood vessels, 2) breakdown of the basement membrane and extracellular matrix, and 3) the migration of endothelial cells to form new blood vessels. The initiation of angiogenesis is known as the angiogenic switch. This switch is turned on when the pro-angiogenic factors in a tumour outweigh the anti-angiogenic factors. The secretion of pro-angiogenic factors are triggered by microenvironmental conditions including hypoxia and acidosis (71), and by genetic factors such as alterations in oncogene (e.g. ras) or tumour suppressor gene (e.g. p53) functions (72,73). The hypoxia-inducible factor 1 (HIF-1) pathway is a well-characterized signaling pathway by which hypoxic tumours initiate and orchestrate cellular responses to hypoxia. HIF-1 activates the transcription of more than 100 genes that help tumour cells “cope” with low oxygen conditions (74). The expression of VEGF, one of the most potent pro-angiogenic factors, is activated by this pathway (71,73).

The initial response to VEGF overexpression includes increased vascular permeability (75–77) and diameter (49). In a normal brain, angiopoietin (Ang-1) binds to its receptor Tie-2 to facilitate a close association between endothelial cells and pericytes...
(48,78). Under hypoxic conditions, Ang-2, an antagonist of Tie-2, is upregulated and is suggested to be involved in the detachment of pericytes from endothelial cells and leads to the regression of blood vessels (79–81). Increased Ang-2 and hypoxia then lead to the expression of matrix-metalloproteinase molecules that mediate the breakdown of the basement membrane and the extracellular matrix (82). At the same time, molecules including VEGF, Ang-1, and Ang-2 stimulate endothelial cell proliferation and migration towards the cancer cells (49,79). The end product of angiogenesis is an abnormal, highly tortuous, sluggish, and leaky vascular network (49,63).

1.5.3.3 Vasculogenesis

Angiogenesis forms new blood vessels from pre-existing ones, whereas vasculogenesis forms blood vessels without pre-existing endothelial cells. It is a process by which bone marrow-derived cells (83–85), such as circulating progenitor cells (86,87), are recruited to the tumour to form new blood vessels. This process is also initiated by hypoxia through the HIF-1 pathway (88,89). It has been shown that blocking vasculogenesis can prevent or delay local recurrence of GBM after irradiation (88). This suggests circulating cells outside the radiation field colonize and stabilize tumour vasculature and support the remaining viable tumour cells after irradiation.

1.5.3.4 Intussusception

Intussusception refers to the remodeling and expansion of pre-existing blood vessels by inserting transluminal pillars into vessel lumens that result in partitioning of vessel lumens (79,90). Intussusception occurs faster than angiogenesis; it does not primarily depend on the proliferation of endothelial cells, degradation of basement membrane, and invasion of connective tissue (90,91). It appears to increase the complexity and density of tumour vascular networks established by angiogenesis (90).
1.6 Conventional Imaging of Malignant Gliomas

Visualization of brain tumours on contrast-enhanced MR and CT is made possible because the compromised BBB in brain tumours allow imaging contrast to extravasate into the brain parenchyma after contrast injection. The standard MR protocol for imaging brain tumours usually involves a T2-weighted or a fluid attenuated inversion recovery (FLAIR) MR and a gadolinium-enhanced T1-weighted MR (Figure 1-2) (92). Gadolinium-enhanced T1-weighted MR provides excellent soft tissue contrast, and depicts the contrast-enhancing component of the tumour. However, malignant gliomas are infiltrative tumours with microscopic processes that extend beyond regions of contrast-enhancement. Vasogenic edema, which may be induced by infiltrating tumour cells, is a major clinical feature of the non-enhancing portions of these tumours and can be visualized on T2-weighted or FLAIR MR.

![Figure 1-2: Contrast-enhanced T1-weighted magnetic resonance (MR) and T2-weighted MR of a patient with glioblastoma multiforme (GBM).](image)

1.7 Criteria for Assessing Treatment Response

Radiographic response assessment of brain tumours is primarily based on changes in the size of the contrast-enhancing part of the tumour. The Macdonald criteria were introduced in 1990 for assessing response in gliomas (93). Tumour size is measured using
the product of the maximal perpendicular diameters of the enhancing tumour depicted on gadolinium-enhanced T1-weighted MR or iodinated contrast-enhanced CT. The use of corticosteroid and clinical status are also taken into account. Response can be categorized into four categories; they are complete response, partial response, stable disease, and progression (Table 1-1).

### Table 1-1: The Macdonald criteria for assessing treatment response of malignant gliomas.*

<table>
<thead>
<tr>
<th>Response</th>
<th>Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Complete Response</td>
<td>Requires all of the following: complete disappearance of all enhancing measurable and non-measurable diseases sustained for at least 4 weeks; no new lesions; no corticosteroid; and stable or improved clinically</td>
</tr>
<tr>
<td>Partial Response</td>
<td>Requires all of the following: ≥ 50% decrease compared with baseline in the sum of products of perpendicular diameters of all measurable enhancing lesions sustained for at least 4 weeks; no new lesions; stable or reduced corticosteroid dose; and stable or improved clinically</td>
</tr>
<tr>
<td>Stable Disease</td>
<td>Requires all of the following: does not qualify for complete response, partial response, or progression; and stable clinically</td>
</tr>
<tr>
<td>Progression</td>
<td>Defined by any of the following: ≥ 25% increase in the sum of products of perpendicular diameters of enhancing lesions; any new lesion; or clinical deterioration</td>
</tr>
</tbody>
</table>


The Macdonald criteria have a few limitations. A two dimensional measurement of tumour size can be influenced by a number of factors (94–96). Measurement is difficult with an irregularly shaped tumour, multifocal tumour, and enhancing wall of a surgical cavity. It is also prone to interobserver variability (97). Contrast-enhanced MR or CT is a snapshot of tissue contrast-enhancement after contrast injection, so it reflects the
extravasation of materials across a disrupted BBB regardless of the cause of disruption. Changes in corticosteroid dose, inflammation, post-surgical changes, pseudoprogession due to treatment effects, radiation-induced necrosis, and pseudoresponse due to antiangiogenic therapies are all factors that can influence contrast-enhancement (98–102). In addition, the Macdonald criteria do not take into account the non-enhancing component of the tumour.

Recently, the Macdonald criteria were updated. In 2010, The Response Assessment in Neuro-Oncology (RANO) Working Group developed new standardized criteria for assessing response in patients with malignant gliomas (92). Size measurement of the non-enhancing component of the tumour using T2-weighted or FLAIR MR is incorporated into the assessment criteria. It also recognized early changes in contrast-enhancement could be treatment related (e.g. pseudopropagation and pseudoresponse), which could confound the diagnosis of tumour progression or response. To address this issue, a time period has been defined for which pseudopropagation can be excluded from true progression. For instance, true progression can only be determined within the first 12 weeks of completion of radiotherapy if the majority of new contrast-enhancement is outside the radiation field (80% isodose line) or if there is pathologic confirmation of tumour progression (92).

The RANO working group recognized that there are still unsolved problems associated with these criteria. Better imaging techniques are needed to predict tumour response, differentiate treatment-induced changes from tumour progression, and differentiate non-enhancing tumours from other etiologies of increased T2-weighted or FLAIR signals. The group also recognized that functional imaging, particularly the imaging of tumour perfusion and permeability, are promising tools to address these challenges.
1.8 Perfusion Imaging of Malignant Gliomas

A growing number of studies demonstrated that perfusion imaging can provide physiologic information about tumour aggressiveness and disease prognosis. Dynamic susceptibility-contrast MR (DSC-MR), dynamic contrast-enhanced MR (DCE-MR), and DCE-CT are commonly used perfusion imaging techniques for evaluating tumour hemodynamics and vessel permeability surface area (PS) product in the research setting. In this thesis, DCE-CT and CT perfusion are used interchangeably.

Perfusion imaging refers to imaging techniques that characterize tissue hemodynamics by tracking the passage of a bolus of contrast agent as it traverses through human tissue. Following injection, contrast passes through the microvasculature of brain tissue and produces a change in image signal intensity. DCE-MR and DSC-MR measure gadolinium contrast concentration via its effect on surrounding water molecules, while DCE-CT measures iodinated contrast concentration via its attenuation of x-rays. Quantitative evaluation of hemodynamics and PS from tracer kinetic analysis (103) consists of three main steps:

1. Image signal intensity is converted to contrast concentration to obtain the time-concentration curve $C_t(t)$ of brain (tumour) tissue.

2. Image signal intensity in pixels corresponding to an input artery to the brain is similarly converted to the arterial input function $C_a(t)$. It is the time-concentration curve of contrast that enters the tissue of interest via the selected input artery.

3. Based on the tracer kinetic model adopted, hemodynamic parameters such as blood flow (BF) and PS can be estimated. Definitions of the different tracer kinetic parameters that can be derived are listed in Table 1-2. The tissue time-concentration curve $C_t(t)$ is equal to blood flow (BF) multiplying the convolution of the arterial input function $C_a(t)$ and an impulse residue function $R(t)$. This relationship can be mathematically expressed as:
\[ C_t(t) = BF \cdot C_a(t) \otimes R(t) = C_a(t) \otimes BF \cdot R(t) \]

\[ C_t(t) = \int_0^t C_a(\tau) \cdot [BF \cdot R(t - \tau)] d\tau \quad \text{… Equation 1-1} \]

The impulse residue function \( R(t) \) describes the tissue time-concentration curve when the arterial input function is \( \frac{1}{BF} \delta(t) \) or when an unit amount of contrast is introduced into the arterial input of the tissue instantaneously. Empirically, it is the fraction of contrast that remains in the tissue as a function of time after instantaneous contrast injection at the arterial input. In practice, contrast is injected intravenously over a period of time (15-25 s) such that the arterial input function \( C_a(t) \) is dispersed in time instead of a delta function \( \delta(t) \). Provided the image signal varies linearly with concentration and BF is stationary (constant within the period of measurement), the tissue time-concentration curve \( C_t(t) \) is by the convolution between the arterial input function \( C_a(t) \) and the impulse residue function \( R(t) \) using the principle of linear superposition.

Below we discuss the technical aspects of DSC-MR, DCE-MR, and DCE-CT.

**Table 1-2: Glossary of perfusion imaging parameters.**

<table>
<thead>
<tr>
<th>Terms</th>
<th>Definitions (units)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blood flow (BF)</td>
<td>Flow rate of blood per unit mass or volume of tissue (ml·min·100g(^{-1}) or ml·min·100ml(^{-1})).</td>
</tr>
<tr>
<td>Blood volume (BV)</td>
<td>Volume of ‘flowing’ blood within the vasculature per unit mass or volume of tissue (ml·100g(^{-1}) or ml·100ml(^{-1})).</td>
</tr>
<tr>
<td>Extraction fraction (E)</td>
<td>Fraction of contrast that extravasates from the intravascular space into the EES in the first pass through the vasculature</td>
</tr>
<tr>
<td>Initial Area Under the Curve (iAUC)</td>
<td>A semi-quantitative measure of contrast enhancement used in DCE-MR. It is related to the dose of contrast injected, the blood volume, and permeability surface product of the BBB.</td>
</tr>
<tr>
<td>mAUCR(_H)</td>
<td>The ratio between the iAUC and the final AUC from a DCE-MR scan gives the AUCR. The histogram of AUCR of a region is bimodal or skewed, the mean for the higher peak of</td>
</tr>
</tbody>
</table>
this distribution is calculated to give the mAUCR\(_H\).

<table>
<thead>
<tr>
<th>Term</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean transit time (MTT)</td>
<td>Average time (s) for blood to traverse from the arterial to the venous end of the vasculature.</td>
</tr>
<tr>
<td>Normalized BV (nBV)</td>
<td>BV of a region-of-interest normalized to the contralateral normal brain. The normal appearing white matter is used for normalization.</td>
</tr>
<tr>
<td>Normalized Maximum Slope</td>
<td>A semi-quantitative estimation of BF. It is the maximum slope of a tissue time-contrast enhancement curve normalized by the maximum of the arterial time-contrast enhancement curve.</td>
</tr>
<tr>
<td>Peak Height (PH)</td>
<td>A measure of maximum contrast enhancement from the baseline signal during the first pass of contrast.</td>
</tr>
<tr>
<td>Normalized Peak Height</td>
<td>PH of the tumour can be normalized to the contralateral normal brain to give the normalized peak height.</td>
</tr>
<tr>
<td>Percent Recovery</td>
<td>It is the measure of how much signal has recovered from the baseline signal after the first pass of contrast. It is a semi-quantitative measure of microvascular leakage in DSC-MR.</td>
</tr>
<tr>
<td>Permeability</td>
<td>Unidirectional flux rate of contrast agent from the blood plasma into the brain parenchyma (i.e. interstitial space) normalized by the total surface area of capillaries per unit mass of tissue. It is often estimated using the parameters permeability-surface area product (PS) and transfer rate constant ((K_{\text{trans}})).</td>
</tr>
<tr>
<td>Permeability-surface area product (PS)</td>
<td>Product of permeability and total surface area of capillaries per unit mass of tissue (ml(\cdot)min(\cdot)100g(^{-1})).</td>
</tr>
<tr>
<td>Efflux Rate constant ((k_{ep}))</td>
<td>Rate constant of contrast efflux rate from the brain parenchyma back into the blood plasma (min(^{-1})).</td>
</tr>
<tr>
<td>Transfer Constant ((K_{\text{trans}}))</td>
<td>Flow rate constant of contrast from the blood plasma to the brain parenchyma (min(^{-1})).</td>
</tr>
<tr>
<td>(V_p)</td>
<td>Volume of ‘flowing’ blood within the vasculature per unit mass or volume of tissue (ml(\cdot)100g(^{-1}) or unitless)</td>
</tr>
<tr>
<td>Extravascular volume ((v_e))</td>
<td>Volume of extravascular extracellular space per unit volume of tissue for contrast to distribute into (ml(\cdot)100g(^{-1}) or unitless).</td>
</tr>
</tbody>
</table>
**Abbreviations:** EES, extravascular extracellular space; DCE-MR, dynamic contrast-enhanced magnetic resonance; BBB, blood brain barrier; DSC-MR, dynamic susceptibility-contrast magnetic resonance

1.8.1 Dynamic Susceptibility-Contrast Magnetic Resonance (DSC-MR)

DSC-MR imaging measures signal change during the first passage of contrast through the tissue vasculature when the contrast remains intravascular using a T2- or T2*-weighted sequence. At high concentration (0.1 – 0.2 mmol/kg), the contrast agent creates a susceptibility gradient in tissue that decreases T2* signal intensity. A temporal resolution of 1 – 2 s is required because the minimum transit time of contrast agent in brain tissue is a few seconds. A typical scan duration of 1 – 2 minutes is used. The indicator dilution method is appropriate for calculating BF and BV in DSC-MR imaging (104). DSC-MR assumes that the degree at which contrast is diluted in the blood is a function of blood flow (BF) and blood volume (BV) and that contrast remains intravascular during imaging. BV is estimated from the ratio of the areas under the tissue time-concentration curve $C_d(t)$ and the arterial time-concentration curve $C_a(t)$. BF can be solved by the deconvolution of Equation 1-1. DSC-MR assumes that the contrast agent compartmentalizes in the intravascular space and does not leak into the brain parenchyma. However, violation of this assumption can underestimate BV when high leakage of contrast material occurs (105). This effect can be minimized by pre-saturating the brain parenchyma with a pre-loading dose of contrast agent, dual echo sequence, or post-processing mathematical correction (105,106).
1.8.2 Dynamic Contrast-Enhanced Magnetic Resonance (DCE-MR)

DCE-MR refers to the acquisition of serial MR images using a T1-weighted sequence. The increase in T1 relaxation rate from corresponding increase in contrast concentration is measured as an increase in signal intensity. DCE-MR scan duration is 5 – 10 min in order to measure the rate of extravasation of contrast from the intravascular space into the extravascular extracellular space (EES) (i.e. PS or $K_{\text{trans}}$). By assuming the intravascular space and the EES as two well-mixed tissue compartments, the compartmental model is used to estimate the rate of contrast transfer from the intravascular space into the EES (107). This quantity is commonly called $K_{\text{trans}}$ and can be solved using the following equation:

$$C_t(t) = BV \cdot C_a(t) + K_{\text{trans}} \int_0^t C_a(u)e^{-\frac{K_{\text{trans}}}{v_e}(t-u)} du \ldots \text{Equation 1-2}$$

where $v_e$ is the volume of extravascular extracellular space per unit volume of tissue. $K_{\text{trans}}$ is generally interpreted as a measure of tissue permeability (107). However, $K_{\text{trans}}$ is the product between BF and extraction fraction (E). Thus, $K_{\text{trans}}$ should be used for permeability interpretation with caution because either BF or E may be the dominating factor. A temporal resolution of 5 – 10 s per image is commonly used to balance spatial resolution, scan coverage, and signal-to-noise ratio, but it is too slow for the measurements of BF and BV where a finer temporal resolution (1 – 2 s) is required (108). However, techniques such as multi-channel parallel imaging and compressed sensing can achieve a finer temporal resolution (109).

1.8.3 Dynamic Contrast-Enhanced Computed Tomography (DCE-CT)

DCE-CT refers to the acquisition of serial CT images to track the passage of a bolus of iodinated contrast agent. The typical DCE-CT protocol takes 2 – 3 minutes, and
it involves rapid acquisition of images (1 – 2 s per image) during the initial phase of imaging (45 s) to capture the first pass of contrast for the calculation of BF and BV. A second phase that involves less frequent acquisition (10 – 15 s per image) is required to calculate PS or $K^{trans}$ (110). Both compartmental and distributed parameter models have been used to calculate tracer kinetic parameters from DCE-CT images. The Johnson and Wilson model (111) is an example of a distributed parameter model. An adiabatic approximation to the Johnson and Wilson model allows the simultaneous determination of BF, BV, and permeability-surface area product (PS) by giving a closed-form solution to the impulse residue function $R(t)$ (112). The $R(t)$ is defined as:

$$
R(t) = \begin{cases} 
1 & 0 < t \leq \frac{BV}{BF} \\
Ee^{\frac{BF}{ve}(t-\frac{BV}{BF})} & t > \frac{BV}{BF}
\end{cases} \quad \text{… Equation 1-3}
$$

The extraction fraction $E$ is calculated as:

$$
E = 1 - e^{\frac{PS}{BF}} \quad \text{… Equation 1-4}
$$

The distributed parameter model enables the separation of BF and E; thus, enabling the calculation of the permeability-surface area product (PS). It assumes a contrast concentration gradient inside the intravascular space along the length of capillaries (110). An advantage of the distributed parameter model is the determination of BF, BV, and PS from a single perfusion scan.

The clinical use of DCE-CT was slow to progress initially due to its relatively limited scan volume (2 – 4 cm coverage) and associated radiation dose (2 – 5 mSv) (113). The advent of large multi-row detector technology enables the coverage of 16 cm of anatomy (114). Shuttle mode imaging can also increase the scan coverage (115). Reconstruction methods such as adaptive statistical iterative reconstruction technique (116) and reducing the temporal resolution of image acquisition (≤ 3 s) in the first phase (117) are effective ways to reduce radiation dose. Figure 1-3 shows maps of BF, BV, and PS from a DCE-CT study of a patient with GBM. Table 1-3 summarizes and compares the key aspects of DSC-MR, DCE-MR, and DCE-CT.
Figure 1-3: Blood flow (BF), blood volume (BV), and permeability-surface area (PS) product maps calculated from dynamic contrast-enhanced computed tomography (DCE-CT) images of the same patient as Figure 1-2.

Table 1-3: Comparison of typical brain perfusion imaging techniques.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>DSC-MR</th>
<th>DCE-MR</th>
<th>DCE-CT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Typical contrast agent</td>
<td>Gadopentetate dimeglumine</td>
<td>Gadopentetate dimeglumine</td>
<td>Iopamidol</td>
</tr>
<tr>
<td>Tracer kinetic analysis method</td>
<td>Indicator dilution theory</td>
<td>Compartmental model</td>
<td>Compartmental and distributed parameter models</td>
</tr>
<tr>
<td>Scan coverage</td>
<td>8 – 10 or 16 – 20 slices covering the entire brain (~10 cm)</td>
<td>16 – 32 slices covering 3 to 16 cm of anatomy</td>
<td>4, 8, and 16 cm coverage with multi-detector CT. Shuttle mode imaging can achieve whole brain coverage</td>
</tr>
<tr>
<td>Molecular weight of contrast agent</td>
<td>938 g/mol (0.938 kDa)</td>
<td>938 g/mol (0.938 kDa)</td>
<td>777 g/mol (0.777 kDa)</td>
</tr>
<tr>
<td>Typical temporal resolution</td>
<td>1 – 2 s</td>
<td>5 – 10 s</td>
<td>First phase: 1 – 2 s Second phase: ≤ 5 s for Patlak analysis and 10</td>
</tr>
<tr>
<td>Typical scan duration</td>
<td>1 – 2 min</td>
<td>5 – 10 min</td>
<td>2 – 3 min</td>
</tr>
<tr>
<td>-----------------------</td>
<td>-----------</td>
<td>------------</td>
<td>-----------</td>
</tr>
<tr>
<td>Source of signal</td>
<td>Decrease in $T_2^*$ (or $T_2$) of surrounding water molecules</td>
<td>Decrease in $T_1$ of surrounding water molecules</td>
<td>Attenuation of x-ray by iodinated contrast</td>
</tr>
<tr>
<td>Change in signal intensity</td>
<td>Signal loss</td>
<td>Signal gain</td>
<td>Signal gain</td>
</tr>
<tr>
<td>Signal-to-contrast concentration relationship</td>
<td>$\Delta R_2^*(t) = -\frac{1}{TE} \ln \left( \frac{S(t)}{S(0)} \right)$</td>
<td>$C = \frac{1}{T_1} - \frac{1}{T_1^0}$</td>
<td>Linear</td>
</tr>
<tr>
<td>Quantitative Techniques</td>
<td>Mostly relative</td>
<td>Relative and absolute</td>
<td>Relative and Absolute</td>
</tr>
</tbody>
</table>

Abbreviations: DSC-MR, dynamic-susceptibility contrast magnetic resonance; DCE-MR, dynamic contrast-enhanced magnetic resonance; DCE-CT, dynamic contrast-enhanced computed tomography; $\Delta R_2^*$, Change in relaxation rate; $S(0)$, baseline signal intensity; $S(t)$, signal intensity at time $t$; $R_1$, longitudinal relaxivity of the contrast agent; $C$, concentration; Hct, hematocrit; $k$, proportionality constant that depends on the tissue, contrast agent, field strength, and pulse sequence parameters.

1.8.4 Other Important Perfusion Imaging Techniques

Arterial spin labeling (ASL) is a promising technique that can measure BF in brain tumours. ASL uses arterial blood water as an endogenous tracer by magnetically labeling blood water that is proximal to the tissue of interest. ASL is a technology that is gaining interest in neuro-oncology in recent years (118,119) since it does not require the injection of exogenous contrast agent and it has no radiation dose. The ASL method makes serial perfusion scans even more feasible for monitoring treatment response.

Tumour perfusion can also be investigated using nuclear medicine techniques. Positron emission tomography (PET) using $^{15}$O-labeled water has been used in previous
reports (120,121), and is considered to be the “gold standard” in quantitative perfusion imaging. However, the need for an onsite cyclotron and the short half-life of $^{15}\text{O}$ (2 minutes) limits its feasibility in the clinic. Limited spatial resolution is also a disadvantage of PET when compared to CT and MR.

1.9 Literature Review of Perfusion Imaging

Here, we provide a review of the literature in perfusion imaging of malignant gliomas. To comprehensively survey the literature, a PubMed search was performed from January 2002 to May 2012 using the terms (‘glioma’ OR ‘glioblastoma’) AND (‘perfusion imaging’, ‘dynamic contrast-enhanced’, ‘DCE’, ‘computed tomography’, ‘CT’, ‘dynamic susceptibility’, ‘DSC’, ‘magnetic resonance’, OR ‘MR’) to identify relevant clinical studies. The search was limited to include studies that involved human subjects and published in the English language. Preclinical studies, studies that evaluated only low-grade gliomas, and studies with a sample size ≤ 5 patients were excluded.

We categorized each article according to the investigated application. Five key areas were identified; they are 1) correlations with molecular and histopathologic markers, 2) diagnostic efficacy of differentiating high grade from low grade gliomas, 3) differentiation of malignant gliomas from other malignant lesions, 4) differentiation of true progression from post-treatment effects, and 5) prediction of survival. Literature search for applications 4 and 5 were extended to include studies published before January 2014. When considering articles that evaluated tumour grade, only articles that reported the sensitivity and specificity to differentiate high and low grade gliomas were included. The article selection process is summarized in Figure 1-4.
1.9.1 Correlation with Molecular and Histopathologic Markers

An understanding of the relationships between histopathologic markers and perfusion imaging could justify the use of perfusion imaging as non-invasive surrogates for these tissue assays (Table 1-4).

<table>
<thead>
<tr>
<th>Histopathologic Markers</th>
<th>Techniques</th>
<th>Parameters</th>
<th>Correlation coefficients (range)</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tumour cellularity or cell density</td>
<td>DSC-MR</td>
<td>nBV</td>
<td>0.57</td>
<td>(122)</td>
</tr>
<tr>
<td></td>
<td>DCE-CT</td>
<td>BF</td>
<td>0.498</td>
<td>(123)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>BV</td>
<td>0.482</td>
<td></td>
</tr>
<tr>
<td><strong>Microvessel density (MVD)</strong></td>
<td><strong>PS</strong></td>
<td><strong>0.409</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-------------------------------</td>
<td>--------</td>
<td>-----------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DSC-MR nBV</td>
<td>0.32 – 0.46</td>
<td>(122,124)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DCE-MR nBV</td>
<td>0.821 – 0.896</td>
<td>(125,126)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DCE-CT BF</td>
<td>0.527</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DCE-CT BV</td>
<td>0.649</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Microvessel area (MVA)</strong></td>
<td><strong>DSC-MR nBV</strong></td>
<td>0.83</td>
<td>(124)</td>
<td></td>
</tr>
<tr>
<td><strong>Microvascular cellular proliferation (MVCP)</strong></td>
<td><strong>DSC-MR nBV</strong></td>
<td><strong>nBV were higher in the presence of MVCP</strong></td>
<td>(127)</td>
<td></td>
</tr>
<tr>
<td>DCE-CT PS</td>
<td>0.647</td>
<td>(123)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Vascular endothelial growth factor (VEGF)</strong></td>
<td><strong>DSC-MR nBV</strong></td>
<td><strong>nBV values correlated with VEGF expression</strong></td>
<td>(128)</td>
<td></td>
</tr>
<tr>
<td>DCE-MR nBV</td>
<td>0.765 – 0.884</td>
<td>(125,126,129)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DCE-MR nBF</td>
<td>0.849</td>
<td>(129)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DCE-MR K&lt;sub&gt;trans&lt;/sub&gt;</td>
<td>0.585</td>
<td>(130)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DCE-MR k&lt;sub&gt;ep&lt;/sub&gt;</td>
<td>0.765 – 0.871</td>
<td>(129,130)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DCE-MR ν&lt;sub&gt;e&lt;/sub&gt;</td>
<td>0.509</td>
<td>(130)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Matrix metalloproteinase-9 (MMP-9)</strong></td>
<td><strong>DCE-MR nBV</strong></td>
<td>0.557</td>
<td>(129)</td>
<td></td>
</tr>
<tr>
<td><strong>Hypoxia inducible factor 1-alpha (HIF1-α)</strong></td>
<td><strong>DCE-MR nBV</strong></td>
<td>0.557</td>
<td>(129)</td>
<td></td>
</tr>
<tr>
<td><strong>Ki-67</strong></td>
<td><strong>DSC-MR nBV</strong></td>
<td>0.628 (marginal significance)</td>
<td>(131)</td>
<td></td>
</tr>
<tr>
<td><strong>MIB-1</strong></td>
<td><strong>DSC-MR nBV</strong></td>
<td>0.66</td>
<td>(132)</td>
<td></td>
</tr>
</tbody>
</table>

**Abbreviations:** DSC-MR, dynamic susceptibility-contrast magnetic resonance; DCE-MR, dynamic contrast-enhanced magnetic resonance; DCE-CT, dynamic contrast-enhanced computed tomography; nBV, normalized blood volume; BF, blood flow; PS, permeability-surface area product; nBF, normalized blood flow; K<sub>trans</sub>, transfer constant;
$k_{eq}$, efflux rate constant; $v_e$, volume of extravascular extracellular space per unit volume of tissue; nMTT, normalized mean transit time.

Microvessel density (MVD) is a histopathologic measure of angiogenesis and a prognosticator of survival (133). Correlations between MVD and BV were weak for DSC-MR ($< 0.4$), moderate for DCE-CT ($< 0.7$), and strong for DCE-MR ($> 0.8$). Microvessel area (MVA) is a more useful predictor of survival than MVD because MVD cannot characterize the morphological complexity of tumour blood vessels, which are often tortuous and different in sizes (134). Tumour normalized BV (nBV) showed a stronger correlation with MVA than MVD ($r = 0.83$ and $0.32$, respectively; $p \leq 0.05$) (124). Moreover, nBV and MVA correlated with overall survival (OS) while MVD did not. Microvascular cellular proliferation and VEGF expression also showed correlations with perfusion imaging parameters (Table 1-4). Together, these studies suggest that perfusion imaging-based measure of BV may be a surrogate marker of the degree of angiogenesis, which in turn is a predictor of patient survival.

One DCE-CT study explored the associations between the expression of genes that regulate angiogenesis in GBM and different DCE-CT parameters (135). Nineteen and nine genes showed significant associations with PS and BV, respectively. BV and/or PS correlated positively with some pro-angiogenic genes (e.g. KDR (VEGFR-2) and HIF1A) and negatively with some anti-angiogenic genes (e.g. VASH2 and C3). This study suggests a molecular genetic basis for PS and BV as candidate imaging biomarkers.

Angiogenesis is crucial for the proliferation and invasion of malignant gliomas, and it was demonstrated that MVD correlated with tumour proliferation (136). For this reason, studies have investigated the associations between perfusion imaging parameters and proliferative potential of malignant gliomas. Tumour cellularity or cell density is a histologic method to quantify the number of tumour cells. Moderate correlations between DSC-MR or DCE-CT parameters and tumour cellularity ($0.4 < r < 0.6$) were reported (122,123) (Table 1-4). However, cell density cannot distinguish between proliferative,
apoptotic, and senescence cells. Ki-67 or MIB-1 are cellular markers of proliferation, and moderate correlations with DSC-MR parameters have been reported \( r > 0.6 \) (131,132).

### 1.9.2 Differentiation of Tumour Grade

Stereotactic biopsy of tumour specimens for grading can be prone to sampling error. In a study that compared biopsied specimens with surgically resected specimens, as much as 60\% of anaplastic astrocytoma (WHO grade III) were upgraded to GBM (137). Imaging techniques that can determine tumour aggressiveness can provide complementary information to establish grade and guide biopsy to sample the most anaplastic part of the tumour. Functional image-guidance can potentially improve the accuracy of diagnosis.

We found 20 studies that reported the sensitivities and specificities of using perfusion imaging to differentiate high versus low grade gliomas (Table 1-5). The sensitivities ranged from 68 to 100\% and specificities ranged from 40 to 100\% (138–157). Different thresholds were used for differentiating high from low grade gliomas. Thus, while perfusion imaging showed promise for grading, standardization of imaging protocols and consensus thresholds for differentiating tumour grade need to be established.

Not all malignant gliomas are enhancing on post-gadolinium T1-weighted MR images. About 9\% of malignant gliomas lack contrast-enhancement and can be mistaken as low-grade gliomas that do not enhance (158). Perfusion imaging can be an important tool in this regard. Using DSC-MR, patients with non-enhancing anaplastic gliomas (WHO grade III) had significantly higher nBV than those with low-grade astrocytomas (WHO grade II) (159). In a study using DCE-CT, nBV demonstrated a sensitivity and specificity of 90.9\% and 83.3\% for differentiating non-enhancing grade III vs. II gliomas (157).
Table 1-5: Summary of sensitivities and specificities of perfusion imaging in differentiating high grade versus low grade gliomas.

<table>
<thead>
<tr>
<th>Modality</th>
<th>Parameter</th>
<th>Median sensitivity and specificity (ranges) (%)</th>
<th>References†</th>
<th>Key points from the literature</th>
</tr>
</thead>
<tbody>
<tr>
<td>DSC-MR</td>
<td>nBV</td>
<td>Sensitivity: 94 (67 – 100) Specificity: 86 (50 – 100)</td>
<td>(138–151)</td>
<td>• Regions-of-interest are usually placed in visually contrast-enhancing regions only</td>
</tr>
<tr>
<td></td>
<td>nBF</td>
<td>Sensitivity: 86 (73 – 100) Specificity: 95 (91 – 100)</td>
<td>(138,142)</td>
<td>• BV and BF values are generally higher in high-grade gliomas than low-grade gliomas.</td>
</tr>
<tr>
<td>DCE-MR</td>
<td>K_{trans}</td>
<td>Sensitivity: 89 (89 – 89) Specificity: 79 (75 – 82)</td>
<td>(152,153)</td>
<td>• Permeability values (i.e. PS and K_{trans}) are higher in high-grade gliomas than low grade gliomas.</td>
</tr>
<tr>
<td></td>
<td>V_p</td>
<td>Sensitivity: 68 (N/A) Specificity: 89 (N/A)</td>
<td>(153)</td>
<td>• Oligodendrogliaomas may demonstrate foci with high blood volume regardless of tumour grade.</td>
</tr>
<tr>
<td></td>
<td>V_e</td>
<td>Sensitivity: 82 (N/A) Specificity: 94 (N/A)</td>
<td>(152)</td>
<td>• Optimal thresholds for differentiating high grade versus low grade gliomas have not been tested in a prospective study</td>
</tr>
<tr>
<td>DCE-CT</td>
<td>BV</td>
<td>Sensitivity: 89 (83 – 100) Specificity: 92 (75 – 100)</td>
<td>(154–157)</td>
<td>• Standardization of imaging protocol is need to reduce the variability in sensitivity and specificity observed in studies</td>
</tr>
<tr>
<td></td>
<td>K_{trans}</td>
<td>Sensitivity: 97 (N/A) Specificity: 100 (N/A)</td>
<td>(156)</td>
<td></td>
</tr>
<tr>
<td>Modality</td>
<td>Parameter</td>
<td>Median sensitivity and specificity (ranges) (%)</td>
<td>References‡</td>
<td>Key points from the literature</td>
</tr>
<tr>
<td>----------</td>
<td>-----------</td>
<td>-----------------------------------------------</td>
<td>-------------</td>
<td>-------------------------------</td>
</tr>
</tbody>
</table>
| PS       | Sensitivity: 100 (N/A)  
Specificity: 83 (N/A) | (154) |                     |
| MTT      | Sensitivity: 93 (N/A)  
Specificity: 40 (N/A) | (155) |                     |

Abbreviations: nBV, normalized blood volume; nBF, normalized blood flow; $K_{trans}$, transfer constant between blood plasma and extravascular extracellular space; $V_p$, volume of ‘flowing’ blood within the vasculature per unit mass; $v_e$, volume of extravascular extracellular space per unit volume of tissue; PS, permeability-surface area product; MTT, mean transit time; DSC-MR, dynamic-susceptibility contrast magnetic resonance; DCE-MR, dynamic contrast-enhanced magnetic resonance; DCE-CT, dynamic contrast-enhanced computed tomography; N/A, not applicable.

‡nBV refers to mean or maximum nBV

†BV and BF refers to absolute or normalized BV and BF, respectively
Almost all low-grade gliomas eventually progress to high-grade gliomas at an unpredictable time. In a cohort of low-grade glioma patients that received repeated DSC-MR, a continuous increase in nBV was found in those with malignant transformation up to the point when contrast-enhancement became apparent on post-gadolinium T1-weighted images. The nBV for transformers significantly increased to 5.36 at the time of transformation \((p < 0.05)\), while nBV remained stable and increased to only 1.52 in non-transformers \((p > 0.05)\) (160). Together, these studies suggest perfusion imaging is a useful method for grading gliomas even in cases where the tumours lack contrast-enhancement, and can be an important tool for active surveillance of low grade gliomas.

Perfusion imaging differentiation of tumour grade in oligodendroglial tumours should be interpreted with caution. Oligodendroglial tumours can have higher BV than astrocytic tumours irrespective of tumour grade (161) while high grade oligodendroglial tumours may or may not have higher BV than low grade oligodendroglial tumours (161,162). Thus, perfusion imaging of oligodendroglial tumours should be considered separately from astrocytic tumours, and perfusion imaging alone is not reliable for differentiating oligodendroglial tumour grade.

1.9.3 Differentiation of Malignant Brain Lesions

Solitary brain metastases with no history of primary cancer are found in approximately 15% of patients and may appear similar to primary malignant gliomas on MR images (163). We found 18 studies that used perfusion imaging to differentiate brain metastases from malignant gliomas. Two factors should be considered when using perfusion imaging to differentiate these two entities. Firstly, current evidence suggests that BV in the contrast-enhancing lesion of metastasis depends on the site of origin. Metastases from melanoma and renal carcinoma are reported to have higher BV than malignant gliomas (164). Studies that considered different sites of origin as one entity (or those that did not mention the sites of origin) showed that BV of the enhancing metastatic lesions were either similar (165–168) or lower (141,169,170) than malignant gliomas. For
example, nBV in studies with mostly lung and breast cancer metastases may be similar to (164,171) or lower than malignant gliomas (141,169). Together, these studies suggest that the differentiation of brain metastasis from malignant glioma based on BV of the contrast-enhancing lesion alone is challenging.

Secondly, BV in the non-enhancing lesion shows more promise for distinguishing metastases from primary malignant gliomas. The non-enhancing lesion is the hyperintense region on T2 or FLAIR images outside the contrast-enhancing lesion. BV in the non-enhancing lesion of brain metastases were lower than that of malignant gliomas (141,166,170–177). T2/FLAIR changes primarily represent edema without tumour infiltration in brain metastases (178). In contrast, the high BV in the non-enhancing lesion of malignant gliomas can be attributed to their aggressive and infiltrative growth, which often extends into the T2-hyperintense region. The median sensitivity and specificity for distinguishing the two entities using non-enhancing lesion nBV were 90% (range, 77 – 100%) and 95% (64 – 100%), respectively (141,169,170). In contrast, the median sensitivity and specificity for contrast-enhancing lesion nBV were 87% (80 – 91%) and 72% (64 – 88%), respectively (141,171,174–176).

Perfusion imaging has also been used to differentiate malignant gliomas from other primary brain tumours. These included differentiating primary lymphomas from malignant gliomas (165,168,176,177,179–183), meningiomas from malignant gliomas (165,167,184), hemangioblastomas from malignant gliomas (165), and schwannomas from malignant gliomas (165). A few studies have used perfusion imaging to differentiate subtypes of primary brain tumours (161,185–189). Grade II and III oligodendroglial tumours showed higher nBV than both grade II and III oligoastrocytic and astrocytic tumours, and oligoastrocytic tumours showed higher maximum nBV than astrocytic tumours (161). A sensitivity and specificity of 100 and 88% were found when nBV was used to differentiate grade II and III oligodendroglial tumours from astrocytic tumours. Although there were differences in BV between different types of primary brain tumours, the number of brain tumour types make this method of differentiation impractical.
1.9.4 Differentiation of Progression from Post-treatment Effects

A change in the size of the contrast-enhancing tumour is used as a radiologic measure of progression, but it can be confounded by other causes of contrast enhancement. Pseudoprogression and treatment-induced necrosis (TIN) are post-treatment scenarios with a better prognosis than true progression, but their changes in contrast enhancement can be indistinguishable from progression. Erroneous diagnosis of pseudoprogression or TIN as tumour progression can lead to unnecessary treatment or premature abandonment of treatment while the opposite scenario will delay treatment.

Pseudoprogression occurs in 20 – 30% of malignant glioma patients treated with chemoirradiation and manifests as a transient increase in tumour contrast-enhancement at one to three months post-treatment that eventually subsides (92,190,191). Although its pathophysiology remains unclear, chemoirradiation is believed to induce a transient local inflammatory reaction, edema and increased vessel permeability, which manifests as increased contrast-enhancement (192). Using DSC-MR, true progression showed a higher maximum nBV than pseudoprogression when confirmed by radiologic and clinical follow-ups (sensitivity and specificity of 81.5% and 77.8%, respectively) (191,193). Another study showed that both nBV and normalized peak height (definition in Table 1-2) could distinguish pseudoprogression from progression with sensitivities and specificities ≥ 75% (194). Histogram analysis of nBV to characterize percent changes in nBV skewness and kurtosis is also a potential biomarker to differentiate pseudoprogression from true progression (195).

In a prospective study, a decrease in nBV at week three of chemoirradiation was associated with a higher risk of early progression (190). It is unclear why a decrease in nBV during chemoirradiation is associated with progression (190) while a higher nBV is found at the time of progression in other studies (191,193). These results suggest that the vascular response to chemoirradiation is complex, and the time of imaging must be considered when using perfusion imaging to distinguish between tumour progression and pseudoprogression.
TIN occurs three to 12 months after radiotherapy in 3 – 24% of patients (192). Histopathologic confirmation of necrosis and recurrence were available in some or all of the patients in each study. Table 1-6 summarizes the performance of 12 perfusion imaging studies for differentiating TIN from progression (118,196–206). Radiation-induced necrosis and pseudoprogression were collectively defined as radiation-induced injury in eight DSC-MR studies (196,207–213). Mean and maximum nBV were reported to differentiate radiation-induced injury from true progression with sensitivities and specificities ranging from 86 – 100% and 80 – 100%, respectively (207–213). Radiation-induced injury and true progression often co-exist in patients. Hu et al. showed that DSC-MR was able to estimate the fractional tumour burden (i.e. progression) and post-treatment effect (i.e. radiation-induced injury) within the same MR contrast-enhancing lesion (213). This fractional tumour burden strongly correlated with the histologic tumour fraction obtained from stereotactic biopsy ($r = 0.82$, $P < 0.0001$) and correlated with the OS ($P < 0.02$). These results demonstrate that DSC-MR may be a useful clinical tool to differentiate progression from post-treatment effects.

Table 1-6: Differentiation between treatment-induced necrosis and true progression.

<table>
<thead>
<tr>
<th>Modality</th>
<th>Parameter</th>
<th>Sensitivity and specificity ranges (%)</th>
<th>References’</th>
</tr>
</thead>
<tbody>
<tr>
<td>DSC-MR</td>
<td>nBV</td>
<td>Sensitivity: 67 – 100% Specificity: 70 – 100%</td>
<td>(118,196–200)</td>
</tr>
<tr>
<td>DSC-MR</td>
<td>% Recovery</td>
<td>Sensitivity: 78% Specificity: 76%</td>
<td>(198)</td>
</tr>
<tr>
<td>DSC-MR</td>
<td>Peak Height</td>
<td>Sensitivity: 89% Specificity: 81%</td>
<td>(198)</td>
</tr>
<tr>
<td>DCE-MR</td>
<td>$K_{trans}$</td>
<td>Sensitivity: 100% Specificity: 83%</td>
<td>(202)</td>
</tr>
<tr>
<td>DCE-MR</td>
<td>iAUC</td>
<td>Sensitivity: 71 – 85% Specificity: 71 – 78%</td>
<td>(201,202)</td>
</tr>
</tbody>
</table>
|                  | mAUCR$_H$   | Sensitivity: 94%
Specificity: 88% | (203) |
|------------------|-------------|-------------------------------|------|
| Normalized       |             | Sensitivity: 95%
maximum slope Specificity: 78% | (201) |
| BV               |             | Sensitivity: 100%
Specificity: 100%     | (204) |
|                  | BF          | Sensitivity: 94%
Specificity: 88%     | (206) |
|                  | BV          | Sensitivity: 82 – 83%
Specificity: 90 – 100% | (205,206) |
|                  | PS          | Sensitivity: 82%
Specificity: 82%     | (205) |
|                  | MTT         | Sensitivity: 94%
Specificity: 75%     | (206) |

**Abbreviations:** DSC-MR, dynamic susceptibility-contrast magnetic resonance; DCE-MR, dynamic contrast-enhanced magnetic resonance; DCE-CT, dynamic contrast-enhanced computed tomography; nBV, normalized blood volume; $K^{trans}$, transfer constant between blood plasma and extravascular extracellular space; iAUC, initial area under curve; mAUCR$_H$, see Table 1-2 for definition; BF, blood flow; PS, permeability-surface area product; MTT, mean transit time.

*nBV refers to mean or maximum nBV

### 1.9.5 Survival after Radiotherapy and Chemotherapy

The value of perfusion imaging in predicting progression-free survival (PFS) and OS has been investigated in numerous studies (124,130,140,148,214–237). The interpretation of perfusion imaging data for predictive survival depends on treatment regimen and imaging schedule. Three perfusion imaging schedules for predicting outcomes have been reported; they are 1) pre-treatment, 2) pre-treatment + mid-treatment, and 3) pre-treatment + post-treatment.
When pre-chemoirradiation DSC-MR images were considered, a higher mean and maximum nBV were associated with poor PFS and OS for gliomas of all grades (140,148,216,221–224,228,235,236). This is also true for gliomas of the same grade. The 2-year OS rate for grade III astrocytomas was significantly lower for patients with maximum nBV > 2.3 (33% vs. 100%, \( P < 0.01 \)), and it was also lower for GBM (5% vs. 25%, \( P = 0.013 \)) (221). Using DCE-CT, a combination of high BV and PS was associated with poor OS for grade III and IV gliomas and grade IV gliomas alone (232,233). In patients with GBM, \( k_{ep} \) values \( \leq 1.2 \), between 1.21 – 2.0, and > 2.0 min\(^{-1} \) had 1-year OS rate of 59%, 33%, and 15%, respectively (\( P \) value was not reported) (130). These studies suggest that pre-treatment BV, PS, and \( k_{ep} \) were associated with more aggressive phenotypes that conferred poor survival.

The prognostic value of comparing pre- and mid-radiotherapy perfusion imaging parameters have been investigated (215,219,220). Based on parametric response map analysis, a decrease in tumour BV and blood flow (BF) at one and three weeks into chemoirradiation were predictive of poor OS (219,220). Specifically, patients with > 6.8% of tumour volume showing a decrease in nBV had shorter OS than those with \( \leq 6.8\% \) of tumour volume showing a decrease in nBV (median OS = 7.1 and 20.4 months, respectively; \( P = 0.001 \)) (219). A drop in BV during treatment suggest increased tumour hypoxia leading to resistance to chemoirradiation. These studies suggest DSC-MR can potentially identify patients with poor survival even before the completion of chemoirradiation.

Tumour perfusion after the completion of chemoirradiation and its association with survival have also been investigated (225–227,231,237). An increase in maximum nBF between baseline and follow-up (Hazard ratio [HR] = 2.67, \( P = 0.010 \)) was a better prognosticator of shorter PFS than an increase in tumour diameter (HR = 1.14, \( p = 0.049 \)) (231). At one month post-radiotherapy, Mangla et al. showed that an increase in nBV was predictive of poor 1-year OS (sensitivity = 90% and specificity = 69%) while tumour size was not (227). One study showed that perfusion imaging was not predictive of survival while T1 and T2-weighted tumour diameters were (225). Using Ferumoxytol as the contrast agent, post-radiotherapy tumour nBV predicted patients with longer OS (\( P <
0.001) (237). In the non-enhancing lesion, Li et al. showed that a higher median nBV immediately after radiation was associated with shorter PFS \((p = 0.026)\) (226).

In summary, a high BV before and after chemoirradiation and a decrease in BV during chemoirradiation were associated with poor survival. A high BV before and after treatment is characteristic of tumour growth and progression, while a decrease in BV during treatment could be indicative of tumour hypoxia.

### 1.9.6 Survival After Anti-angiogenic Therapies

Radiologic assessment of response to anti-angiogenic agents, especially those that target VEGF, should be interpreted with caution because a drop in contrast-enhancement is not necessarily indicative of true response (i.e. pseudoresponse) (92). Batchelor et al. showed that patients treated with Cediranib demonstrated decreased gadolinium enhancement as early as one day after the initiation of treatment despite considerable variability in tumour response (238). Given the vascular effects of anti-angiogenic agents, perfusion imaging could play an important role in assessing response to these agents.

For recurrent GBM, high nBV and \(K_{trans}\) prior to anti-VEGF monotherapy or in combination with Temozolomide were associated with poor survival (239,240). Tumour BF (238), nBV (238,241), \(K_{trans}\) (238,240,242–246), and \(v_e\) (238,242,243,247) decreased shortly after the initiation of Bevacizumab or Cediranib. In the non-enhancing lesion, nBV could also decrease after Bevacizumab treatment suggesting an anti-edema effect (statistical significance was not reported) (248).

There is no consensus on whether a decrease in these parameters is a positive prognosticator. A decrease in \(K_{trans}\) and nBV after Bevacizumab treatment did not show a significant association with PFS or OS in some studies (239,240,246). In another study, a decrease in tumour subvolume with nBV > 1.00 after Bevacizumab treatment was associated with longer time-to-progression (229). A reduction in \(K_{trans}\) after Cediranib treatment was associated with improved PFS and OS (244). A moderate correlation
(Spearman’s $\rho = 0.58$, $P = 0.036$) between OS and $K^{\text{trans}}$ at 1 week after stereotactic radiosurgery and Bevacizumab was reported in patients with recurrent malignant gliomas (234).

The inconsistent relationships between perfusion imaging parameters and survival suggest that not all patients responded equally to anti-angiogenic agents. Sorensen et al. showed that 25% of patients with recurrent GBM treated with Cediranib exhibited elevated perfusion, and these patients had higher PFS and OS than those with stable or decreased perfusion (230,238,244). This was demonstrated again in patients with newly diagnosed GBM that were treated with radiotherapy, Temozolomide, and Cediranib. Patients with increased perfusion had a significantly longer median OS than patients with decreased perfusion (OS = 504 vs. 321 days; log-rank $P < 0.05$) (249). Increased perfusion was also associated with improved tumour oxygenation, which could potentially improve the sensitization of tumour cells to chemoirradiation and enhance the delivery of Temozolomide to the tumour. In a study involving patients with recurrent malignant gliomas, independent component analysis of DSC-MR images was used to characterize the extent of abnormal vasculature before and after Bevacizumab treatment. A decrease in the arterio-venous overlap (i.e. a decrease of abnormal vasculature) was associated with longer OS in these patients ($P < 0.04$), whereas a change in the tumour volume and nBV was not predictive of OS (250). These results suggest that perfusion imaging may be a tool for selecting the appropriate patients for anti-angiogenic therapies.

1.9.7 Future of Perfusion Imaging

Our review reflected the results from more than 6500 brain tumour patients scanned using CT or MR perfusion. These studies were primarily conducted in small cohorts of patients ($\text{median} N = 31$ patients) in a research setting. Different perfusion imaging protocols were used, and these variations could have led to uncertainties in the measurements of different perfusion imaging parameters (117,251). Standardization of imaging protocol is very important for incorporating perfusion imaging into prospective multi-institutional trials (252). In addition, different perfusion imaging software packages
were used in these studies. It has been shown that BF and BV values calculated from different commercial software packages can deviate from the true values (253). The uncertainties in the acquisition and analysis of these perfusion imaging studies make optimization and standardization difficult.

In a clinical trial, the imaging protocol should be consistent across the study population. The software and version used to calculate tumour perfusion parameters should also be consistent and reported. Quality control should be performed to ensure consistency in image quality. For example, the Radiation Therapy Oncology Group (RTOG) 0825 trial comparing “radiation + Temozolomide” versus “radiation + Temozolomide + Bevacizumab” is incorporating DSC-MRI and DCE-MRI to study these patients. Participating sites must be qualified through the American College of Radiology Imaging Network (ACRIN). The participating site must perform all advanced MR (e.g. perfusion MR) scans following the protocol-specific parameters, and one set of test MR images acquired from the designated MR scanner must be approved by ACRIN. This study will yield valuable information on the value of serial perfusion imaging.

Our literature review on perfusion imaging showed that perfusion changes in response to chemoirradiation and in combination with anti-angiogenic therapies are complex. Optimization and standardization of image acquisition and analysis can help facilitate the implementation of perfusion imaging in clinical settings. Serial imaging of perfusion changes in response to treatment will improve the understanding of the effect of treatment on tumour hemodynamics, and determine the optimal time for evaluating response and prognosis in patients.

1.10 Animal Models of Malignant Glioma

Animal models of brain tumours play very important roles in understanding the pathophysiology cancer, and in evaluating the safety and efficacy of treatments. There are three general categories of brain tumour models: 1) xenograft models, 2) chemically induced syngeneic models, and 3) genetically engineered mouse models (254). Rat
models have several advantages over mouse models. The rat brain is about three times larger than the mouse brain (1200 vs. 400 mg, respectively) (255). This allows more precise implantation of tumour cells in rat brains and stereotactic radiosurgery of tumours. A larger brain also permits a longer time period for tumour growth before death, and better visualization and localization of the tumour using a variety of imaging modalities. In addition, there are more in vitro and in vivo studies of rat brain tumours than mouse brain tumours (255).

Xenograft tumour models refer to the growth of human brain tumours within the brains of immunodeficient rats. For example, the U87MG cell line is a commonly used xenograft GBM model. These models exhibit some features of human GBMs, including the expression of mutated genes and display some levels of angiogenesis. However, they do not display many characteristics that are typical in human GBM. For instance, growth patterns are often circumscribed with limited single cell infiltration that are not as extensive as spontaneous human GBM (256,257). Necrosis and microvascular abnormalities, which are typical in human GBM, are also limited or absent in many human cell-derived xenografts (254,256,257).

Chemically induced syngeneic rat models have been used extensively since the 1970s (255). Popular examples include C6, 9L, BT4C, F98, RT-2, and CNS-1 gliomas (255). The C6 glioma model was created by administering methylNitrosourea to rats (258,259). It was morphologically similar to GBM, and showed overexpression of many genes that are also overexpressed in human gliomas. This model has been widely used to evaluate the safety and efficacy of a variety of treatments including radiotherapy (260–262), chemotherapy (263,264), and anti-angiogenic therapy (265,266). Chemically induced syngeneic models can grow in immunocompetent rats; thus, spontaneous tumour rejection is a drawback. A previous report showed that 11% of rats survived after implantation of C6 glioma cells (267). Another drawback of chemically induced syngeneic models is their growth patterns. For example, both C6 and 9L tumour models demonstrate circumscribed masses as opposed to the highly infiltrative growth of human gliomas (255). Despite these drawbacks, the C6 model remains attractive because it is useful for the study of glioblastoma growth, angiogenesis, and development of new
therapies (266). The C6 glioma model is used in the preclinical work presented in this thesis.

1.11 Research Goals and Objectives

The work presented in this thesis is focused on two major goals: 1) improving measurements of DCE-CT parameters, and 2) using DCE-CT to assess treatment response in malignant gliomas. This was accomplished by achieving the following objectives which span the spectrum from technical optimization to preclinical imaging to pilot clinical studies:

1. To improve the measurements of BF, BV, and PS by evaluating the effect of DCE-CT scan duration on these measurements.

2. To reduce measurement errors of BF, BV, and PS by filtering DCE-CT images using principal component analysis.

3. To show that DCE-CT can be used as a potential early imaging biomarker of response to stereotactic radiosurgery in the C6 malignant rat glioma model.

4. To assess the relationship between DCE-CT imaging measurements and eventual sites of tumour progression in patients with malignant gliomas.

5. To correlate patient survival with DCE-CT and MR volumetric imaging measurements.
1.12 Thesis Outline

1.12.1 The Effect of Scan Duration on the Measurement of DCE-CT Parameters (*Chapter 2*)

Scan duration is a key factor that influences the measurement of different perfusion parameters. We investigated the effect of scan duration on BF, BV, and PS measurements in human gliomas and evaluated the systematic and random errors associated with reduced scan durations. This chapter is adapted from the published paper entitled “The effect of scan duration on the measurement of perfusion parameters in CT perfusion studies of brain tumours”, published in *Academic Radiology* 20(1): 69-65 (2013) by Yeung TPC, Yartsev S, Bauman G, He W, Fainardi E, and Lee TY.

1.12.2 Improving Quantitative DCE-CT Measurements Using Principal Component Analysis (*Chapter 3*)

The measurements BF, BV, and PS are affected by DCE-CT image contrast-to-noise ratio (CNR). We validated whether principal component analysis (PCA) filtering can improve the accuracy and precision of these measurements by using a digitally designed CT phantom. We then evaluated the improvement in image CNR and changes in tumour BF, BV, and PS after filtering DCE-CT images of tumour bearing rats. This chapter is adapted from the published paper entitled “Improving quantitative CT perfusion parameter measurements using principal component analysis”, published in *Academic Radiology* 21(5): 624-632 (2014) by Yeung TPC, Dekaban M, De Haan N, Morrison L, Hoffman L, Bureau Y, Chen X, Yartsev S, Bauman G, and Lee TY.
1.12.3 DCE-CT Imaging as an Early Biomarker of Differential Response to Stereotactic Radiosurgery (Chapter 4)

Stereotactic radiosurgery delivers radiation in one or few large dose fractions of 8 to 30 Gy that can result in vascular damage. Timely and accurate assessment of tumour response is crucial for treatment modification if no response to radiation is detected. This chapter evaluated serial vascular changes following stereotactic radiosurgery using DCE-CT, and determined whether DCE-CT can be an early predictor of survival. This chapter is based on the paper entitled “CT perfusion imaging as an early biomarker of differential response to stereotactic radiosurgery”, which will be submitted to the journal PLOS ONE in July 2014 by Yeung TPC, Kaurdi M, Wang Y, Al-Khazraj B, Morrison L, Hoffman L, Jackson D, Crukley C, Lee TY, Bauman G, and Yartsev S.

1.12.4 Relationship of DCE-CT and PET to Tumour Progression in Malignant Glioma (Chapter 5)

Over 80% of malignant gliomas progress within 2 cm of the irradiated volume after chemoirradiation. Although an increase in the size of the contrast-enhancing lesion is one of the criteria for diagnosing progression, early changes in contrast-enhancement during and after radiotherapy lack utility in identifying active tumour sites that are likely to persist and progress. This chapter investigates whether multiparametric imaging with DCE-CT and 18F-Flurodeoxyglucose PET can identify tumour sites that are likely to correlate to the eventual sites of tumour progression. The chapter is based on the published paper entitled “Relationship of computed tomography perfusion and positron emission tomography to tumour progression in malignant glioma”, published in the Journal of Medical Radiation Sciences 61(1): 4-13 (2014) by Yeung TPC, Yartsev S, Lee TY, Wong E, He W, Fisher B, VanderSpek L, Macdonald D, and Bauman G.
1.12.5 Treatment Monitoring of Malignant gliomas in using DCE-CT and MR (Chapter 6)

Using DCE-CT, this is the first study to evaluate serial changes in tumour BF, BV, and PS in the contrast-enhancing lesion and the non-enhancing lesion of patients with malignant gliomas for up to a year after radiotherapy. This study also tested the predictive values of these data in relation to OS. The chapter is based on the paper entitled “Treatment monitoring in high-grade gliomas: A serial CT perfusion and MR study”, which will be submitted to the Journal of Neuro-Oncology in July 2014 by Yeung TPC, Wang Y, Urbini B, Yartsev S, Bauman G, Lee TY, Fainardi E, and The Project of Emilia-Romagna region on Neuro-Oncology (PERNO) study group.

1.12.6 Conclusion and Future Work (Chapter 7)

In the final chapter, major findings of this thesis are summarized, and their clinical and experimental relevance are discussed. Future investigations pertaining to perfusion imaging of brain tumours are proposed.

1.13 References


64. Dewhirst MW. Intermittent hypoxia furthers the rationale for hypoxia-inducible factor-1 targeting. Cancer Res. 2007; 67:854–5.


184. Hakyemez B, Yildirim N, Erdoğan C, Kocaeli H, Korfali E, Parlak M. Meningiomas with conventional MRI findings resembling intraaxial tumors: Can


211. Hu LS, Baxter LC, Smith KA, et al. Relative cerebral blood volume values to differentiate high-grade glioma recurrence from posttreatment radiation effect:


Chapter 2

2 The Effect of Scan Duration on the Measurement of Perfusion Parameters in CT Perfusion Studies of Brain Tumours

This chapter is adapted from the research article, “The effect of scan duration on the measurement of perfusion parameters in CT perfusion studies of brain tumours” published in Academic Radiology, 2013;20(1):59-65 by Yeung TPC, Yartsev S, Bauman G, He W, Fainardi E, Lee TY.

2.1 Introduction

Malignant gliomas are highly aggressive brain tumours that are characterized by increased vascularity with immature and highly permeable blood vessels (1). Given that blood-brain barrier disruption and neovascularity play an essential role in the progression of malignant gliomas, recent studies have investigated the use of perfusion imaging for evaluating brain tumours. Blood flow (BF), blood volume (BV), and permeability–surface area product (PS) obtained from computed tomography (CT) perfusion studies have been demonstrated to be useful in differentiating glioma grade (2–4) and distinguishing treatment-induced necrosis from recurrent or progressive tumours (5). CT perfusion parameters have also demonstrated correlations with microvascular cellular proliferation (6) and proangiogenic gene expressions (7).

Although CT perfusion may be helpful in providing important physiologic information for evaluating brain tumours, there is no consensus regarding the optimal scan protocol. A scan duration of ≥2 minutes has been suggested for accurate calculation of tumour permeability (8,9), but scan durations in the range of 45 to 199 seconds have been used to evaluate tumour perfusion parameters for brain and other tumour sites (7,10). For example, a 65-second scan was recommended when the Johnson-Wilson model was used for the calculation of permeability (ie, PS) in colorectal cancer (11),
while a scan duration of ≥40 seconds was recommended when the Patlak method was used to calculate permeability (ie, $K_{trans}$, transfer constant) in lung cancer (12).

Given that scan duration is a key factor influencing perfusion measurements, it would be beneficial to investigate the effect of scan duration on CT perfusion studies of brain tumours. Standardizing a CT perfusion protocol for diagnostic and research settings could facilitate comparison among different studies. We evaluated the effect of scan duration (≤150 seconds) on perfusion parameter measurements in human gliomas and evaluated the systematic and random errors associated with different reduced scan durations (<150 seconds) relative to the values obtained from the 150-second scans.

### 2.2 Materials and Methods

#### 2.2.1 CT Perfusion Imaging

The local research ethics boards approved this study, and all patients provided written informed consent prior to imaging. Patients ($n = 14$) with histopathologically confirmed malignant glioma (World Health Organization grade III and IV) underwent CT perfusion imaging. Eight patients were scanned on a hybrid positron emission tomography/CT scanner (Discovery VCT; GE Healthcare, Waukesha, WI) with a nonionic contrast bolus (Omnipaque, 300 mg iodine/mL, 60–70 mL; GE Healthcare, Princeton, NJ), and six patients were scanned on a CT scanner (GE LightSpeed VCT; GE Healthcare, Waukesha, WI) with a nonionic contrast bolus (Iomeron, 350 mg iodine/mL, 40 mL; Bracco Imaging Scandinavia, Göteborg, Sweden). A two-phase CT perfusion scan, guided by a prior noncontrast CT scan that identified eight 5-mm sections to maximally cover the tumour, was performed for each patient. The bolus of contrast was injected into the antecubital vein at a rate of 2 to 4 mL/s at 3 to 5 seconds after the first phase started. The preselected brain sections were scanned for 45 seconds at 1-second intervals during the first phase and for a period of 105 seconds at 15-second interval during the second phase. A tube current of 190 mA was used for the hybrid positron
emission tomography/CT scanner, and 100 mA was used for the CT scanner. All patients were scanned at 80 kVp with a 25-cm field of view.

2.2.2 Image Analysis

The 150-second human CT perfusion studies were truncated to scan times of 120, 90, and 60 seconds to simulate the effect of shorter scans. Fifty-six CT perfusion studies were analyzed using the prototype version of CT Perfusion 4D (GE Healthcare, Waukesha, WI), which is based on the Johnson-Wilson model and is insensitive to the delay between arterial and tissue time-attenuation curve (TAC) to generate maps of BF, BV, and PS.

For each patient, the arterial and venous regions of interest (ROIs) were automatically chosen by the software from the 150-second study, and the same ROIs were used for the truncated studies to minimize estimated parameter variability due to differences in arterial and venous TACs. The arterial and venous ROIs were usually found in one of the anterior cerebral arteries and the posterior superior sagittal sinus, respectively. Partial volume averaging of the arterial TAC was corrected using the venous TAC as a reference (8). Tissue TACs were measured from 2 × 2 pixel blocks of CT images. Parametric maps of BF, BV, and PS were calculated by deconvolving the arterial TAC with each tissue TAC using the Johnson-Wilson model (8). The generation of parametric maps was repeated for different scan durations by using the same arterial and venous ROIs for each patient. ROIs of 15 mm² were randomly placed in the normal white and gray matter and contrast-enhanced tumour rim and nonenhancing tumour core to measure BF, BV, and PS (20 ROIs per tissue).

2.2.3 Measurement Errors of Perfusion Parameters Due to Truncation

We used the systematic and random errors to evaluate the mean and standard deviation of measurement errors associated with a reduced scan time relative to the 150-
second scan time, respectively. The differences between parameter values obtained from the original study and the truncated study in the same ROI of the same tissue type were accepted as the measurement error. The mean and standard deviation of measurement errors were, respectively, the systematic and random errors for each tissue type for each patient.

We also used the percentage error to examine whether the differences in parameter values associated with a reduced scan time were clinically meaningful. The percentage error for each parameter in each ROI was calculated using the equation

\[
\text{Percent Error(\%)} = \frac{|\text{value from a shorter scan} - \text{value from the original scan}|}{(\text{value from a shorter scan} + \text{value from the original scan})/2} \times 100
\]

(2.1)

### 2.2.4 Statistical Analysis

Values of BF, BV, and PS were first transformed using the Box-Cox transformation to obtain a normal distribution (13). The normality of the Box-Cox-transformed data for each parameter and each tissue type was checked using the Shapiro-Wilk test \((P > .05)\). Student's \(t\) test confirmed that there was no difference between the hybrid positron emission tomography/CT and CT scanners when measuring BF, BV, and PS in the different tissue types at 150 seconds \((P > .05)\). Differences in each parameter obtained from different scan durations were tested using repeated-measures analysis of variance with post hoc paired \(t\) test and Bonferroni correction applied. Systematic and random errors were correlated with scan durations using Spearman’s rank correlation. All statistical tests were done using SPSS version 19.0 (SPSS, Inc, Chicago, IL), and \(P\) values < .05 were considered significant.

### 2.3 Results

Box plots of BF, BV, and PS values of different tissue types measured from different scan durations are shown in Figure 2-1. BF and BV values were not affected by
shorter scan durations ($P > .05$). PS values in the tumour rim at 60 seconds were significantly higher than in the 150-second scans ($P < .01$). Median percentage errors and interquartile ranges associated with different scan durations are presented in Table 2-1. Median percentage error was highest at 60 seconds for tumour core PS (median, 32.1%; interquartile range, 16.5%–43.0%). Systematic and random errors associated with different scan durations are displayed in Figure 2-2 and Figure 2-3, respectively. Tumour rim BV and PS and tumour core BF systematic errors were correlated with scan durations ($r = 0.42$, $−0.50$, and $−0.50$, respectively; $P < .01$). Random errors were negatively correlated with scan durations for all tissue types ($P ≤ .01$) except for white matter BV (Table 2-2). Figure 2-4 demonstrates the visual differences in the maps of BF, BV, and PS due to scan-time truncation in a sample patient.

Figure 2-1: Box plots of (a) blood flow (BF), (b) blood volume (BV), and (c) permeability–surface area product (PS) values measured from different scan durations. Outliers (circles) are defined as data that are 1.5 box lengths away from the 25th or 75th quartile. *Significantly different from the 150-second scan ($P < .01$).
Table 2-1: Median (interquartile range) percentage errors associated with scan durations of < 150 seconds.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Scan Duration (seconds)</th>
<th>Gray Matter</th>
<th>White Matter</th>
<th>Tumor Rim</th>
<th>Tumor Core</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blood flow</td>
<td>60</td>
<td>2.7 (1.9-4.5)</td>
<td>4.3 (3.3-6.9)</td>
<td>7.9 (6.0-10.3)</td>
<td>10.6 (8.7-16.8)</td>
</tr>
<tr>
<td></td>
<td>90</td>
<td>2.4 (1.5-3.3)</td>
<td>2.9 (2.6-4.4)</td>
<td>4.7 (3.1-6.3)</td>
<td>6.1 (5.2-7.1)</td>
</tr>
<tr>
<td></td>
<td>120</td>
<td>1.6 (1.2-2.2)</td>
<td>2.3 (2.0-2.9)</td>
<td>3.2 (2.5-3.8)</td>
<td>4.0 (2.6-6.8)</td>
</tr>
<tr>
<td>Blood volume</td>
<td>60</td>
<td>1.0 (0.7-2.0)</td>
<td>2.1 (1.5-3.1)</td>
<td>5.8 (4.8-7.5)</td>
<td>13.9 (8.1-21.4)</td>
</tr>
<tr>
<td></td>
<td>90</td>
<td>0.9 (0.6-1.1)</td>
<td>1.6 (1.1-3.0)</td>
<td>3.3 (2.4-4.3)</td>
<td>7.6 (4.7-9.6)</td>
</tr>
<tr>
<td></td>
<td>120</td>
<td>0.5 (0.4-0.9)</td>
<td>0.9 (0.7-1.6)</td>
<td>2.0 (1.4-2.4)</td>
<td>4.2 (2.4-6.9)</td>
</tr>
<tr>
<td>Permeability–surface area product</td>
<td>60</td>
<td>29.2 (21.3-32.8)</td>
<td>28.7 (24.2-34.3)</td>
<td>21.9 (17.1-29.6)</td>
<td>32.1 (16.5-43.0)</td>
</tr>
<tr>
<td></td>
<td>90</td>
<td>22.0 (15.4-30.6)</td>
<td>21.7 (12.6-27.6)</td>
<td>11.3 (7.9-16.0)</td>
<td>19.3 (11.3-24.3)</td>
</tr>
<tr>
<td></td>
<td>120</td>
<td>15.5 (13.9-17.6)</td>
<td>16.6 (11.0-20.3)</td>
<td>6.4 (4.0-8.1)</td>
<td>9.6 (4.9-12.7)</td>
</tr>
</tbody>
</table>

Figure 2-2: Box plots of (a) blood flow (BF), (b) blood volume (BV), and (c) permeability–surface area product (PS) systematic errors associated with different scan durations. Outliers (circles) are defined as data that are 1.5 box lengths away from the 25th or 75th quartile. Extreme outliers that are three box lengths away from the quartiles are not displayed.

Figure 2-3: Box plots of (a) blood flow (BF), (b) blood volume (BV), and (c) permeability–surface area product (PS) random errors associated with different scan durations. Outliers (circles) are defined as data that are 1.5 box lengths away from the 25th or 75th quartile. Extreme outliers that are three box lengths away from the quartiles are not displayed.
Table 2-2: Spearman's rank correlation of systematic and random errors with scan duration.

<table>
<thead>
<tr>
<th>Error Type</th>
<th>Tissue Type</th>
<th>Blood Flow</th>
<th>Blood Volume</th>
<th>Permeability–Surface Area Product</th>
</tr>
</thead>
<tbody>
<tr>
<td>Systematic error</td>
<td>Gray matter</td>
<td>−0.01</td>
<td>−0.09</td>
<td>−0.10</td>
</tr>
<tr>
<td></td>
<td>White matter</td>
<td>−0.12</td>
<td>−0.06</td>
<td>−0.10</td>
</tr>
<tr>
<td></td>
<td>Tumor rim</td>
<td>−0.30</td>
<td>0.42</td>
<td>−0.50</td>
</tr>
<tr>
<td></td>
<td>Tumor core</td>
<td>−0.50</td>
<td>0.15</td>
<td>−0.13</td>
</tr>
<tr>
<td>Random error</td>
<td>Gray matter</td>
<td>−0.43</td>
<td>−0.34</td>
<td>−0.64</td>
</tr>
<tr>
<td></td>
<td>White matter</td>
<td>−0.47</td>
<td>−0.25</td>
<td>−0.56</td>
</tr>
<tr>
<td></td>
<td>Tumor rim</td>
<td>−0.50</td>
<td>−0.53</td>
<td>−0.62</td>
</tr>
<tr>
<td></td>
<td>Tumor core</td>
<td>−0.60</td>
<td>−0.46</td>
<td>−0.64</td>
</tr>
</tbody>
</table>

* *01 < P < .05.*

* *P < .01.*
Figure 2-4: Differences between perfusion maps obtained from a 150-second scan versus a 60-second scan. The 15-mm² regions of interest in the contrast-enhancing rim (1) and nonenhancing core (2) are displayed. Maps of blood flow (BF), blood volume (BV), and permeability–surface area (PS) are enlarged and centered at the tumour. White arrows point to regions with PS values that appeared to be higher at 60 seconds relative to 150 seconds. The window and level used for computed tomography, BF, BV, and PS were 20 to 100 Hounsfield units, 0 to 180 mL/min/100 g, 0 to 12 mL/100 g, and 0 to 25 mL/min/100 g, respectively.

2.4 Discussion

There is no consensus regarding the optimal CT perfusion scan duration, and durations of 45 to 199 seconds have been reported in the literature for calculating tumour perfusion parameters (7,10). This study sought to investigate the effect of scan duration on the measurements of BF, BV, and PS.

Perfusion parameters were calculated using the Johnson-Wilson model (8,14). It models the diffusion of a bolus of contrast across the capillary endothelium into the interstitial space as it traverses from the arterial to the venous end of a tissue region. A theoretical function, called the impulse residue function, represents the fraction of contrast that remains in the tissue as a function of time after a bolus injection of a unit amount of contrast into the arterial inlet. The impulse residue function has two distinct phases. The first phase is a rectangular function at a height of unity that represents the retention of the contrast in the tissue region, regardless of its distribution either in the vascular or extravascular space, before any venous outflow occurs. The duration (or width) of the first phase is the minimum transit time of this bolus. The second phase starts at a height of the extraction fraction at the minimum transit time and decays exponentially toward baseline with time. This describes the clearance of the extravasated
contrast from the interstitial space via back flux into the bloodstream. The BF-scaled impulse residue function is derived by deconvolving the arterial TAC with the tissue TAC (8). The peak value and area under the first phase of the BF-scaled impulse residue function are the BF and BV, respectively. PS is obtained using the equation $PS = -BF \times \ln(1 - \text{extraction fraction})$.

We did not find a statistical difference in BF and BV when comparing the 150-second to the 120-second, 90-second, and 60-second studies. Hirata et al (15) found that the first circulation time is approximately 40 seconds in brain tissue, and scanning up to the first circulation time is sufficient for measurements of BF and BV. Our results are consistent with their results and are expected given that a scan time of 60 seconds is well beyond the first circulation time of contrast through the brain and would permit an accurate determination of the first phase of the impulse residue function.

A scan time of 60 seconds is not adequate for the estimation of PS in brain tumour rim. The significantly higher permeability that we observed with a shorter scan is consistent with other studies (11,12). Goh et al (11) found that 45 seconds was too short for PS measurements in colorectal cancer. The longer scan time required could be explained by the fact that the accumulation of contrast in a brain tumour is much slower than that of colorectal cancer because PS is lower in a brain tumour. A longer scan duration is required to have sufficient signal-to-noise ratio to estimate PS values accurately and reproducibly. PS values in the normal brain, which should be close to zero, were unaffected by scan duration because the estimation algorithm was constrained only to give nonzero PS values.

The effect of scan duration on the systematic and random errors of CT perfusion parameters was also investigated. With the exception of white matter BV, the random error of perfusion parameter measurements increased with shorter scan duration. Systematic error in tumour rim BV and PS and tumour core BF also increased with shorter scan durations because fewer data were available for estimating BF, BV, and PS. The optimization algorithm for estimating these parameters was a constrained optimization algorithm, in which all parameters were constrained to give only values that
are zero or higher. The random error increased with a shorter scan time because the signal-to-noise ratio deteriorated with a shorter scan time. This is analogous to the decrease in the standard error when more samples are used to estimate the mean. With the use of a constrained optimization algorithm, the random error would not go up as much as a nonconstrained optimization process, because all parameter values had to be zero or higher. This constraint led to the increase in systematic bias that we observed when the signal-to-noise ratio deteriorated with reduced scan time.

Other technical settings of a CT perfusion protocol can also affect perfusion parameter values. For instance, the frequency of image acquisition, particularly in the first circulation phase, could result in significantly different values of BF and BV (16-18). The molecular weight of contrast agent can influence the estimation of tissue permeability as well. Most iodinated CT contrast agents are low–molecular weight agents (about 0.75 kDa) and leak more easily from the blood into the interstitial space compared to higher molecular weight contrast agents (19,20). Because endothelial permeability is dependent on the molecular weight of a contrast agent, PS values measured with a lower molecular weight agent will be higher than the values measured with a higher molecular weight agent. As such, perfusion protocols to measure PS need standardization with respect to contrast agent used as well as scan time.

Radiation dose is of concern when performing a CT perfusion scan. At 80 kVp and 190 mA, the estimated effective doses for scan durations of 150, 120, 90, and 60 seconds are 5.4, 5.2, 5.0, and 4.8 mSv, respectively. Similarly, the imaging doses at 80 kVp and 100 mA are 2.9, 2.7, 2.6, and 2.5 mSv, respectively. Because the second phase of a CT perfusion scan involves x-ray exposures that are taken every 15 seconds, the reduction in radiation dose by truncating the scan time is minimal. Reducing the scan time is not an effective way to reduce radiation dose. Adaptive statistical iterative reconstruction and reducing the imaging frequency during the first phase are more effective at reducing the radiation dose (17,21).

Some limitations of this study must be considered. The number of patients was relatively small, and there was little variation in terms of brain tumour types, because all
patients were diagnosed with malignant glioma, which accounts for approximately 70% of all adult primary brain tumours (22). In addition, patients were not scanned with the same CT scanner or the same contrast agent. As the molecular weights for the two contrast agents used in this study were both approximately 0.8 kDa, the small difference in molecular weights should have minimal effect on the measurement of CT perfusion parameters. Although there was no statistical difference in terms of perfusion parameter values measured from the two scanners using two different tube currents, a simulation study showed that x-ray tube current could potentially affect the accuracy of perfusion parameters in the brain (23). A subgroup analysis using the patients acquired with 100-mA tube current showed that BF and BV at 60 seconds were significantly different from the values obtained at 150 seconds (data not shown). A lower signal-to-noise ratio due to a lower tube current could have affected the measurement of BF and BV when the scan time was reduced. Our recommendation of 90 seconds is a conservative estimate of the shortest scan time required to be consistent with the above results. In both cases (100 and 190 mA), the 120-second and 90-second data were not significantly different from the 150-second data. Additional study scanning patients with various types of brain tumours using the same scanner and contrast agent is needed to confirm the current results.

2.5 Conclusions

Relative to a 150-second scan duration, BF and BV values in the normal brain and brain tumours were not affected by reducing scan duration to 60 seconds, whereas PS values in the tumour rim were significantly higher at 60 seconds. The random errors associated with BF, BV, and PS could suffer with shorter scan durations. A scan duration of ≥90 seconds is recommended, and investigation of the effects of other scanning parameters on the measurement of perfusion parameters is warranted.
2.6 References


Chapter 3

3  Improving Quantitative CT Perfusion Parameter Measurements Using Principal Component Analysis

This chapter is adapted from the research article, “Improving quantitative CT perfusion parameter measurements using principal component analysis” published in Academic Radiology, 2014;21(5):624-632 by Yeung TPC, Dekaban M, De Haan N, Morrison L, Hoffman L, Bureau Y, Chen X, Yartsev S, Bauman G, Lee TY.

3.1 Introduction

Computed tomography (CT) perfusion is a diagnostic tool for the evaluation of acute ischemic stroke, and it is becoming increasingly used for measuring blood flow (BF), blood volume (BV), and permeability–surface area product (PS) in malignant brain tumours (1). The measurements of BF, BV, and PS in tumours are affected by CT perfusion image contrast-to-noise ratio (CNR). Recently, Balvay et al. (2) showed that filtering CT perfusion images with principal component analysis (PCA) improved CNR in CT perfusion images of patients with ovarian and metastatic renal tumours. It is not known whether PCA can improve CNR of CT perfusion images of patients with malignant brain tumours, which have a lower CNR because of lower tumour blood flow in the brain compared to other malignancies such as metastatic renal tumours (3-6). In preclinical imaging of cancer models with a clinical CT scanner, a high spatial resolution is desirable to detect small tumours. However, CNR from scanning small animals is low because: (1) image noise increases with higher spatial resolution (ie, smaller pixel size); and (2) the effect of partial volume averaging is more prominent in small animals than in humans. Therefore, we hypothesized that CT perfusion images of a preclinical model of malignant glioma are useful to evaluate the ability of PCA in improving image quality under low-CNR condition. It has not been demonstrated that an increase in CNR after PCA filtering improves the measurements of BF, BV, and PS. Accurate and precise measurements of these parameters are important because they have been shown to be
valuable for grading gliomas (1,6) and for distinguishing recurrent tumour from treatment-induced necrosis (7).

In this study, we first designed a digital phantom to validate PCA image filtering by comparing the accuracies and precisions of BF, BV, and PS without and with PCA filtering of simulated CT perfusion images. We then evaluated the improvement in CNR and changes in BF, BV, and PS measurements after PCA filtering CT perfusion images of a malignant rat glioma model.

3.2 Materials and Methods

3.2.1 Validation of PCA by Simulation

A digital phantom of CT perfusion images with time-attenuation curves (TAC) reflecting known values of BF, BV, and PS was developed. The phantom consisted of 16 CT slices and 44 sequential images for each slice simulating a two-phase CT perfusion protocol. Images were simulated at 1.4-second intervals during the first phase of 30-seconds and then at 15-second intervals during the second phase of 300-seconds. Each image contained 3 × 4 tiles of 10 × 10 pixels, which resembled the number of pixels in an axial rat brain CT image. Pixels in each tile had the same TAC simulating known values of BF, BV, and PS. Each tile was assigned with increasing mean transit times (MTTs; 4, 4.5, 5.0, …, 9.5 s) and extraction fraction (E; 0.05, 0.06, …, 0.14, 0.3, 0.4). Each slice was assigned to two different BV values, the range of values were 0.5, 1.0, 1.5, …, 8 mL/100 g. BF values (3.2–120 mL/min/100 g) were calculated as BV/MTT, and PS values (0.4–25.8 mL/min/100 g) were obtained using $-BF \times \ln(1-E)$ (8). Based on the Johnson–Wilson model, these values were used to simulate different impulse residue functions for each tile (9). A population-averaged arterial TAC was generated by averaging TACs from carotid arteries of nine Wistar rats.

Each impulse residue function was convolved with the population-averaged arterial TAC to generate a tissue TAC. A time-attenuation curve (TAC), $Q(t)$, can be described by the following equation:
\[ Q(t) = BF \cdot C_a(t) \otimes H(t) = C_a(t) \otimes [BF \cdot H(t)] \]  

Equation 3-1

where BF is blood flow, \( C_a(t) \) is the arterial TAC (also known as the arterial input function), \( \otimes \) is the convolution operator, \( H(t) \) is the impulse residue function. This mathematical operation is graphically illustrated in Figure 3-1.

**Figure 3-1:** Graphical illustration showing how a tissue time-attenuation curve (TAC), \( Q(t) \), is simulated from a population-averaged arterial TAC, \( C_a(t) \), and a blood flow–scaled impulse residue function, \( H(t) \), with known values of blood flow (BF), blood volume (BV), permeability–surface area product (PS), extraction fraction (E), and mean transit time (MTT).

The arterial TAC used in this simulation was a population-averaged arterial TAC. The impulse residue function describes the fraction of contrast that remains in the tissue as a function of time after a bolus injection into the arterial inlet. The blood flow–scaled impulse residue function, \( BF \cdot H(t) \), has two phases. The first phase is a rectangular function with a height of BF that is maintained for the duration of the mean transit time and has an area equal to blood volume (BV). It represents the retention of contrast in the tissue region before venous outflow. The second phase starts at a height of the extraction fraction and decays exponentially; it describes the back flux of extravasated contrast from the interstitial space into the intravascular space. The values of the TACs at different time points were embedded into the corresponding pixels to generate CT perfusion images of the digital phantom. In total, the set of noise-free CT perfusion images in the digital phantom gave rise to 192 different TACs with different combinations of BF, BV, and PS.
values. This phantom reflected values of BF, BV, and PS in the physiological range of a rat. The design of this phantom is illustrated in Figure 3-2.

![Figure 3-2: An example of one slice (out of 16 slices) of the digital computed tomography (CT) perfusion phantom with image noise. Each tile contains tissue-enhancement curves reflecting a combination of extraction fraction (E), mean transit time (MTT), blood volume (BV), blood flow (BF), and permeability–surface area product (PS).](image)

To add image noise to the set of noise-free CT perfusion images, a rat was scanned without contrast injection in high-resolution mode with a clinical CT scanner (Discovery 750 HD; GE Healthcare, Waukesha, WI) using the same two-phase CT perfusion protocol as the simulation. The scanning parameters were 80 kVp, 120 mAs,
0.4 s/rotation, 10 cm field of view, 16 slices, and 1.25 mm slice thickness (voxel size is 0.2 × 0.2 × 1.25 mm). A high-definition bone filter with a limiting in-plane resolution of 0.33 mm was used to reconstruct the images. Adaptive statistical iterative reconstruction (ASIR) was used to reconstruct the images. The skull was used to rigidly register the images using the prototype version of CT Perfusion 4D (GE Healthcare) to minimize misregistration due to motion in the axial plane. A “noiseless” CT image for each slice was generated by averaging the series of noncontrast CT images of the same slice. The set of noise only images of each slice was obtained by subtracting the average CT image from each CT image of the same slice. This set of noise images was added one by one to the set of noise-free CT perfusion images. The final set of noisy images was designated as the unfiltered CT perfusion images of the digital phantom, and they were then filtered using PCA.

3.2.2 Principal Component Analysis

Principal component analysis (PCA) is a statistical technique that linearly transforms a set of multidimensional observations into different principal components that describe the variance of the original set of observations (2). In the context of a series of m dynamic images from a computed tomographic perfusion study, attenuation in each pixel p as a function of time was measured as a time-attenuation curve (TAC). If one interprets a TAC as a set of observations of x-ray attenuation changes (due to contrast) versus time, then each TAC consists of m number of variables and can be written as an m × 1 vector $Q_p$ with p as the index for the image pixel. PCA linearly transforms the possibly correlated m variables into a set of transformed variables called principal components, which are linear combinations of the original variables and are uncorrelated with each other. These linear transformations are defined so that the first principal component has the largest variance. Each subsequent principal component would describe the next largest variance with the condition that it is uncorrelated to all the previous principal components.
It can be shown that the coefficients defining these linear transformations are the eigenvectors of the covariance matrix of the TACs whereas the corresponding eigenvalues are the variances of the principal components. In addition, each TAC can be noise filtered by expressing it as the weighted sum of the eigenvectors with the weights given by the scores of the TAC on the principal components (or loadings of the eigenvector in the TAC):

\[
\tilde{Q}_p = \sum_{i=1}^{N} w_{ip} \cdot a_i
\]

where \( N \) is the number of principal components with the largest variances used to noise filter \( Q_p \), \( a_i \) is the \( i \)th eigenvector and \( w_{ip} \) is the corresponding weight which can be calculated as:

\[
w_{ip} = a_i^T \cdot (Q_p - \bar{Q})
\]

where \( \bar{Q} \) is the mean of all TACs and \( a_i^T \) is the transpose of \( a_i \).

CT perfusion images can be noise filtered using the first few principal components. In general, more temporal TAC smoothing is achieved with lesser number of principal components used. CT perfusion images of each slice of the phantom were analyzed with an in-house PCA program developed using the C++ programming language. Two, four, six, eight, and ten principal components were used to reconstruct five different sets of noise-filtered CT perfusion images.

3.2.3 In Vivo Experiments

All experiments were approved by the Animal Use Subcommittee of the Canadian Council on Animal Care at our institution. C6 glioma cells (10^6 cells in 10 μL) were stereotactically implanted into the right caudate putamen of eight Wistar rats (10). At an average of 13 days (range, 11–17 days) after tumour implantation, the brain of each animal was scanned in high-resolution mode with a clinical CT scanner using the same
two-phase protocol as the simulation. A bolus of contrast (Isovue; Bracco Diagnostics Inc, Vaughan, Canada; 300 mg iodine/mL, 2.5 mL/kg body weight) was injected into the lateral tail vein at a rate of 8 mL/min, at 3–4 seconds after the start of the first phase. Two, four, and six principal components were used to reconstruct three different sets of noise-filtered CT perfusion images for each animal.

3.2.4 Assessment of Image Quality and Information Loss after PCA Filtering

For both simulation and in vivo experiments, pixel noise and CNR were used to evaluate the image quality of CT perfusion images after PCA noise filtering (2). To evaluate the enhancement of contrast, the mean baseline attenuation is subtracted from the TAC to give the corresponding time-enhancement curve. The standard deviations (SD) of the baseline (first four to five time points) and the late steady state phase (last 10 time points) were calculated and averaged for each of the original and filtered image sets to give $SD_o$ and $SD_f$, respectively. These values ($SD_o$ and $SD_f$) were used as measurements of pixel noise.

For each CT perfusion image set, the average norm of the time-enhancement curves $\|Q\|$ is composed of the average norm of signal $\|S\|$ and average norm of noise $\sqrt{m \cdot SD^2}$, where $m$ is the number of time points. The average norm of signal $\|S\|$ was estimated using $\sqrt{\|Q\| - m \cdot SD^2}$. The CNR of the original and filtered image sets were defined as $\frac{\|S\|_o}{m \cdot SD_o^2}$ and $\frac{\|S\|_f}{m \cdot SD_f^2}$, respectively.

The fractional residual information (FRI) was described by Balvay et al (2) and was used to evaluate the amount of information loss due to filtering. The residual signal of pixel $p$, $R_p$, was the difference between the original TAC, $Q_p$, and the filtered TAC ($\tilde{Q}_p$). The residual signal ($R_p$) of pixel $p$ has two components: informative signal ($S_p$) and noise ($N_p$). The FRI for a pixel ($FRI_p$) after filtering with PCA was defined as:
\[ FRI_p = \frac{\| S_p \|^2}{\| R_p \|^2} = \frac{\| S_p \|^2}{\| S_p + N_p \|^2} \]  

Equation 3-4

\( FRI_p \) ranges from 0 to 1, and the optimal number of principal components that should be used for filtering TACs minimizes the FRI in order to keep as much valuable information as possible in the filtered data in both the tumour and normal brain tissue. To estimate \( \| S_p \|^2 \) we used the autocorrelation function of the residual, \( R_p \), between the original and filtered TAC of pixel \( p \), which is defined as:

\[ C_p(k) = \frac{1}{m - |k|} \sum_{i=1}^{m-k} R_p(i) \cdot R_p(i + k) \]  

Equation 3-5

where \( m \) is the number of time points, \( k \) is the time lag and \( R_p(i) \) is the \( i^{th} \) element of the \( m \times 1 \) residual vector \( R_p \). \( C_p(k) \) can identify signal \( (S_p) \) hidden in the noise \( (N_p) \) of \( R_p \) in the following way. In general, the autocorrelations of \( N_p \) and \( S_p \) are approximately zero for time lag \( k > k_n \) and \( k_s \), respectively. If \( k_s > k_n \), then the autocorrelation of the residual \( C_p(k) \) can be used to approximate \( S_p \) for time lag \( k_n < k < k_s \). In particular, extrapolation of \( C_p(k) \) in the range \( k_n < k < k_s \) to \( k = 0 \) will give the autocorrelation of \( S_p \) at \( k = 0 \), which by analogy to Equation 3-5 gives \( \| S_p \|^2 \) when multiplied by \((m-|k|)\). We used a second order polynomial to extrapolate \( C_p(k) \) in the range \( k_n < k < k_s \) to \( k = 0 \). The \( k_n \) and \( k_s \) used were fixed to 1 and 30 time lags, respectively.

3.2.5 Calculation of BF, BV, and PS

For both simulation and in vivo experiments, maps of BF, BV, and PS of the unfiltered and filtered image sets were generated using CT Perfusion 4D. Tissue TACs were measured from 2 \( \times \) 2 pixel blocks of CT images. Parametric maps of BF, BV, and PS were calculated by deconvolving the arterial TAC with each tissue TAC using the Johnson–Wilson model (8,9). The population-averaged TAC was used for the simulation.
while a region of interest (ROI) was placed in the carotid artery to measure the arterial TAC for each animal.

### 3.2.6 Statistical Analysis

For digital phantom maps, a square-shaped ROI of $8 \times 8$ pixels was placed at the center of each tile to measure the mean BF, BV, and PS. Intraclass correlation coefficient was used to assess the reliability of measurements between the simulated true values and the values obtained without or with PCA filtering (11). Measurement error was the difference between the mean with the simulated true value of each tile. Map noise was the SD of each tile. The agreement in measurement errors and map noises in BF, BV, and PS without and with PCA filtering was assessed using Bland–Altman analysis (12). Repeated measures analysis of variance (ANOVA) followed by Bonferroni multiple comparisons was used to compare the differences in absolute measurement errors and map noise before and after PCA filtering (SPSS, version 20.0; SPSS, Chicago, IL) (13).

For animal experiments, the tumour and contralateral normal brain were delineated. Noise level, CNR, BF, BV, and PS in each ROI were expressed as mean ± SD. These metrics before and after filtering were compared using repeated measures ANOVA followed by Bonferroni multiple comparisons to evaluate the differences between the normal brain and tumour without or with PCA filtering. The mean percentages of pixels that had an FRI $\geq 5\%$ in the normal brain and tumour were calculated. All statistical tests were done using SPSS (SPSS, version 20.0; SPSS, Chicago, IL), and a $P \leq .05$ was considered significant.

### 3.3 Results

For simulation, filtering with four or lesser principal components resulted in intraclass correlation coefficients that were significantly greater than the intraclass correlation coefficients without PCA filtering for BF, BV, and PS (Table 3-1). Figure 3-3 illustrates
visual improvements in maps of BF, BV, and PS after PCA filtering. The mean error and the 95% limits of agreement (mean ± 2 SD) decreased after PCA filtering and with lesser number of principal components (Figure 3-4). Similarly, the mean map noise and 95% limits of agreement decreased after PCA filtering (Figure 3-5). Reductions in absolute measurement errors and map noises for BF, BV, and PS were significant \((P < .05)\). The mean FRI ± SD was \(\leq 0.5\% ± 0.7\%\) after filtering with any number of principal components. The maximum mean FRI for ten, eight, six, four, and two principal components were 3.0\%, 2.9\%, 3.7\%, 4.9\%, and 6.5\%, respectively.

### Table 3-1: Intraclass correlation coefficient of different CT perfusion parameters with the true values.

<table>
<thead>
<tr>
<th>Number of PCs</th>
<th>BF</th>
<th>BV</th>
<th>PS</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Intraclass correlation coefficient (95% CI)</td>
<td>P value*</td>
<td>Intraclass correlation coefficient (95% CI)</td>
</tr>
<tr>
<td>No PCA</td>
<td>0.73 (0.34 – 0.86)</td>
<td>0.57</td>
<td>0.96 (0.95 – 0.97)</td>
</tr>
<tr>
<td>10 PCs</td>
<td>0.79 (0.64 – 0.87)</td>
<td>0.19</td>
<td>0.98 (0.96 – 0.98)</td>
</tr>
<tr>
<td>8 PCs</td>
<td>0.79 (0.68 – 0.86)</td>
<td>0.12</td>
<td>0.98 (0.97 – 0.99)</td>
</tr>
<tr>
<td>6 PCs</td>
<td>0.79 (0.66 – 0.86)</td>
<td>0.15</td>
<td>0.98 (0.97 – 0.99)</td>
</tr>
<tr>
<td>4 PCs</td>
<td>0.82 (0.75 – 0.87)</td>
<td>\textbf{0.01}#</td>
<td>0.98 (0.97 – 0.99)</td>
</tr>
<tr>
<td>2 PCs</td>
<td>0.82 (0.77 – 0.86)</td>
<td>\textbf{0.00}#</td>
<td>0.98 (0.97 – 0.98)</td>
</tr>
</tbody>
</table>

*Statistical comparison with intraclass correlation coefficient = 0.73
†Statistical comparison with intraclass correlation coefficient = 0.96
‡Statistical comparison with intraclass correlation coefficient = 0.77
#Statistically significant at a \(P < 0.01\)

Abbreviations: PCs = principal components; BF = blood flow; BV = blood volume; PS = permeability-surface area product; PCA = principal component analysis; CI = confidence interval
Figure 3-3: Maps of blood flow (BF), blood volume (BV), and permeability–surface area product (PS) of the digital phantom without noise (ie, truth), with noise, and after principal component analysis (PCA) filtering with four principal components. Some values of BF, BV, and PS are labeled.

Figure 3-4: Mean error and 95% limits of agreement (ie, mean ± 2 standard deviation from Bland–Altman analysis) without and with principal component analysis (PCA) filtering for (a) blood flow (BF), (b) blood volume (BV), and (c)
permeability–surface area product (PS). Solid line is the mean and dashed lines are the upper and lower limits of agreement.

Figure 3-5: Mean map noise and 95% limits of agreement (ie, mean ± 2 standard deviation from a Bland–Altman analysis) without and with principal component analysis (PCA) filtering for (a) blood flow (BF), (b) blood volume (BV), and (c) permeability–surface area product (PS). Solid line is the mean and dashed lines are the upper and lower limits of agreement.

For experiments, Figure 3-6 shows the removal of noise from a sample time-enhancement curve in the tumour. Figure 3-7 shows examples of source CT perfusion images and maps of BF, BV, and PS without and with PCA filtering; the first four principal components used for filtering are also shown. Table 3-2 reports the significant improvements in noise reduction and CNR in animal CT perfusion images. The loss of signal was minimal after filtering the images with four or more principal components, in which no >1% of pixels had an FRI of ≤5% in both the normal brain and the tumour. An
average of 26% (range, 11%–49%) of pixels in the tumour had an FRI of ≥5% when filtering with only two principal components (Table 3-2). PCA showed significant effect on BV and PS irrespective of ROI (ie, normal brain vs. tumour), and ROI had a significant effect on BF, BV, and PS irrespective of PCA (Table 3-3). Although PCA had no overall effect on BF, the interaction between PCA and ROI had a significant effect, suggesting that ROI had an effect on PCA filtering. Figure 3-8 shows that there was no regional difference in BF without PCA ($P = .72$), but tumour BF was significantly different than brain BF after filtering with four or lesser principal components ($P < .03$). This supports the effect of region on the PCA as indicated in Table 3-3, which led to a higher contrast between tumour and normal brain tissue in BF maps. Figure 3-8 also illustrates measurements of BV and PS in the normal brain and tumour before and after PCA filtering.

Figure 3-6: Examples of tumour time-enhancement curves obtained without and with principal component analysis (PCA) filtering. Filtering with two principal components can lead to loss of information as represented by the reduced height in the time-enhancement curve.
Figure 3-7: (A) Examples of source computed tomography (CT) images and maps of blood flow (BF), blood volume (BV), and permeability–surface area product (PS) without and with filtering using four principal components (PCs). (B) The first four PCs as a function of time.
Table 3-2: Evaluation of quality of computed tomography perfusion image filtering.

<table>
<thead>
<tr>
<th>Number of PCs</th>
<th>Noise level ± SD (HU)</th>
<th>CNR ± SD</th>
<th>% of voxels with FRI ≥ 5%</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Brain</td>
<td>Tumour</td>
<td>Brain</td>
</tr>
<tr>
<td>No PCA</td>
<td>16.9 ± 0.5</td>
<td>16.6 ± 0.6</td>
<td>0.6 ± 0.1</td>
</tr>
<tr>
<td>6 PCs</td>
<td>5.2 ± 0.6*</td>
<td>5.6 ± 0.6*</td>
<td>1.9 ± 0.3*</td>
</tr>
<tr>
<td>4 PCs</td>
<td>3.3 ± 0.4*</td>
<td>3.9 ± 0.7*</td>
<td>2.9 ± 0.4*</td>
</tr>
<tr>
<td>2 PCs</td>
<td>1.6 ± 0.3*</td>
<td>2.2 ± 0.6*</td>
<td>6.2 ± 1.3*</td>
</tr>
</tbody>
</table>

*Significantly different than No PCA of the same region (P < 0.05)

Abbreviations: PCA = principal component analysis; PCs = principal components; SD = standard deviation; HU = Hounsfield unit; CNR = contrast-to-noise ratio; FRI = fractional residual information; N/A = not applicable

Table 3-3: P values of repeated-measures ANOVA for measurements of BF, BV, and PS.

<table>
<thead>
<tr>
<th>Factor</th>
<th>BF</th>
<th>BV</th>
<th>PS</th>
</tr>
</thead>
<tbody>
<tr>
<td>PCA</td>
<td>0.21</td>
<td>&lt;0.02</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Region</td>
<td>&lt;0.05</td>
<td>&lt;0.03</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Interaction between PCA and region</td>
<td>&lt;0.01</td>
<td>&lt;0.01</td>
<td>&lt;0.01</td>
</tr>
</tbody>
</table>

Abbreviations: BF, blood flow; BV, blood volume; PCA, principal component analysis; PS, permeability–surface area product.
Figure 3-8: Brain and tumour blood flow (BF), blood volume (BV), and permeability–surface area product (PS) before and after filtering with different number of principal components. Asterisk (*) indicates a marginal significance of $P = .06$. Dagger (†) indicates $0.01 \leq P < .03$. Double dagger (‡) indicates $P < .01$.

3.4 Discussion

CT perfusion provides crucial information regarding brain tumour hemodynamics for the evaluation of tumour angiogenesis (1). The visualization of small objects of interest, such as tumours and ischemia, and accurate and precise measurements of BF, BV, and PS require good CNR. Balvay et al. (2) demonstrated an automated method to perform PCA. Our simulation provides the first evidence that PCA is effective in improving the reliability, accuracy, and precision of BF, BV, and PS measurements.
We applied PCA in this study to improve CNR of CT perfusion images of malignant rat gliomas that have an even lower CNR than previously reported (2). PCA is a statistical technique that separates image noise from signal by determining principal components with successively decreasing variance. Filtering with too many principal components results in ineffective denoising of the data whereas filtering with too few principal components runs the risk of removing genuine signal from the original data. We used the noise level, CNR, and FRI as metrics to evaluate the tradeoff between the improvement in image contrast and the loss of information. In this study, both image noise and CNR of CT perfusion images were improved after PCA. Filtering with only two principal components resulted in substantial information loss in the tumour that was not observed with greater than four principal components. Rat brain CT perfusion images required few principal components for filtering because there are few tissue types with different patterns of contrast enhancement in rat brain tissues. Unlike human brain, which has substantial amount of white matter, the rat brain consists mostly of gray matter (14). Furthermore, the rat brain, like human brain, is not permeable to most exogenous molecules including iodinated contrast. The shape of the time-enhancement curve in the normal rat brain is mainly governed by that of the arterial input and venous output. However, in the implanted glioma, contrast agent is able to extravasate into the brain parenchyma. The extravasation of contrast agent contributes to the higher contrast enhancement during the latter phase of the time-enhancement curves. Because there are only two major tissue types (normal and tumour) with two different patterns of contrast uptake (minimal vs. high extravasation) in the rat gliomas of this study, four principal components were able to filter the CT perfusion images without substantial loss of information. After filtering the CT perfusion images, differences in BF, BV, and PS measured in the tumour and contralateral normal brain were consistent with reported data measured using synchrotron radiation CT perfusion of the same tumour model (15).

There have been advances in the development of new CT reconstruction methods that can improve CT image quality. ASIR is one example of these advances and has been shown to provide equal image quality in brain imaging with ≥30% reduction in radiation dose when compared to filtered back projection (16). Images from this study were reconstructed with 80% ASIR. Thus, the improvement in image quality from PCA was
additional gain in CNR of the time-enhancement curves after ASIR was applied, suggesting that PCA further contributes to the improvement in CT perfusion image quality.

PCA has important potential application for lowering radiation dose when performing repeated CT perfusion studies to evaluate treatment response. A typical human brain CT perfusion protocol produces an effective dose of 2.9–5.4 mSv (17). Radiation dose is inversely proportional to the square of image noise. For instance, a nine-fold reduction in radiation dose can be achieved by filtering CT perfusion images with six principal components to achieve a three-fold improvement in image noise (Table 3-2). PCA filtering of CT perfusion images can improve the accuracy and precision of BF, BV, and PS measurements obtained with low CNR CT perfusion images; thus, making repeated low dose CT perfusion studies feasible. Lowering radiation exposure for better radiation safety or increasing spatial resolution of CT images will increase image noise, which in turn lowers CNR. Effective filtering of CT perfusion source images without the loss of information to obtain more accurate and precise measurements of BF, BV, and PS is imperative for both improving visibility of small objects of interest and for lowering radiation dose.

There are several limitations in this study. A simulation was performed to evaluate the improvement in accuracy and precision of BF, BV, and PS measurements. Although we did not perform an in vivo validation, CT perfusion imaging of brain tumour tissue has been validated in vivo (18). PCA analysis of the experimental data was applied to each slice of the brain separately (ie, two-dimensional analysis). A three-dimensional PCA of the entire brain could improve the quality of filtering by increasing the number of pixel TACs used to determine the principal components. It is important to note that the simulation results obtained in this study may not be applicable to other pharmacokinetic models (ie, the analysis software). Using a similar digital phantom, Kudo et al. (19) showed that different commercial software packages showed discrepancies in BF and BV measurements from simulated values. This is because available commercial software may or may not correct the arrival delays of the TACs, and the impulse residue functions are constrained differently in these software packages.
because of the different assumptions used in their tracer kinetic models. A separate simulation using our digital phantom is needed to validate the measurement of different tracer kinetic parameters after PCA filtering of CT perfusion images for each commercial software.

3.5 Conclusions

PCA filtering of CT perfusion images improved CNR in vivo and reduced measurement errors of BF, BV, and PS by simulation. PCA is an effective tool for filtering CT perfusion images of malignant rat gliomas with low CNR. Filtering with four principal components could achieve the gain in CNR without substantial loss of information.

3.6 References


Chapter 4

CT Perfusion Imaging as an Early Biomarker of Differential Response to Stereotactic Radiosurgery

This chapter is adapted from the manuscript entitled “CT perfusion imaging as an early biomarker of differential response to stereotactic radiosurgery”. This manuscript will be submitted to the journal PLOS ONE in July 2014 to be considered for publication. The authors of this manuscript are Yeung TPC, Kurdi M, Wang Y, Al-Khazraji B, Morrison L, Hoffman L, Jackson D, Crukley C, Lee TY, Bauman G, Yartsev S.

4.1 Introduction

Patients with glioblastoma multiforme, the most common form of adult brain tumours, have a median survival of approximately 12 – 15 months (1). Radiotherapy has played an important role in prolonging the survival of these patients since the 1970s (2). Magnetic resonance (MR) and computed tomography (CT) are currently the standard imaging modalities for assessing treatment response. Tumour progression is usually detected by increased contrast-enhancement on gadolinium-enhanced T1-weighted MR images, and T2-weighted or fluid-attenuated inversion recovery MR images (3). However, early changes in contrast enhancement after radiotherapy is not a specific tool to predict treatment failure as changes in contrast enhancement can occur in pathophysiological processes that disrupt the blood brain barrier. For instance, radiation-induced injury (e.g. radiation-induced necrosis and pseudoprogression) can mimic the appearance of tumour progression on T1-weighted MR (3).

Due to the poor survival rates, timely and accurate assessment of response to radiation is important as treatment can be altered if a non-responder to radiation can be identified early enough. In preclinical studies, radiotherapy is usually delivered using a technique called stereotactic radiosurgery (SRS). It is delivered in one or few large dose fractions of 8 – 30 Gy and would result in tumour growth delay and survival benefit (4-7). Radiotherapy, particularly SRS, can result in vascular damage in the irradiated area
(4, 8-10), and radiosensitivity of tumour vasculature can augment response to SRS (11). Hypofractionation schemes that also use a large dose per fraction to treat patients with malignant gliomas is also an attractive treatment strategy. Recently, clinical studies have investigated the use of hypofractionated intensity modulated radiotherapy to treat these patients (12-14). Hypofractionation have some advantages over conventional fractionation. Hypofractionation is expected to increase the biological effect of radiation due to increased cell damage resulting from a higher dose per fraction (15). It also reduces the effect of tumour repopulation by reducing treatment time (16). Thus, imaging of tumour perfusion is a promising biomarker of response to high dose per fraction radiotherapy (e.g. SRS and hypofractionation) that warrants investigation.

The C6 rat glioma is a widely used experimental model for the study of malignant glioma (17), including the effects of SRS (6,7,9,10). Tumour microcirculation can be noninvasively measured by CT or MR perfusion imaging techniques. In particular, CT perfusion imaging is a validated method that allows simultaneous mapping of blood flow (BF), blood volume (BV), and permeability-surface area product (PS) (18,19). CT scanners and iodinated contrast agents are also widely available, and they are ubiquitous in radiation oncology departments. The purpose of this study was to evaluate vascular changes following SRS using CT perfusion, and determine whether acute vascular changes within one week of SRS is predictive of survival. In addition, early (four days post-SRS) and late (eight weeks post-SRS) histopathologic findings were examined.

### 4.2 Materials and Methods

#### 4.2.1 C6 Glioma Model

All experiments were compliant with our institutional Animal Use Subcommittee guidelines. Wistar rats weighing 300 – 400 g (N = 33) were used in this study. The animals were anaesthetized with 2% isoflurane during all procedures. C6 glioma cells (American Type Culture Collection, Manassas, VA) were cultured in F12k 15% horse serum, 2.5% bovine serum, and 1% penicillin-streptomycin. For the implantation of C6
glioma cells, each animal was secured into a stereotactic surgical frame. After scalp incision at midline and exposing the bregma, a 1 mm diameter burr hole was drilled at 1 mm anterior and 3 mm right of the bregma. A total of $10^6$ C6 glioma cells were slowly injected for 5 minutes at 3 – 4 mm below the burr hole, which corresponded to the location of the caudate putamen (20). The burr hole was sealed with bone wax, and the scalp was closed with sutures.

4.2.2 Baseline CT Perfusion Imaging

All rats underwent the first CT perfusion scan on an average of 11 days (range, 7 – 16 days) after implantation of C6 glioma cells to monitor tumour growth and prepare for SRS. The rats were scanned using a clinical CT scanner (Discovery 750 HD, GE Healthcare, Waukesha, WI). A two-phase CT perfusion scan, guided by a prior non-contrast CT scan that identified $16 \times 1.25$ mm thick sections to cover the entire brain, was performed for each animal. The brain was scanned with high resolution mode for 32 s at 1.4 s intervals during the first phase and for a period of 165 s at 15 s intervals during the second phase. A bolus of contrast (Iovue, Bracco Diagnostics Inc, Vaughan, Canada, 300 mg iodine/ml, 2.5 mL/kg body weight) was injected into the lateral tail vein at a rate of 8 mL/min at 3 – 4 s after the start of the first phase. The scanning parameters were 80 kVp, 120 mAs, 10 cm field of view, and high-definition bone filter. The visibly distinguishable spatial resolution was 1 line pair per 500 μm measured on a rat-size phantom (21).

CT perfusion images of the same slice were averaged over the whole scan duration using the prototype version of CT perfusion 4D (GE Healthcare) to produce a set of contrast-enhanced images called averaged CT images. The tumour diameter on the averaged CT images was measured immediately after the scan. The rats were assigned randomly to either the control group ($N = 8$) or the SRS group ($N = 25$) once a tumour diameter of 4 mm was reached.
4.2.3 Stereotactic Radiosurgery

A custom-made plastic stereotactic frame was used to secure the animals for treatment planning. A non-contrast helical CT scan was performed (25 cm field-of-view, 80 kV, 110 mAs, 1.25 mm slice thickness) for treatment planning. CT images were transferred to the Helical Tomotherapy Treatment Planning System (Accuray Inc, Madison, WI, USA). Using the averaged CT images for anatomical guidance, a dose of 12 Gy was prescribed to at least 80% of the contrast-enhanced tumour volume with the brainstem receiving no more than 4 Gy and less than 10% of the normal brain receiving more than 8 Gy.

For SRS, the rats were fixed in the same plastic stereotactic frame. A 3.5 MV CT study was acquired prior to treatment. This MV CT study was co-registered with the planning kV CT study and couch position was shifted in the lateral, anterior-posterior, and superior-inferior directions. The rats were repositioned in the stereotactic frame if there were rotational positioning errors. The average SRS delivery time was 6 minutes. Rats in the control group were put under anesthesia and secured in the stereotactic frame for 6 minutes to mimic the procedure without radiation.

4.2.4 Follow-up CT Perfusion Imaging

Rats in the SRS group were further assigned to either 1) acute imaging group \((N = 12)\) or 2) the longitudinal imaging group \((N = 13)\). Rats in the acute imaging group were imaged with CT perfusion at 4 days post-SRS, and were euthanized on the same day. Rats in the longitudinal group and control group were imaged for a maximum of 8 weeks post-SRS to monitor tumour changes and survival. Rats were euthanized if they showed any of the following signs and symptoms: weight loss of \(\geq 15\%\) from the heaviest recorded weight, lethargy, refusal to eat, neurologic signs such as one-sided limb weakness.
4.2.5 Image Analysis

Maps of BF, BV, and PS were generated using the prototype version of CT perfusion 4D (GE Healthcare). The time-attenuation curve (TAC) from the carotid artery was selected as the arterial input. The arterial TAC was deconvolved with tissue TACs measured from $2 \times 2$ pixel blocks of CT images using the Johnson-Wilson model to produce maps of BF, BV, and PS (18,22). Using the averaged CT images for anatomical guidance, tumour volume, BF, BV, and PS in the tumour, peritumoural region, and contralateral normal brain were measured. Peritumoural region was defined as normal brain that is $2 - 3$ mm adjacent to the tumour. Mean BF and BV values were normalized to the contralateral normal brain to obtain the relative BF (rBF) and relative BV (rBV) values.

4.2.6 Histopathologic Examination

On the same day as the last CT perfusion scan, the animals were euthanized with an overdose of potassium chloride. The animals were perfusion-fixed with phosphate buffered saline followed by 4% paraformaldehyde. The brains were removed and fixed in 4% paraformaldehyde for 24 hours. The brain specimens were sectioned into 3 mm thick blocks, paraffin-embedded, then sectioned at 5 $\mu$m. Hematoxylin and eosin stain (H&E) was applied on each section.

A blinded neuropathology resident (M.K.) examined all H&E slides at different magnifications (20x and 40x) to evaluate histologic signs of radiation damage. The presence of tumour was evaluated as “no”, “yes”, or “diminished due to radiation effect”. “Diminished due to radiation effect” means the presence of a circumscribed hypocellular lesion showing features of irradiation. The diameter of each lesion (control and SRS-treated animals) was measured. Tumour cellularity was defined as 1) hypercellular when less than 30% of the tumour area appeared pale or major tumour was found, and 2) hypocellular when more than 50% of the tumour area appeared pale excluding necrosis. Tumour was graded based on the World Health Organization criteria (23). Tumour edema was defined as the presence of extensive intracellular cytoplasmic swelling or
intercellular spaces between tumour cells. Peritumoural edema was defined as intracellular cytoplasmic swelling or presence of intercellular spaces and reactive gliosis in the peritumoural region. Necrosis was described as 1) pseudopalisading necrosis that indicates high-grade glioma, 2) fibrinoid necrosis, or 3) background necrosis (neither pseudopalisading nor fibrinoid necrosis) that indicate post-radiation effect. 8) Presence of endothelial hyperplasia was recorded as a feature of angiogenesis in high-grade glioma. Increased vascularity and hyalinized blood vessels were recorded as features of post-radiation effect. Percentage of animals exhibiting these signs was calculated. Mean percent necrosis by area was also calculated.

The brain sections were also stained with monoclonal anti-actin, α-smooth muscle antibody (α-SMA) (1:500, clone 1A4, Sigma-Aldrich) to identify mature vessels (24-26). The α-SMA positive vessels were qualitatively classified as intact or fragmented vessels. α-SMA positive vessel density was defined as the number of vessels that stained positive for α-SMA in 6 separate fields (20×) in the most vascular region of the tumour and peritumoural region. Intact and fragmented α-SMA positive vessel densities were measured separately. The percentage of fragmented α-SMA positive vessels was also recorded.

4.2.7 Statistical Analysis

The Shapiro-Wilk test was used to test the normality of the data. Temporal changes in the acute imaging group were tested by the Wilcoxon signed-rank test. The end point of the longitudinal imaging group was survival at 8 weeks post-SRS. The longitudinal group was also subdivided into those that survived more than 2 weeks (responder group), and those that survived less than 2 weeks post-SRS (nonresponder group). The omnibus Kruskal-Wallis test was used for comparisons between groups followed by the Mann-Whitney U test. The omnibus Friedman test was used for longitudinal comparisons within-group followed by the Wilcoxon signed-rank test. All data were reported as mean ± standard error of the mean (SE). Survival of the groups was compared using the log-rank test. Spearman’s rank correlation was used to assess the
associations between different imaging parameters (tumour volume, rBF, rBV, PS) and the percentage of fragmented α-SMA positive vessels. PS is the product between microvessel surface area and permeability, and BV has been shown to correlate with microvessel area (27). We used the PS:BV ratio as a surrogate of permeability and correlated this parameter with the percentage of fragmented α-SMA positive vessels as well.

We investigated whether the imaging parameters correlated with overall survival, and whether these parameters on day 7 post-SRS could predict survival. Each imaging parameter was assessed by applying a threshold that is below the lower 50% confidence interval (CI) boundary of the variations across all treated animals derived from the between-subject variation on day 7 post-SRS. This threshold was used to categorize each animal into two groups (i.e. higher or lower than the threshold). Survivals of the different groups were compared. The sensitivity, specificity, and accuracy of each parameter in predicting survival were assessed. A \( P \leq 0.05 \) was considered statistically significant.

4.3 Results

4.3.1 Acute Vascular Changes and Histopathologic Features

Irradiated rats received 12 Gy in the tumour and peritumoural region, and different CT perfusion changes were observed in these two regions. Tumour volume, rBF, and rBV decreased significantly while peritumoural rBF, rBV, and PS increased significantly in the SRS group (Table 4-1). These opposite CT perfusion changes in the tumour and peritumoural regions are illustrated in Figure 4-1.
Table 4-1: Acute changes (± standard error) in CT perfusion parameters.

<table>
<thead>
<tr>
<th>Regions-of-interest</th>
<th>Treatment</th>
<th>Tumour volume</th>
<th>rBF</th>
<th>rBV</th>
<th>PS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tumour</td>
<td>SRS</td>
<td>-37.3 ± 13.2*</td>
<td>-18.2 ± 7.9*</td>
<td>-23.1 ± 7.6*</td>
<td>-9.2 ± 9.7</td>
</tr>
<tr>
<td></td>
<td>Control</td>
<td>95.1 ± 34.7*</td>
<td>-13.1 ± 9.3</td>
<td>-6.4 ± 9.4</td>
<td>7.4 ± 15.1</td>
</tr>
<tr>
<td>Peritumoural</td>
<td>SRS</td>
<td>N/A</td>
<td>20.9 ± 7.9*</td>
<td>28.7 ± 7.7**</td>
<td>54.3 ± 11.6**</td>
</tr>
<tr>
<td></td>
<td>Control</td>
<td>N/A</td>
<td>-5.0 ± 5.3</td>
<td>2.0 ± 5.0</td>
<td>13.9 ± 20.2</td>
</tr>
</tbody>
</table>

* Significantly different compared to baseline at \(P \leq 0.05\) level
** Significantly different compared to baseline at \(P \leq 0.01\) level

Abbreviations: SRS, stereotactic radiosurgery; rBF, relative blood flow; rBV, relative blood volume; PS, permeability-surface area product.

Figure 4-1: Acute CT perfusion changes on the fourth day after stereotactic radiosurgery (SRS). Tumour relative blood flow (rBF) decreased from 1.48 to 0.68, relative blood volume (rBV) decreased from 1.70 to 0.78, while permeability surface-area (PS) decreased from 4.67 to 3.87 ml/min/100g. On the contrary, peritumoural rBF increased from 0.96 to 1.49, rBV increased from 1.06 to 1.52, and PS increased from 2.13 to 3.81 ml/min/100g.

H&E histological examination revealed that all tumours were grade IV gliomas. Hypercellularity, mitosis, pseudopalisading necrosis, and endothelial hyperplasia were observed as signs of grade IV glioma in the control animals. For the acute imaging group that received SRS, fibrinoid or background necrosis, increased vascularity, and
hyalinized blood vessels were identified. Atypical nuclei, calcification, and gliosis were also observed in some lesions. Examples of H&E images of unirradiated tumour, acute effects of SRS, and late effects of SRS are demonstrated in Figure 4-2, and a summary of histological findings is provided in Table 4-2.

Figure 4-2: Histological examples of stereotactic radiosurgery (SRS) effects. Representative Hematoxylin & Eosin images of an untreated control, acute histological change at 4 days post-SRS, and late histological change at 59 days post-SRS. Hypercellularity (four point star) and pseudopalisading necrosis (five point star) are classic signs of grade IV glioma, and these were observed in the control animals. Hyalinized blood vessels (arrow) and hypocellularity can be observed shortly after SRS. Regression of tumour and hyalinization of tissue were observed at a later stage after SRS.
Table 4-2: Summary of histological finding on Hematoxylin and Eosin (H&E) specimens.

<table>
<thead>
<tr>
<th></th>
<th>Presence of Tumour</th>
<th>Tumour Diameter (mm)</th>
<th>Hypo-cellularity</th>
<th>Types of Necrosis</th>
<th>% Area Necrosis</th>
<th>Vascularity</th>
<th>Tumour Edema</th>
<th>Peritumoural Edema</th>
</tr>
</thead>
<tbody>
<tr>
<td>Controls</td>
<td>88% Yes 0% Diminished</td>
<td>7.3 ± 4.0</td>
<td>0%</td>
<td>88% PPN 13% FN</td>
<td>46 ± 27</td>
<td>75% EH 25% Increased 25% HBV</td>
<td>0%</td>
<td>0%</td>
</tr>
<tr>
<td>Acute Histology</td>
<td>75% Yes 25% Diminished</td>
<td>5.8 ± 3.0</td>
<td>25%</td>
<td>50% PPN 25% FN 33% BN</td>
<td>37 ± 19</td>
<td>58% EH 58% Increased 100% HBV</td>
<td>25%</td>
<td>42%</td>
</tr>
<tr>
<td>Responder</td>
<td>0% Yes 0% Diminished</td>
<td>N/A</td>
<td>N/A</td>
<td>None</td>
<td>N/A</td>
<td>0% EH 43% Increased 14 % HBV</td>
<td>0%</td>
<td>0%</td>
</tr>
<tr>
<td>Non-responder</td>
<td>50% Yes 33% Diminished</td>
<td>4.6 ± 1.5</td>
<td>33%</td>
<td>67% PPN 0% FN 17% BN</td>
<td>55 ± 13</td>
<td>67% EH 50% Increased 67% HBV</td>
<td>17%</td>
<td>33%</td>
</tr>
</tbody>
</table>

*Abbreviations:* PPN, pseudopalisading necrosis; FN, fibrinoid necrosis; BN, background necrosis; EH, endothelial hyperplasia; HBV, hyalinized blood vessels
Immunohistochemical staining revealed fragmented α-SMA positive vessels were identified mostly in the SRS-treated tumours (Figure 4-3). Fragmented α-SMA positive vessel densities in the tumour ($P = 0.006$) and peritumoural regions ($P < 0.001$) were significantly higher in the irradiated animals than the control animals (Figure 4-4). In the tumour, a positive borderline significant correlation between the percentage of fragmented α-SMA positive vessels and PS:BV ratio was identified for the treated animals ($\rho = 0.58$, $P = 0.06$) while a significant negative correlation was found for the control animals ($\rho = -0.84$, $P = 0.02$). However, the amount of fragmented α-SMA positive vessels in the controls was very small (Figure 4-4). In the peritumoural region of the treated animals, negative correlations were found between the percentage of fragmented α-SMA positive vessels with rBF ($\rho = -0.62$, $P = 0.03$) and rBV ($\rho = -0.58$, $P = 0.05$).

![Image](image.png)

**Figure 4-3:** α-smooth muscle actin (α-SMA) positive vessels in the normal brain, peritumoural region, and tumour of a control and a treated animal after stereotactic radiosurgery (SRS). Intact α-SMA positive vessels were observed in control animals, but fragmented coverage of vessels by α-SMA is mostly seen in treated animals (red arrow).
4.3.2 Treatment Response, Longitudinal Changes, and Late Histopathologic Features

Median survival of the control group was 10 days post-baseline scan (95% CI = 6 – 14 days), and median survival of the SRS group was not reached (log-rank $P < 0.04$). However, survival in the SRS group was heterogeneous with 46% of the animals not surviving for more than 15 days. We designated these relative low survival animals as non-responders and animals with survival $> 15$ days as responders. Statistical comparisons were performed for the first 4 time points because all controls died before the 5th time point. Changes in tumour volume, rBF, rBV, and PS of these three groups are shown in Figure 4-5. Significant tumour growth was observed in the controls (Friedman $P = 0.001$, Wilcoxon signed-rank $P < 0.03$). Significant tumour shrinkage was observed in the responders (Friedman $P = 0.04$, Wilcoxon signed-rank $P < 0.05$). There was no significant tumour volume change in the non-responders. Tumour rBF in the responders was significantly lower than the non-responders and controls on day 14 post-SRS.
Tumour rBV in responders were significantly lower than the non-responders and controls on day 4 (Kruskal Wallis $P = 0.04$, Mann-Whitney U $P < 0.04$) and day 7 post-SRS (Kruskal Wallis $P = 0.01$, Mann-Whitney U $P = 0.01$). Responders’ tumour PS was significantly lower than the other groups on day 7 post-SRS (Kruskal Wallis $P = 0.007$, Mann Whitney U $P \leq 0.008$). Between-group differences and longitudinal changes in PS:BV ratio in the tumour were not significant.

![Figure 4-5](image)

**Figure 4-5:** Changes in (i) tumour volume, (ii) relative blood flow (rBF), (iii) relative blood volume (rBV), and (iv) permeability-surface area (PS) in the tumour for controls, responders, and non-responders. *Significantly different from baseline (Friedman test and Wilcoxon-signed rank test). †Significantly different from controls and #significantly different from non-responders (Kruskal-Wallis followed by Mann-Whitney $U$ test).

Figure 4-6 shows an elevation in peritumoural rBF in both responders and non-responders on days 4 and 7 post-SRS compared to the controls (Kruskal Wallis $P \leq$
Significant elevation was observed in peritumoural rBV of responders when compared to controls (Kruskal Wallis $P < 0.01$, Mann-Whitney U $P = 0.001$), and a similar trend was observed for peritumoural PS albeit not significant. This elevation in CT perfusion parameters eventually dissipated with time. Between-group differences and longitudinal changes in PS:BV ratio in the peritumoural region were not significant.

**Figure 4-6:** Changes in (i) rBF, (ii) rBV, and (iii) PS in the peritumoural region for controls, responders, and non-responders. *Significantly different from baseline (Friedman test and Wilcoxon-signed rank test). †Significantly different from controls (Kruskal-Wallis followed by Mann-Whitney U test).

Histological examination revealed no presence of tumour in any of the responders. Increased vascularity was the major sign of late radiation-induced histologic change (Table 4-2). Figure 4-2 shows an example of late radiation-induced damage after the regression of tumour. For the non-responders, tumours were detected on H&E histology;
pseudopalisading necrosis was the major type of necrosis observed. Increased vascularity, endothelial hyperplasia, and hyalinized blood vessels were also observed.

4.3.3 Early Prediction of Survival after Stereotactic Radiosurgery

Tumour volume, rBF, rBV, PS, and PS:BV ratio at baseline and on day 4 post-SRS did not correlate with overall survival. However, tumour rBV ($\rho = -0.61, P < 0.05$) and PS ($\rho = -0.85, P = 0.001$) on day 7 post-SRS correlated with overall survival. We evaluated whether each of the imaging parameter was predictive of overall survival by grouping the treated animals based on the measurement on day 7 post-SRS. Kaplan-Meier survival plots are shown on Figure 4-7. SRS-treated animals with lower tumour rBF, rBV, and PS had significantly longer survival than SRS-treated animals with higher rBF, rBV, and PS (log-rank $P \leq 0.02$). Treated animals with lower tumour volumes were associated with longer survival than those with higher tumour volumes, but this was not significant. Similarly, animals with a low PS:BV ratio did not have significantly different survival than those with high PS:BV ratio. In terms of predictive performance, both rBV and PS had the highest sensitivity (86%), specificity (100%), and accuracy (92%). rBF had a sensitivity, specificity, and accuracy of 71%, 100%, and 83%, respectively. Tumour volume had a sensitivity, specificity, and accuracy of 57%, 80%, and 67%, respectively. The PS:BV ratio had sensitivity, specificity, and accuracy of 67%, 60%, and 64%, respectively.
Figure 4-7: Kaplan-Meier plots of response to treatment categorized by (A) tumour volume, (B) relative blood flow (rBF), (C) relative blood volume (rBV), and (D) permeability-surface area product (PS). For each imaging parameter, two response groups were identified based on whether the measured value was less than the lower 50% confidence interval of variations across all treated animals derived from the between-subject variation on day 7 post-SRS. Those that met this criteria were ranked as “low” by applying this threshold, and the others were ranked as “high”. Animals with low rBF, rBV, and PS on day 7 post-SRS showed significantly longer survival than the rest of the treated animals (i.e. high rBF, rBV, and PS) and control animals. *Significantly different from control group. †Significantly different from the other treated animals with a “high” value. Significant at $P \leq 0.02$ level (log-rank test).
4.4 Discussion

Although radiotherapy offers an overall survival benefit at the population level, accurate assessment of tumour response for each patient is crucial for treatment modification if no response to radiation is detected. Therefore, we need to develop non-invasive imaging biomarkers as early indicators of response to radiation. Such biomarkers may help design combination therapies (drugs + radiation) in future clinical trials. Combining SRS with an anti-angiogenic agent is an attractive treatment option (28) because Bevacizumab appeared to ameliorate radiation-induced necrosis (29). Preclinical studies also suggested that anti-angiogenic agent like DC101 is a radiosensitizer to SRS (30).

From preclinical studies, overall survival benefits post-SRS are commonly reported, with some treated animals surviving substantially longer than others (4-6). In our study, SRS demonstrated an overall survival benefit and histological confirmation of radiation-induced damage. Similar to previous studies, we observed substantial heterogeneity in treatment response. We found that CT perfusion can be a potential noninvasive imaging method to predict response to SRS, and that rBF, rBV, and PS showed better predictive performance of survival than tumour volume.

In clinical studies, the survival benefit of SRS in combination with fractionated radiotherapy is unclear with some studies suggesting a 2-year overall survival benefit (31,32), while randomized trials showed that SRS did not confer a survival benefit over fractionated radiotherapy alone (33,34). Current clinical evidence from fractionated radiotherapy support our preclinical results in that a higher rBV after the completion of radiotherapy is associated with poor survival (35,36). However, the correlation between survival post-SRS and perfusion imaging parameters is lacking in the clinical literature, and there is no imaging biomarker to assess patients who might respond to SRS. Our results provide corroborating evidence to support the hypothesis that CT perfusion is an early biomarker of response to SRS. Use of CT perfusion parameters to characterize tumour vascular profiles and correlate with treatment response might identify patients who would benefit from SRS or hypofractionation treatment schemes. The use of an early
imaging biomarker to assess response to SRS or hypofractionated treatment schemes in randomized clinical trials might better define the role of altered fractionation schemes in this group of patients.

From the acute imaging study, PS did not correlate with the percentage of fragmented α-SMA positive vessels, this could because PS is the product between permeability and surface area of the endothelium (18). Since BV has been shown to correlate with microvessel area (27), we investigated the PS:BV ratio as a surrogate marker of permeability. After SRS, a positive correlation between PS:BV and the percentage of fragmented α-SMA positive vessels points to the effect of radiation on the permeability of the blood-tumour barrier. From our survival study, it is PS that correlated with survival and not the PS:BV ratio. This suggests a low permeability (i.e. poor delivery) but a high surface area of SMA coverage after SRS is associated with poor survival. Vessels that are covered by SMA are mature vessels (24-26), and tumour vessel maturity is associated radiation resistance (8,37-38). Together, this points to a possible link between the vessel SMA coverage and survival. We were unable to show a correlation between survival and SMA coverage of mature vessels directly since any assessment of tumour vessels would require the sacrifice of animals. Further investigation into the direct associations between tumour PS and SMA coverage of mature vessels with tumour response is warranted.

It is important to study the effect of radiation on the adjacent normal brain tissue (i.e. peritumoural region) because it is usually included in the irradiated volume that receives a significant dose of radiation in clinical practice, particularly for linear accelerator-based SRS. Complications and radiation-induced changes of brain tissue, such as edema and blood-brain barrier breakage, after SRS of arteriovenous malformations correlated with the volume of irradiated tissue that received 12 Gy (39-40). The effect of SRS on peritumoural normal brain region in malignant glioma is not well understood and seldom reported (10). Zawaski et al. showed that radiation caused significant changes in permeability and leukocyte-endothelial interactions in the peritumoural normal brain that were indicative of acute inflammatory reaction and
radiation-induced astrogliosis. Our study provides supporting evidence by showing an increase in blood-brain barrier PS.

A few limitations of this study must be considered. First, a relationship exists between radiation effect and dose (2,4). We chose 12 Gy because this dose can be delivered safely using Helical Tomotherapy, and it is used in the SRS boost of newly diagnosed glioblastoma (31-32) and salvage therapy of recurrent glioblastoma for linear accelerator-based SRS (41). Second, different tumour cell lines display different radiosensitivities (42). Therefore, dose-response of vascular changes measured by CT perfusion in other glioma models could be different. Thirdly, the sample size was relatively small and all untreated rats and most of the non-responders have died after the fourth CT perfusion scan. Thus, we could not compare the imaging data between these groups at later time points. Finally, while we used stereotactic techniques for radiation of the tumours, treatment volumes were still large relative to the size of the rat brain with the irradiated volume encompassing the ipsilateral cerebral hemisphere. Thus, the volume of normal brain irradiated was larger than would be the case in clinical radiosurgery treatments. It is possible that these volume differences have contributed to the perfusion changes seen in the peritumoural region.

4.5 Conclusions

This study showed that CT perfusion is a candidate to be an early biomarker of response to SRS. A CT perfusion imaging study in the clinical setting would potentially allow for timely and accurate assessment of early response to radiosurgery. It could help understand the role of SRS in these patients and also in combination with anti-angiogenic therapies. Evaluation of CT perfusion in prospective clinical studies are necessary to validate this technique as a predictive assay. Validation of the relevant CT perfusion indices used in this study for response assessment is warranted.
4.6 References


Chapter 5

5 Relationship of Computed Tomography Perfusion and Positron Emission Tomography to Tumour Progression in Malignant Glioma

This chapter is adapted from the research article, “Relationship of computed tomography perfusion and positron emission tomography to tumour progression in malignant glioma” published in Journal of Medical Radiation Sciences, 2014;61(1):4-13 by Yeung TPC, Yartsev S, Lee T-Y, Wong E, He W, Fisher B, VanderSpek LL, Macdonald D, Bauman G.

5.1 Introduction

In malignant glioma, over 80% of tumour progression occurs within 2 cm of the original tumour site after radiotherapy and concurrent and adjuvant temozolomide chemotherapy (1). Radiological assessment of tumour progression is primarily based on gadolinium-enhanced magnetic resonance (MR) or iodinated contrast-enhanced computed tomography (CT) (2). An increase in the size of the contrast-enhancing lesion is one of the criteria for diagnosing progression (2). However, early changes in contrast enhancement after treatment lack utility in identifying active tumour sites that are likely to persist after treatment.

Functional imaging is gaining popularity as it has demonstrated utility in differentiating tumour grade, predicting treatment response and survival and in identifying active tumour after treatment prior to progression (3). Pre-treatment functional imaging measurements of tumour perfusion and metabolism have been shown to predict survival in newly diagnosed and recurrent malignant glioma (4-7). Similarly, changes in blood flow (BF) and blood volume (BV) during radiotherapy have been shown to be predictive of survival (8,9). The use of multiparametric imaging data may have an added value for predicting survival. For example, tumour metabolism and BF were combined into a metric called the metabolism-flow ratio, and this was found to be
predictive of poor survival in pancreatic cancer (10). Metabolism and BF are usually tightly coupled in normal tissue; however, an increase in metabolism in the presence of low BF may be indicative of a tumour's adaptation to hypoxia (11). This suggests that the metabolism-flow ratio may be a valuable biomarker of hypoxia, which is associated with treatment resistance.

CT perfusion can simultaneously measure BF, BV and permeability-surface area product (PS) in brain tumours (12), and 18-Fluorodeoxyglucose positron emission tomography (FDG-PET) is in routine clinical use for measuring tumour metabolism. The combination of FDG-PET and CT perfusion using a hybrid PET/CT scanner is a practical technique for assessing metabolism and perfusion in quick succession. This can also be used to calculate the metabolism-flow ratio, which circumvents the need for specialized synthesis capabilities to produce hypoxia tracers such as 18-Fluoro-azomycin arabinoside.

No functional imaging studies have been reported near the completion of radiotherapy as an attempt to detect residual malignant gliomas. This study investigated the associations between the pre-radiotherapy gross tumour as defined on contrast-enhanced MR, near-end-of-radiotherapy enhancing lesion as defined on contrast-enhanced CT, near-end-of-radiotherapy CT perfusion and FDG-PET parameters with post-treatment MR-defined tumour progression. We then assessed the value of using these imaging parameters for predicting post-treatment MR-defined tumour progression. Therefore, the goal of this study was to assess whether functional imaging has the potential in predicting sites of future progressive tumour on a voxel-by-voxel basis after radiotherapy and chemotherapy. This can help identify biologically significant volumes of disease present at the end of conventional radiotherapy that could serve as a target for treatment intensification.
5.2 Methods

5.2.1 Patients

All study procedures were approved by Institutional Research Ethics Board. Patients with newly diagnosed malignant glioma were prospectively recruited to the study with informed consent prior to the last week of radiotherapy. The inclusion criteria were: (1) at least 18 years of age, (2) histologically confirmed malignant glioma, (3) Karnofsky Performance Status ≥60, (4) no previous cranial radiotherapy and (5) pre-radiotherapy MR were performed within 12 weeks of radiotherapy treatment planning. Recurrent gliomas, multiple intracranial lesions, or patients that were not suitable for radical radiotherapy (40–60 Gy in 15–30 fractions) were excluded.

5.2.2 Multi-modality Imaging Schedule

After surgery but before radiotherapy, each patient underwent a standard MR imaging comprised of at least one series of T1- and T2-weighted images using a 1.5 T MR scanner (Signa Excite, General Electric Medical Systems, Milwaukee, WI). This MR scan was performed within 12 weeks of the treatment planning CT. Contrast-enhanced T1-weighted images were acquired using a fast spoiled gradient echo sequence (repetition time = 10 msec, echo time = 4 msec and flip angle = 15°) after an intravenous injection of gadopentetate dimeglumine (0.2 mL/kg; Magnevist; Berlex Laboratories, Wayne, NJ).

A FDG-PET and CT perfusion scan was performed during the final week of radiotherapy using a hybrid PET/CT scanner (Discovery VCT, General Electric Healthcare, Waukesha, WI). After an intravenous injection of FDG (385 MBq), positron emission data were collected in list mode for 60 min and binned into 5 min frames in the last 40 min. Each PET data set consisted of 47 axial PET images with a 3.26 mm slice thickness and a 26 cm axial field of view (FOV).

The FDG-PET CT attenuation correction maps in the FDG-PET study were used to select eight 5 mm sections to maximally cover the tumour for a 150 sec two-phase CT perfusion scan. A non-ionic contrast bolus (Omnipaque, General Electric Healthcare,
Princeton, NJ, 300 mg iodine per mL, 0.8 mL/kg of body weight) was injected at a rate of 2–4 mL/sec at 3–5 sec before the start of the scan. While the selected brain sections were scanned continuously for 45 sec and the images reconstructed at 1-sec intervals during the first phase, the same sections were scanned once every 15 sec for seven times during the second phase. The scanning parameters for both phases were 80 kVp, 190 mA, 1 sec per rotation and a 25-cm FOV.

Post-radiotherapy follow-ups were both clinical and radiological. Routine MR images were obtained at 4–6 weeks post-radiotherapy and every 3 months thereafter, and were reviewed by a neuro-oncologist or radiation oncologist. Tumour progression was defined as a continual enlargement of new enhancing lesion (without subsequent resolution) on serial MR imaging along with deterioration of clinical signs and symptoms (2).

5.2.3 Image Processing

CT perfusion images were analyzed using the prototype version of CT Perfusion 4D (Advantage Windows, GE Healthcare, Waukesha, WI). Arterial and venous time-attenuation curves were measured from an anterior cerebral artery and the posterior superior sagittal sinus respectively. BF, BV and PS maps were calculated by deconvolving the arterial time-attenuation curve with the tissue time-attenuation curve from 2 × 2 voxel blocks of CT images (12). The CT images were averaged together to produce average CT images, which have better grey and white matter contrast than conventional contrast-enhanced CT images.

Software provided with the PET/CT scanner was used to correct the PET emission data for random and scatter coincidences, dead time and attenuation. PET images from the last 5 min bin were rigidly co-registered with the average CT using the 3D Slicer software (13). The registered PET voxel values were converted to standard uptake values (SUV) corrected for body surface area (14). SUV maps were divided by the BF maps to generate SUV:BF ratio maps.
Gadolinium-enhanced T1-weighted MR images from pre-radiotherapy and at progression were rigidly co-registered with the near-end-of-radiotherapy average CT. All images (MR and average CT) and functional maps (CT perfusion and PET SUV) were then resampled to 170 × 170 voxels to minimize registration error. From here on, the contrast-enhancing lesion in the pre-radiotherapy T1-weighted MR lesion is the gross tumour, the contrast-enhancing lesion on the average CT acquired at the last week of radiotherapy is the near-end-of-radiotherapy enhancing lesion, and the contrast-enhancing lesion on follow-up T1-weighted MR at the time of progression is the progressive tumour. Contours around the pre-radiotherapy gross tumour, near-end-of-radiotherapy enhancing lesion and progressive tumour were delineated by a radiation oncologist (G.B.). Table 5-1 summarizes the labelling and time of acquisition of the images.

Table 5-1: Summary of images acquired in this study.

<table>
<thead>
<tr>
<th>Name</th>
<th>Type of Image(s)</th>
<th>Image signal</th>
<th>Time of acquisition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gross tumour volume</td>
<td>T1-weighted MR</td>
<td>Gadolinium enhancement</td>
<td>Post-surgery/biopsy and pre-radiotherapy (must be within 12 weeks of treatment planning CT)</td>
</tr>
<tr>
<td>Near-end-of-radiotherapy enhancing lesion</td>
<td>Averaged CT</td>
<td>Iodine enhancement (HU)</td>
<td>Last week of radiotherapy</td>
</tr>
<tr>
<td>BF</td>
<td>BF map</td>
<td>mL/min/100g</td>
<td>Last week of radiotherapy</td>
</tr>
<tr>
<td>BV</td>
<td>BV map</td>
<td>mL/100g</td>
<td>Last week of radiotherapy</td>
</tr>
<tr>
<td>PS</td>
<td>PS map</td>
<td>mL/min/100g</td>
<td>Last week of radiotherapy</td>
</tr>
<tr>
<td>PET</td>
<td>SUV map</td>
<td>FDG uptake</td>
<td>Last week of radiotherapy</td>
</tr>
<tr>
<td>Progressive tumour</td>
<td>T1-weighted MR</td>
<td>Gadolinium enhancement</td>
<td>Time of progression based on routine clinical and radiological follow-up assessments (4 – 6 weeks post-radiotherapy and every 3 months after)</td>
</tr>
</tbody>
</table>

Abbreviations: MR, magnetic resonance; CT, computed tomography; BF, blood flow; BV, blood volume; PS, permeability-surface area product; PET, positron emission tomography; SUV, standard uptake value; FDG, 18-Fluorodeoxyglucose.
5.2.4 Logistic Regression

A custom MATLAB (MathWorks Incorporated, Natick, MA) program was developed for this analysis. A 2-cm bounding box around the union of the pre-radiotherapy gross tumour and the progressive tumour was created to reduce the amount of information for analysis for each patient. Major blood vessels, surgical cavities, ventricles and voxels outside the bounding box were excluded. Each voxel inside the bounding box was assigned three binary statuses: pre-radiotherapy gross tumour (yes/no), near-end-of-radiotherapy enhancing lesion (yes/no) and progressive tumour (yes/no). Logistic regression was used to assess the association between tumour progression and the following sets of independent imaging variables: (1) pre-radiotherapy gross tumour, (2) near-end-of-radiotherapy enhancing lesion, (3) BF, BV, PS and SUV and (4) BV, PS, SUV:BF (15). The last regression was used to investigate the association between tumour progression and SUV:BF as a marker of hypoxia. The strength of association between each parameter and progressive tumour status was evaluated by the odds ratio. Odds ratios were converted to probabilities of recurrence for easier interpretations.

5.2.5 Cross-validation

Leave-one-out cross-validation was used to assess the value of using different imaging parameters to predict tumour progression (16). Each round of cross-validation used one patient data set as the validation set and the data sets from the other patients as the training set. Probability maps of progression for an individual patient (i.e. the validation set) were calculated using the logistic regression equation from the training set. We first considered seven single variable models: (1) Pre-radiotherapy gross tumour, (2) Near-end-of-radiotherapy enhancing lesion, (3) BF, (4) BV, (5) PS, (6) SUV and (7) SUV:BF. We then considered two multivariate models: (1) BV, PS, SUV:BF and (2) BF, BV, PS and SUV. Using receiver operating characteristic (ROC) analysis, the area under the ROC (AUC) curve was calculated. The optimal sensitivity and specificity was calculated using the Youden Index, which is the probability threshold that maximizes the sum of sensitivity and specificity for all possible probabilities from 0% to 100% (16).
5.2.6 Statistical Analysis

Pre-radiotherapy gross tumour, near-end-of-radiotherapy enhancing lesion and progressive tumour volumes within the 4 cm CT perfusion scan length were compared using the Wilcoxon signed-rank test. AUCs of the different logistic models were compared using the Friedman test followed by the Wilcoxon signed-rank test. Models with AUCs that are significantly higher than the AUCs of the pre-radiotherapy gross tumour and end-of radiotherapy enhancing lesion were reported. All statistical tests were done using SPSS version 19.0 (SPSS Incorporated, Chicago, IL), and $P$-values $<0.05$ were considered significant.

5.3 Results

Ten patients with newly diagnosed malignant glioma were prospectively recruited to the study between the years 2008 and 2011. After surgery, all patients underwent radiotherapy (60 Gy in 30 fractions) with concurrent and adjuvant temozolomide chemotherapy. Patient characteristics are listed in Table 5-2. Tumour progression with no evidence of necrosis was histopathologically confirmed in two patients (Patient 9 and 10 in Table 5-2); the remaining patients had tumour progression defined on clinical and imaging grounds only.
<table>
<thead>
<tr>
<th>Patient No.</th>
<th>Age</th>
<th>WHO Grade</th>
<th>Tumour Location</th>
<th>Type of Resection</th>
<th>Months Between RT and Appearance of Progressive Tumours</th>
<th>Site of Tumour Progression</th>
<th>Treatment</th>
<th>Steroid Use</th>
<th>Survival Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>36</td>
<td>3</td>
<td>Left Frontal Temporal</td>
<td>Partial</td>
<td>8.6</td>
<td>aIn-field</td>
<td>RT, TMZ</td>
<td>Yes</td>
<td>Deceased</td>
</tr>
<tr>
<td>2</td>
<td>47</td>
<td>4</td>
<td>Left Parietal</td>
<td>Partial</td>
<td>12.0</td>
<td>In-field</td>
<td>RT, TMZ</td>
<td>Yes</td>
<td>Deceased</td>
</tr>
<tr>
<td>3</td>
<td>55</td>
<td>4</td>
<td>Left temporal</td>
<td>Partial</td>
<td>2.3</td>
<td>In-field</td>
<td>RT, TMZ</td>
<td>Yes</td>
<td>Deceased</td>
</tr>
<tr>
<td>4</td>
<td>37</td>
<td>3</td>
<td>Left frontal temporal</td>
<td>Partial</td>
<td>8.4</td>
<td>In-field and bout-of-field</td>
<td>RT, TMZ</td>
<td>No</td>
<td>Deceased</td>
</tr>
<tr>
<td>5</td>
<td>50</td>
<td>4</td>
<td>Left Frontal lobe</td>
<td>Partial</td>
<td>5.0</td>
<td>In-field</td>
<td>RT, TMZ</td>
<td>Yes</td>
<td>Deceased</td>
</tr>
<tr>
<td>6</td>
<td>71</td>
<td>4</td>
<td>Right temporal parietal</td>
<td>Biopsy</td>
<td>2.1</td>
<td>In-field</td>
<td>RT, TMZ</td>
<td>Yes</td>
<td>Deceased</td>
</tr>
<tr>
<td>7</td>
<td>71</td>
<td>4</td>
<td>Left frontal</td>
<td>Biopsy</td>
<td>4.3</td>
<td>In-field</td>
<td>RT, TMZ</td>
<td>Yes</td>
<td>Deceased</td>
</tr>
<tr>
<td>8</td>
<td>61</td>
<td>4</td>
<td>Left posterior frontal parietal inter-axial tumour</td>
<td>Partial</td>
<td>14.8</td>
<td>In-field</td>
<td>RT, TMZ</td>
<td>Yes</td>
<td>Deceased</td>
</tr>
<tr>
<td>9</td>
<td>60</td>
<td>4</td>
<td>Left Frontal Parietal</td>
<td>Partial</td>
<td>11.0</td>
<td>In-field</td>
<td>RT, TMZ</td>
<td>Yes</td>
<td>Alive</td>
</tr>
<tr>
<td>10</td>
<td>54</td>
<td>4</td>
<td>Left Temporal</td>
<td>Partial</td>
<td>15.6</td>
<td>In-field</td>
<td>RT, TMZ</td>
<td>Yes</td>
<td>Alive</td>
</tr>
</tbody>
</table>

*Abbreviations: WHO, World Health organization; RT, radiation therapy; TMZ, concurrent + adjuvant temozolomide

aIn-field = within 2 cm of the primary contrast-enhancing tumour; bOut-of-field = beyond 2 cm of the primary contrast-enhancing tumour
The mean volumes ± standard deviation (SD) of pre-radiotherapy gross tumour, near-end-of-radiotherapy enhancing lesion and the progressive tumour within the CT perfusion scan volume were 10.8 ± 11.1, 14.1 ± 20.8 and 16.1 ± 18.0 cm$^3$ respectively. The differences in volumes were not significant ($P > 0.05$). Figure 5-1 displays the images of patient 3.

**Figure 5-1**: Pre-radiotherapy gross tumour (T1-weighted MR), near-end-of-radiotherapy enhancing lesion (averaged CT) and progressive tumour (T1-weighted MR); and the corresponding parametric maps of blood flow (BF), blood volume (BV), permeability-surface area (PS) product, standard uptake value (SUV) and
SUV:BF acquired using CT perfusion and FDG-PET. Blue outlines show the contrast-enhancing lesions delineated by a radiation oncologist. Yellow outline is the 2-cm bounding box that was set for performing logistic regression. MR, magnetic resonance; CT, computed tomography; FDG-PET, 18-Fluorodeoxyglucose positron emission tomography.

### 5.3.1 Multivariate Logistic Regression

When compared with normal brain tissue, the pre-radiotherapy gross tumour and the near-end-of-radiotherapy enhancing lesion had odds ratios of 12.7 (95% confidence interval [CI], 12.1–13.4) and 43.3 (95% CI, 41.4–45.3), respectively, for tumour recurrence. These odds can be expressed as recurrence probabilities of 54.4% and 69.8% respectively. Multivariate logistic regression showed that the odds of tumour progression increased with lower BF, BV and SUV; and with higher PS and SUV:BF ($P < 0.0001$) (Table 5-3).

#### Table 5-3: Multivariate logistic regression.

<table>
<thead>
<tr>
<th>Model</th>
<th>Parameter</th>
<th>$P$</th>
<th>${^a}$Regression Coefficients ($\beta$)</th>
<th>Odds Ratio ($e^\beta$)</th>
<th>95% Confidence Interval</th>
<th>Probability (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>BV</td>
<td>$&lt;0.0001$</td>
<td>-0.15</td>
<td>0.86</td>
<td>0.84–0.87</td>
<td>7.1</td>
</tr>
<tr>
<td></td>
<td>PS</td>
<td>$&lt;0.0001$</td>
<td>0.41</td>
<td>1.51</td>
<td>1.49–1.52</td>
<td>11.9</td>
</tr>
<tr>
<td></td>
<td>SUV:BF</td>
<td>$&lt;0.0001$</td>
<td>2.63$^b$</td>
<td>13.88</td>
<td>11.38–16.94</td>
<td>55.4</td>
</tr>
<tr>
<td></td>
<td>Constant</td>
<td>$&lt;0.0001$</td>
<td>-2.41</td>
<td>0.09</td>
<td>0.09–0.09</td>
<td>8.2</td>
</tr>
<tr>
<td>2</td>
<td>BF</td>
<td>$&lt;0.0001$</td>
<td>-0.01</td>
<td>0.99</td>
<td>0.99–0.99</td>
<td>23.1</td>
</tr>
<tr>
<td></td>
<td>BV</td>
<td>$&lt;0.0001$</td>
<td>-0.07</td>
<td>0.93</td>
<td>0.91–0.95</td>
<td>22.1</td>
</tr>
<tr>
<td></td>
<td>PS</td>
<td>$&lt;0.0001$</td>
<td>0.39</td>
<td>1.48</td>
<td>1.47–1.50</td>
<td>31.0</td>
</tr>
<tr>
<td></td>
<td>SUV</td>
<td>$&lt;0.0001$</td>
<td>-0.93</td>
<td>0.39</td>
<td>0.37–0.41</td>
<td>10.7</td>
</tr>
<tr>
<td></td>
<td>Constant</td>
<td>$&lt;0.0001$</td>
<td>-1.19</td>
<td>0.30</td>
<td>0.29–0.32</td>
<td>23.3</td>
</tr>
</tbody>
</table>

*Abbreviations: BV, blood volume; PS, permeability-surface area product; SUV, standard uptake value; BF, blood flow.*

$^a$Degrees of freedom = 128,330

$^b$An increase in SUV:BF value by 0.01 was associated with an odds ratio = 1.03; this corresponded to a probability of 8.4%.
5.3.2 Cross-validation

The AUCs for the three models (1) PS alone, (2) BV, PS, SUV:BF and (3) BF, BV, PS and SUV were 0.72 ± 0.12, 0.74 ± 0.13 and 0.77 ± 0.11 respectively. These AUCs were significantly higher than the AUCs of the pre-radiotherapy gross tumour and near-end-of-radiotherapy enhancing lesion (Friedman \( P < 0.001 \); Wilcoxon signed-rank \( P \leq 0.03 \)), which were 0.64 ± 0.14 and 0.65 ± 0.14 respectively. Although the AUCs of the two multivariate models were higher than that of PS, the differences were not statistically significant (\( P > 0.05 \)). Table 5-4 shows model pairs that are significantly higher than the pre-radiotherapy gross tumour and the end-of-radiotherapy enhancing lesion. The model using PS alone had a sensitivity and specificity of 0.6 ± 0.1 and 0.7 ± 0.1, respectively (Figure 5-2). The model using BF, BV, PS and SUV had the highest combination of sensitivity and specificity (0.7 ± 0.1 and 0.7 ± 0.1). Probability maps of progression were generated using these logistic models, examples of probability maps for patient 3 are shown in Figure 5-3.

Table 5-4: Statistical differences in area under the receiver operating characteristics curve.

<table>
<thead>
<tr>
<th>Model 1</th>
<th>Model 2</th>
<th>% Difference = (Model 2 – Model 1)/(Model 1)×100</th>
<th>± SD</th>
<th>( p )</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pre-radiotherapy gross tumour</td>
<td>PS</td>
<td>14.2</td>
<td>18.1</td>
<td>0.03</td>
</tr>
<tr>
<td></td>
<td>BV, PS, SUV:BF</td>
<td>16.4</td>
<td>18.6</td>
<td>0.03</td>
</tr>
<tr>
<td></td>
<td>BF, BV, PS, SUV</td>
<td>21.4</td>
<td>18.6</td>
<td>&lt; 0.01</td>
</tr>
<tr>
<td>End-of-radiotherapy enhancing lesion</td>
<td>PS</td>
<td>12.7</td>
<td>10.7</td>
<td>0.02</td>
</tr>
<tr>
<td></td>
<td>BV, PS, SUV:BF</td>
<td>15.4</td>
<td>16.7</td>
<td>0.03</td>
</tr>
<tr>
<td></td>
<td>BF, BV, PS, SUV</td>
<td>21.1</td>
<td>20.4</td>
<td>0.02</td>
</tr>
<tr>
<td>PS</td>
<td>BV, PS, SUV:BF</td>
<td>2.1</td>
<td>7.2</td>
<td>0.29</td>
</tr>
<tr>
<td></td>
<td>BF, BV, PS, SUV</td>
<td>7.5</td>
<td>15.9</td>
<td>0.29</td>
</tr>
</tbody>
</table>
Figure 5-2: Area under the operating characteristic curve (AUC) (top), sensitivities (middle) and specificities (bottom) for the selected logistic regression models. Models with an AUC that is significantly higher than the pre-radiotherapy gross tumour and the end-of-radiotherapy enhancing lesion are indicated with an asterisk (*). 1, Pre-radiotherapy gross tumour; 2, End-of-radiotherapy enhancing lesion; 3, BF; 4, BV; 5, PS; 6, SUV; 7, SUV:BF; 8, BF, PS, SUV:BF; 9, BF, BV, PS, SUV.
Figure 5-3: Probability of tumour progression (patient 3) within the 2-cm bounding box generated using the different logistic regression models. Black line outlines the boundary of the progressive tumour. Based on cross-validation, the magenta line delineates the region with the probability threshold that maximizes the sum of sensitivity and specificity in predicting progression.

5.4 Discussion

We investigated whether near-end-of-radiotherapy CT perfusion and FDG-PET can add value to the assessment of malignant glioma in terms of predicting voxels that are likely to progress after treatment. PS alone was found to be the best predictor of tumour progression when compared to other CT perfusion and FDG-PET parameters; however, voxel-based prediction of progression had only modest sensitivity and specificity.

PS describes the unidirectional flow of contrast as it leaks from the intravascular space into the interstitial space (i.e. brain parenchyma) (12). It is not the same as contrast
enhancement because it quantitatively measures the rate of contrast extravasation. In this study, not only did PS show a significant association with progressive tumour but it had a higher AUC than the pre-radiotherapy gross tumour and near-end-of-radiotherapy enhancing lesion for identifying tumour voxels that are more likely to progress. This suggests that PS adds value to contrast enhancement in determining active tumour regions after treatment, and also provides corroborating evidence to support that PS is associated with tumour aggressiveness. PS can be a potential biomarker of tumour aggressiveness because of the underlying pathological aspect that it represents. PS has larger value in high-grade gliomas compared to low-grade gliomas (17), which is important for prognosis. It also showed correlations with aggressive phenotypes including microvascular cellular proliferation (18) and the expression of pro-angiogenic genes (19). Finally, PS has been used to distinguish true tumour progression from treatment effect like treatment-induced necrosis (20).

The observation that both lower BF and BV showed significant associations with tumour progression is noteworthy. A lower BF and BV may suggest resistance to therapy due to the presence of hypoxia. In support of this, dynamic susceptibility contrast MR studies at pre- and mid-radiotherapy showed that a drop in relative BF and BV were predictors of poor survival (8,9). However, the associations observed in this study were obtained from one time point only, and they do not suggest a causal relationship with progression.

We found that a lower SUV, when considering the entire tumour, is associated with an increased risk of progression. This is contrary to studies that showed an increased FDG uptake is associated with poor survival in patients at various stages of treatment (21) or in patients with recurrent tumours (7,22). In these prior studies, FDG uptake in the hypermetabolic region was used to assess correlation with survival. This usually coincides with the contrast-enhancing region of the tumour where the perfusion is high; hence, an FDG delivery was unimpeded. Our results suggest that when considering the tumour as a whole, a lower FDG uptake is associated with higher odds of progression. A low FDG uptake does not necessarily infer a lack of metabolic demand. We instead showed a higher SUV:BF ratio was associated with an increased risk of recurrence,
which suggests that a low SUV was due to poor delivery resulting in uncoupling between metabolism and perfusion. This is consistent with PET-based measure of SUV:BF in pancreatic cancer in which a higher SUV:BF was associated with poor survival (10). These observations provide evidence to support the Warburg Effect hypothesis (10,11). Cancer cells can maintain anaerobic respiration to keep up with its metabolic demand under hypoxic stress and can be therapeutically resistant. This could lead to tumour regions that remain active despite treatment.

Some limitations of this study must be considered. Although the AUCs of the multivariate models were higher than those of the univariate PS model, we were unable to demonstrate the statistical significance of multivariate models superiority. A larger sample size is required to determine whether (1) BF, BV, PS and SUV and (2) BV, PS and SUV:BF can provide more information than PS alone for identifying tumour regions that are likely to progress. Other radiotracers with a higher tumour-to-background ratio in the brain can improve the detection of residual tumour at the end of radiotherapy. For example, both 3′-Deoxy-3′-18F-fluorothymidine (FLT) (23) and 11C-methionine PET (24) were reported to be more sensitive than FDG in evaluating progressive tumours. Deformable registration could potentially improve the quality of registration. Most deformation of the tumour would occur from before and after surgery. This study used only post-surgery images; thus, physical deformation of the tumour is minimal. In addition, the majority of patients received dexamethasone during radiotherapy, which could decrease tumour permeability resulting in less edema and hence less deformation (25). The use of dexamethasone can also decrease cerebral glucose metabolism (26,27). The effect of dexamethasone on glucose metabolism is global rather than localized; it is unlikely to affect the current results because the logistic regression is based on imaging data obtained from both the normal brain and tumour tissues. Finally, we focused our investigation on the tumour site and its immediate surroundings, the potential effects of radiation on normal brain tissue perfusion and metabolism were not investigated in detail. A small radiation dose-dependent relationship (<10%) was observed for both brain tissue metabolism and perfusion (28). We evaluated the relationship between normal brain tissue BF, BV and PS with radiation dose in seven patients and did not find a significant
relationship (data not shown). Thus, the effect of radiation on normal tissue BF, BV and PS is unlikely to affect the current results.

5.5 Conclusions

We developed a technique for voxel-wise analysis of CT perfusion and FDG-PET images acquired at the end of radiotherapy for patients treated for malignant glioma. On the basis of our analysis, near-end-of-radiotherapy PS was the best predictor of tumour progression on a voxel-by-voxel basis when compared to other CT perfusion and FDG-PET parameters. However, voxel-based analysis had only modest sensitivity and specificity. Exploration of these findings among a larger patient cohort would help confirm the value of PS imaging in predicting recurrence and in confirming the trend towards improved prediction with multivariate imaging data.

5.6 References


Chapter 6

6 Treatment monitoring in high-grade gliomas: A serial CT perfusion and MR study

This chapter is adapted from the manuscript entitled “Treatment monitoring in high-grade gliomas: A serial CT perfusion and MR study”. This manuscript will be submitted to the Journal of Neuro-Oncology in July 2014 to be considered for publication. The authors of this manuscript are Yeung TPC, Wang Y, Urbini B, Yartsev S, Bauman G, Lee TY, Fainardi E, and the Project of Emilia-Romagna region on Neuro-Oncology (PERNO) Study Group. Member of the Perno Study Group is provided in Appendix E.

6.1 Introduction

High-grade gliomas account for over 70% of all malignant brain tumours, and survival rates remain dismal even after maximal safe resection, radiotherapy, and temozolomide chemotherapy. The typical median survival for patients with World Health Organization (WHO) grade IV gliomas is typically 12 – 15 months, and it is 2 – 5 years for those with WHO grade III gliomas (1). However, there is considerable heterogeneity in patients’ treatment response. At present, widely accepted prognostic factors of survival in high-grade gliomas are WHO grade, extent of surgical resection, age, and performance status (2). Molecular biomarkers, such as isocitrate dehydrogenase 1 (IDH1) methylation status, O6-methylguanine-DNA-methyltransferase (MGMT) methylation status and 1p19q loss of heterozygosity, are also recognized as predictive and prognostic biomarkers in these patients (3).

High-grade gliomas, particularly WHO grade IV gliomas, are highly infiltrative tumours with recurrence typically arising within 2 cm of the irradiated volume (4,5). Magnetic resonance (MR) imaging is the standard imaging method for brain tumour diagnosis, treatment planning, and response assessment. The typical MR protocol involves a T2-weighted or fluid-attenuated inversion recovery (FLAIR) MR and a
gadolinium-enhanced T1-weighted MR (6). Following this protocol is preferable because it detects two types of anatomical abnormalities. The gadolinium-enhanced T1-weighted MR images depict the contrast-enhancing lesion (CEL) with disrupted blood-brain barrier. The T2-weighted or FLAIR MR images detect regions of T2 hyperintensity that are suspicious of tumour infiltration and vasogenic edema. Such T2 hyperintense region is the non-enhancing lesion (NEL) that cannot be seen on T1-weighted MR.

Functional imaging techniques are non-invasive methods to provide quantifiable information regarding tumour biology that may be related to tumour aggressiveness and patient prognosis (7). One important functional imaging technique is perfusion imaging. Measurements of perfusion imaging parameters such as tumour blood flow (BF), blood volume (BV), and permeability have been shown to correlate with WHO grade (8,9), histopathologic marker of tumour angiogenesis (e.g. microvessel density) (10,11), and survival (12,13,14). Most perfusion imaging studies that evaluated the relationships between tumour perfusion parameters and overall survival (OS) have focused on MR perfusion at a single time point (15) or two time points (16). CT perfusion has not been studied extensively (17) despite the ubiquity of CT scanners in radiation oncology departments. However, CT perfusion can help distinguish between high and low grade gliomas (8,18-20) and between tumour recurrence and radiation necrosis (21,22). In addition, CT perfusion can simultaneously measure absolute BF, BV, and permeability-surface area (PS) in a single scan. Therefore, CT perfusion should be considered as a valuable perfusion imaging modality in oncology.

This study is the first study to evaluate serial changes in tumour BF, BV, and PS in the CEL and NEL of patients with high-grade gliomas for up to a year after radiotherapy. The objective of this study was to evaluate the prognostic value of CT perfusion for predicting overall survival (OS) of patients with high-grade gliomas.
6.2 Materials and Methods

6.2.1 Patient Population

This study was conducted in compliance with the local research ethics committee, and informed consent was obtained from patients. Patients with suspected WHO grade III and IV gliomas were prospectively recruited prior to surgery. Exclusion criteria were 1) a brain lesion that is not WHO grade III and IV gliomas after histopathologic confirmation, 2) prior diagnosis or therapy of brain lesion, 3) unwillingness to participate during follow-up examinations, 4) clinically unstable, 5) contraindications to intravenous administration of iodinated or gadolinium contrast materials, 6) poor quality images due to motion artifacts, and 7) inability to undergo MR due to contraindications such as metallic implants, claustrophobia, and obesity. Our study included 29 patients with high-grade gliomas. Patients with WHO grade III gliomas ($N = 5$) had anaplastic oligodendrogliomas and the rest had WHO grade IV glioblastoma multiforme. The median age of diagnosis was 61 years (range, 31 – 81 years). Patients underwent serial MR and CT perfusion examinations prior to surgery and one, three, six, nine, and 12 months after radiotherapy. The median follow-up was 18.2 months (range, 4.7 – 60.4 months).

After the pre-surgery MR and CT perfusion examinations, all patients underwent surgery followed by external beam radiotherapy ($60 \text{ Gy in 30 fractions}, N = 28; 45 \text{ Gy in 15 fractions with stereotactic boost of 24 Gy in 3 fractions}, N = 1$). Twenty-six patients received concurrent and adjuvant temozolomide chemotherapy. Six patients underwent additional surgery after radiotherapy, and corticosteroids were administered to patients before the second surgery. At the time of progression, glioblastoma patients were given Fotemustine while anaplastic oligodendroglioma patients were given Procarbazine + CCNU (Lomustine).
6.2.2 Conventional MR and CT Perfusion Examinations

MR images were acquired with either a 1.5T Signa HDXT (GE Healthcare, Milwaukee, WI) or a 1.5 T Achieva scanner (Philips Medical Systems, Best, The Netherlands). The MR protocol consisted of the following sequences: axial T1-weighted spin-echo, axial T2-weighted spin-echo or axial FLAIR, coronal FLAIR, and post-gadolinium axial T1-weighted spin echo.

All CT perfusion studies were performed using a multidetector-row CT scanner (Lightspeed VCT, GE). A noncontrast CT scan (350 mA, 120 kV, 5 mm slice thickness) of the head was acquired to locate the brain volume for the CT perfusion scan that would cover eight 5-mm sections of tissue. Ten patients were imaged with a one-phase CT perfusion protocol while 19 patients were imaged with a two phase CT perfusion protocol. A bolus of non-ionic contrast (Iomeron, Bracco Imaging, Konstanz, Germany; 350 mg I/ml, 40 ml) was injected at a rate of 4 mL/s. For the one-phase CT perfusion protocol, a cine scan was initiated at 5 s after the injection. The imaging parameters were 100 mA, 80kV, 1 rotation/s for a duration of 50 s, and images were reconstructed at 0.5 s intervals. For the two-phase protocol, the initial 50 s cine scan was acquired with images reconstructed at 0.5 s intervals, then 8 additional axial images were acquired for each section at 15 s intervals for another 105 s. The total scan duration was 150 s. The CT gantry was tilted to avoid radiation dose to the lens, signs of radiation toxicities from CT perfusion scans were documented. Skin erythema, dizziness, loss of equilibrium, modified gait, stupor of thought, loss of memory, air loss, cataract formation during the CT and MR follow-ups were some of the radiation-induced side effects assessed by the attending radiologist.

6.2.3 Image Analysis

Maps of BF, BV, and PS were computed using the prototype version of CT Perfusion 4D (GE Healthcare) (23,24). Averaged CT images were produced by averaging the cine CT images of the same sections. Axial gadolinium-enhanced T1-weighted MR and axial T2-weighted or FLAIR MR images were rigidly registered to the averaged CT
images using 3D Slicer (25). A radiologist with 8 years of experience manually delineated the contrast-enhancing lesion (CEL) on gadolinium-enhanced T1-weighted images and the non-enhancing lesion (NEL). The NEL was the entire T2 hyperintense lesion outside the CEL, necrosis, and surgical cavity. Mean volume, BF, BV, and PS in both CEL and NEL at each time point were used for statistical analysis.

6.2.4 Statistical Analysis

Statistical analysis was performed using SPSS software package (IBM® SPSS®, version 21.0, Chicago, IL). OS was the time between the first surgery and death. OS was censored for patients that were alive at their last follow-up. Patients were stratified by their OS using 12, 18, and 24 months OS as cut points. Longitudinal analyses examined the imaging parameter differences in patients with short versus long OS. The omnibus Friedman test followed by the Wilcoxon signed-rank test were used for longitudinal comparisons within-group, and the Mann-Whitney U test examined the differences between groups. The imaging time points that were analyzed were pre-surgery, one, three, and six months post-radiotherapy. Nine and 12 months post-radiotherapy data were not analyzed due to patient dropouts resulting from deaths or complete regression of tumours.

A series of statistical analyses were carried out to evaluate whether the imaging parameters were prognostic of OS. Receiver operating characteristic analyses were performed to consider all possible cut points to differentiate patients with long and short OS. The imaging parameter cut points with the highest combination of sensitivity and specificity were selected for use in Cox proportional hazards regression and Kaplan-Meier survival analyses.

Cox proportional hazards regression analyses were performed to determine the relationships between OS and each of the imaging parameters. Separate Cox proportional hazards regression models were computed for each of the imaging parameters (volume, BF, BV, and PS) at each time point while adjusting for age, performance status.
(Karnofsky Performance Status), extent of surgical resection, and WHO grade. The hazard ratios (HR) and their 95% confidence intervals (CI) were computed. We did not consider the impact of change in imaging parameters over time on OS by treating the serial imaging measurements as time-dependent covariates. This is because this study sought to evaluate whether one of these imaging time points can be used as an early biomarker of OS in a prospective setting. We then used Kaplan-Meier survival analysis and log-rank test to compare the OS of patients with high versus low values of imaging parameters. A $P$ value $\leq 0.05$ was considered statistically significant.

6.3 Results

6.3.1 Patient Characteristics and Outcomes

A total of 150 CT perfusion and 150 MR examinations were obtained from 29 patients. No radiation toxicity from serial CT perfusion scans was noted. The median OS was 18 months (range, 5 – 60 months) with three patients censored. Table 6-1 summarizes the characteristics of this patient cohort and OS estimates based on patient characteristics. In univariate analyses, differences in gender, extent of surgical resection, Karnofsky Performance Status, and re-operation were not significant predictors of OS. Older patients ($\geq 50$ years) had worse OS than younger patients, but this was marginally significant ($P = 0.06$). Patients with WHO grade IV tumours were associated with significantly shorter OS compared to those with WHO grade III tumours ($P = 0.04$). The six patients who received reoperation did not show significantly different OS than the rest.

### Table 6-1: Patient characteristics, percentages of patients alive 12, 18, and 24 months, and median OS estimates.

<table>
<thead>
<tr>
<th>Demographics</th>
<th>n</th>
<th>12 Months OS</th>
<th>18 Months OS</th>
<th>24 Months OS</th>
<th>Median OS in months (95% CI)</th>
<th>$P$ Value$^*$</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age &lt; 50</td>
<td>5</td>
<td>100%</td>
<td>80%</td>
<td>75%</td>
<td>32.7 (20.7 - 44.7)</td>
<td>0.06</td>
</tr>
</tbody>
</table>
### Abbreviations:

OS, Overall survival; CI, Confidence interval; WHO, World Health Organization

*Log-rank P value comparing OS for the demographic factor

### 6.3.2 Longitudinal Analysis

Figure 6-1 shows the serial changes of each imaging parameter in the CEL in terms of 12, 18, and 24 months OS. Patients appeared to show a reduction in CEL volumes after surgery and radiotherapy compared to baseline, and this was significant for patients with OS over 18 months ($P < 0.04$). There were also decreasing trends in BF, BV, and PS in the CEL after surgery. These trends were significant for BF and BV in patients who lived over 12 ($P < 0.02$) and 18 months ($P < 0.05$ and $P < 0.03$, respectively), and for BV in patients who lived less 24 months ($P < 0.04$). With the exception of BV in the CEL of patients who survived beyond 18 months, CEL volumes, BF, BV, and PS were stable between one to six months post-radiotherapy. In general, CEL volumes, BF, BV, and PS appeared to be higher in patients that survived below 18 and 24 months compared to other patients. BV at three months ($P = 0.03$) and PS at one month ($P = 0.04$) post-radiotherapy were significantly higher in patients with OS < 24 months compared to other patients.
Figure 6-1: Serial changes in mean volumes (top row), blood flow (BF, second row), blood volume (BV, third row), and permeability-surface area product (PS, bottom row) in the contrast-enhancing lesions (CEL) of patients stratified by 12 (left column), 18 (middle column), and 24 months (mo) overall survival (OS, right column). Horizontal line represents significant changes between two highlighted time points of the same group. Dotted box represents a significant difference between the groups. Error bar represents one standard deviation.
Figure 6-2 illustrates the serial changes in the NEL by different OS. NEL volumes decreased after surgery and radiotherapy. This change (compared to baseline) was significant for patients who lived more than 12 months ($P < 0.05$), more than 18 months ($P < 0.03$), more than 24 months ($P < 0.05$), and also for patients who lived less than 24 months ($P < 0.03$). However, there was no between-group difference in NEL volumes in patients with long ($\geq 12, 18, \text{ and } 24 \text{ months}$) versus short OS ($< 12, 18, \text{ and } 24 \text{ months}$).

BF values in the NEL were stable over time with the exception of a significant decrease between pre-surgery and 6 months post-radiotherapy in patients that lived less than 24 months ($P < 0.005$). BF values in the NEL before surgery were significantly higher in patients that deceased before 18 ($P = 0.003$) and 24 months ($P = 0.004$); and they were also significantly higher at three months post-radiotherapy ($P = 0.05$) in patients with OS below 18 months. In comparison with pre-surgery measurements, BV values in the NEL decreased significantly ($P < 0.04$) at three and six months post-radiotherapy in patients with OS below 24 months. However, BV values in the NEL were significantly higher at one and three months post-radiotherapy in patients with OS below 18 months ($P = 0.04$ and 0.02, respectively) when compared to those with OS beyond 18 months. BV values were also significantly higher at pre-surgery and one month post-radiotherapy for those with OS less than 24 months when compared to those that lived beyond 24 months ($P = 0.01$ and 0.03, respectively).

PS values in the NEL significantly decreased after surgery and radiotherapy in patients who survived beyond 12 and 18 months ($P < 0.01$, and $\leq 0.03$, respectively), and also in patients who survived less than 18 and 24 months ($P < 0.04$ and $< 0.04$, respectively). More importantly, PS values in the NEL at one month post-radiotherapy were significantly higher in patients who deceased before 18 and 24 months ($P < 0.01$), and these values measured at three months post-radiotherapy were also significantly higher in patients with OS below 18 months ($P = 0.02$).
Figure 6-2: Serial changes in mean volumes (top row), blood flow (BF, second row), blood volume (BV, third row), and permeability-surface area product (PS, bottom row) in the non-enhancing lesions (NEL) of patients stratified by 12 (left column), 18 (middle column), and 24 months (mo) overall survival (OS, right column). Horizontal line represents significant changes between two highlighted time points of the same group. Dotted box represents a significant difference between the groups. Error bar represents one standard deviation.
6.3.3 Survival Analysis

The Cox proportional hazards regression model of the classical prognostic factors (i.e. age, performance status, extent of resection, and WHO grade) showed that higher WHO grade (HR = 49.6, 95% CI = 5.1 – 483.2, P < 0.001) and lower extent of resection (HR = 19.0, 95% CI = 3.6 – 99.5, P < 0.001) were associated with significant hazards of death. A total of 96 Cox proportional hazards regression models were considered while adjusting for age, performance status, extent of resection and WHO grade. Table 6-2 reports parameters with cut points that were associated with both significant hazard ratios and significant differences in OS, and Figure 6-3 illustrates the Kaplan-Meier plots of these parameters.
<table>
<thead>
<tr>
<th>Imaging Time</th>
<th>Region</th>
<th>Cut point selected based on</th>
<th>Parameter Cut Point</th>
<th>Hazard ratios (95% CI)</th>
<th>Cox regression P Value</th>
<th>Median OS (95% CI)</th>
<th>Log-rank P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pre-surgery</td>
<td>NEL</td>
<td>12 mo OS</td>
<td>BF ≥ 16.1 ml/min/100g</td>
<td>10.9 (2.9 – 41.5)</td>
<td>&lt; 0.001</td>
<td>High: 16.4 (9.3 – 23.4) Low: 28.8 (19.3 – 38.3)</td>
<td>0.001</td>
</tr>
<tr>
<td></td>
<td></td>
<td>18 mo OS</td>
<td>BF ≥ 16.8 ml/min/100g</td>
<td>9.9 (2.3 – 42.5)</td>
<td>0.002</td>
<td>High: 16.4 (9.8 – 23.0) Low: 24.4 (16.5 – 32.3)</td>
<td>0.003</td>
</tr>
<tr>
<td></td>
<td></td>
<td>24 mo OS</td>
<td>BF ≥ 16.1 ml/min/100g</td>
<td>10.9 (2.9 – 41.5)</td>
<td>&lt; 0.001</td>
<td>High: 16.4 (9.3 – 23.4) Low: 28.8 (19.3 – 38.3)</td>
<td>0.001</td>
</tr>
<tr>
<td>1 month post-radiotherapy</td>
<td>CEL</td>
<td>12 mo OS</td>
<td>Volume ≥ 12.3 cm³</td>
<td>7.4 (1.9 – 28.5)</td>
<td>0.004</td>
<td>High: 9.1 (5.8 – 12.4) Low: 18.0 (15.0 – 20.9)</td>
<td>0.007</td>
</tr>
<tr>
<td></td>
<td>NEL</td>
<td>18 mo OS</td>
<td>Volume ≥ 11.6 cm³</td>
<td>4.1 (1.1 – 15.3)</td>
<td>0.04</td>
<td>High: 16.6 (7.2 – 26.0) Low: 32.7 (26.5 – 38.9)</td>
<td>0.03</td>
</tr>
<tr>
<td></td>
<td>NEL</td>
<td>24 mo OS</td>
<td>Volume ≥ 11.6 cm³</td>
<td>4.1 (1.1 – 15.3)</td>
<td>0.04</td>
<td>High: 16.6 (7.2 – 26.0) Low: 32.7 (26.5 – 38.9)</td>
<td>0.03</td>
</tr>
<tr>
<td></td>
<td>NEL</td>
<td>24 mo OS</td>
<td>PS ≥ 1.4 ml/min/100g</td>
<td>4.9 (1.4 – 17.3)</td>
<td>0.01</td>
<td>High: 12.6 (6.3 – 18.9) Low: 28.8 (19.7 – 37.9)</td>
<td>0.002</td>
</tr>
<tr>
<td>3 months post-radiotherapy</td>
<td>CEL</td>
<td>12 mo OS</td>
<td>BV ≥ 1.7 ml/100g</td>
<td>5.2 (1.2 – 21.7)</td>
<td>0.03</td>
<td>High: 11.7 (9.2 – 14.2) Low: 23.6 (5.6 – 41.7)</td>
<td>0.007</td>
</tr>
<tr>
<td></td>
<td>18 mo OS</td>
<td>24 mo OS</td>
<td>BV ≥ 1.7 ml/100g</td>
<td>5.2 (1.2 – 21.7)</td>
<td>0.03</td>
<td>High: 11.7 (9.2 – 14.2) Low: 23.6 (5.6 – 41.7)</td>
<td>0.007</td>
</tr>
<tr>
<td></td>
<td>18 mo OS</td>
<td>24 mo OS</td>
<td>BV ≥ 1.7 ml/100g</td>
<td>5.2 (1.2 – 21.7)</td>
<td>0.03</td>
<td>High: 11.7 (9.2 – 14.2) Low: 23.6 (5.6 – 41.7)</td>
<td>0.007</td>
</tr>
<tr>
<td>6 months post-radiotherapy</td>
<td>CEL</td>
<td>18 mo OS</td>
<td>VOL ≥ 13.9 cm³</td>
<td>5.7 (1.1 – 28.7)</td>
<td>0.04</td>
<td>High: 12.6 (6.3 – 18.9) Low: 18.2 (12.2 – 24.1)</td>
<td>0.05</td>
</tr>
<tr>
<td></td>
<td>NEL</td>
<td>18 mo OS</td>
<td>BV ≥ 1.3 ml/100g</td>
<td>12.9 (2.8 – 58.9)</td>
<td>0.001</td>
<td>High: 12.6 (5.4 – 19.8) Low: 24.4 (20.7 – 28.1)</td>
<td>0.004</td>
</tr>
<tr>
<td></td>
<td>24 mo OS</td>
<td>24 mo OS</td>
<td>BV ≥ 1.3 ml/100g</td>
<td>12.9 (2.8 – 58.9)</td>
<td>0.001</td>
<td>High: 12.6 (5.4 – 19.8) Low: 24.4 (20.7 – 28.1)</td>
<td>0.004</td>
</tr>
</tbody>
</table>

Abbreviations: NEL, non-enhancing lesion; CEL, contrast-enhancing lesion; mo, month, OS, overall survival; BF, blood flow; PS, permeability-surface area product; BV, blood volume
Figure 6-3: Kaplan-Meier survival plots of blood flow in the non-enhancing lesion (BF\textsubscript{NEL}), volume of the contrast-enhancing lesion (VOL\textsubscript{CEL}), volume in the NEL (VOL\textsubscript{NEL}), permeability-surface area product in the NEL (PS\textsubscript{NEL}), blood volume in the CEL (BV\textsubscript{CEL}), and BV in the NEL (BV\textsubscript{NEL}) measured at different time points. Higher values in these parameters were associated with worse overall survival (log-rank $P < 0.05$ for all comparisons).
Although some imaging parameters did not show a significant association with OS, they could still be useful in stratifying patients by OS. Table 6-3 shows the sensitivities and specificities of imaging parameters that are ≥ 70% in stratifying patients based on OS. While some CT perfusion parameters showed sensitivities and specificities ≥ 70%, volumes of NEL and CEL did not. In addition, BF in the NEL at pre-surgery and BV in the CEL at three months post-radiotherapy had the highest combination of sensitivities (83% and 82%, respectively) and specificities (86% and 100%, respectively) in stratifying patients based on 24 months OS. Figure 6-4 illustrates pre-surgery CT perfusion and MR images of two patients with different survival (16.7 vs. 41.6 months). Higher BF, BV, and PS in the NEL can be seen in the patient with shorter survival.

<table>
<thead>
<tr>
<th>Imaging Time</th>
<th>Region</th>
<th>Cut-point selected based on</th>
<th>Parameter cut point</th>
<th>AUC</th>
<th>Sensitivity</th>
<th>Specificity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pre-surgery</td>
<td>NEL</td>
<td>18 mo OS</td>
<td>BF ≥ 16.8 ml/min/100g</td>
<td>0.76</td>
<td>80%</td>
<td>77%</td>
</tr>
<tr>
<td></td>
<td>CEL</td>
<td>24 mo OS</td>
<td>BF ≥ 16.1 ml/min/100g</td>
<td>0.88</td>
<td>83%</td>
<td>86%</td>
</tr>
<tr>
<td>1 Month Post-radiotherapy</td>
<td>NEL</td>
<td>18 mo OS</td>
<td>PS ≥ 1.4 ml/min/100g</td>
<td>0.76</td>
<td>71%</td>
<td>79%</td>
</tr>
<tr>
<td></td>
<td>CEL</td>
<td>24 mo OS</td>
<td>PS ≥ 3.4 ml/min/100g</td>
<td>0.81</td>
<td>75%</td>
<td>80%</td>
</tr>
<tr>
<td>3 Months Post-radiotherapy</td>
<td>CEL</td>
<td>24 mo OS</td>
<td>BV ≥ 1.7 ml/100g</td>
<td>0.85</td>
<td>82%</td>
<td>100%</td>
</tr>
</tbody>
</table>

**Abbreviations**: NEL, non-enhancing lesion; CEL, contrast-enhancing lesion; mo, months, OS; overall survival; BF, blood flow; BV, blood volume; PS, permeability-surface area product; AUC, area under the receiver operating characteristic curve
Figure 6-4: Illustrative pre-surgery CT perfusion and MR images of patients with WHO grade IV gliomas. Both patients presented with a contrast-enhancing lesion on post-gadolinium T1-weighted MR images, which also had elevated blood flow (BF), blood volume (BV), and permeability-surface area product (PS). Patient A presented with low BF, BV, and PS in the non-enhancing lesion (NEL, asterisk). However, Patient B presented with regions of elevated BF, BV, and PS in the NEL (red arrows). The survival for patient A was 41.6 months and Patient B was 16.7 months. Identical window and level were used for the color maps.
6.4 Discussion

OS in patients with high-grade gliomas remains poor despite aggressive treatments. Deployment of advanced functional imaging that can stratify patients by expected OS can potentially facilitate timely selection of appropriate treatments for these patients. This study examined the serial changes in CT perfusion parameters in conjunction with volumetric changes in the CEL and NEL of patients with high-grade gliomas. We also examined whether these imaging parameters could predict OS.

Perfusion changes after radiotherapy have previously been studied only in a few reports (26,27). An increase in BV was associated with progression (26) and poor survival (27). This is the first study to investigate serial changes in BF, BV, and PS in both the CEL and NEL for up to one year post-radiotherapy. The initial decline of all imaging parameters in the CEL after surgery and radiotherapy could be attributed to surgical debulking of the tumour and therapeutic effect of radiotherapy and chemotherapy. After stratifying patients based on 18 and 24 months OS, all three perfusion parameters in the CEL started to diverge three months after radiotherapy with elevated BF and BV seen in patients with shorter OS. On the other hand, BF, BV, and PS in the NEL were consistently higher in two groups of patients with shorter OS (< 18 and 24 months). Although statistical differences were identified only at some of the time points, in general our data provided corroborating evidence that part of the heterogeneity in OS is related to variation in tumour perfusion characteristics both in the CEL and NEL regions. This variation in perfusion characteristics presumably reflected the differences in angiogenesis and vascularity between patients. Angiogenesis as a mechanism for promoting tumour growth is now an active target in cancer therapies (28). Angiogenesis leads to an increase in tumour microvessel area, which has been shown to correlate with tumour BV and patient survival (11). More recently, vasculogenesis, a process by which bone marrow-derived cells are recruited to form new tumour blood vessels, has been shown to govern tumour recurrence after radiotherapy (29). It is not known what percentage of tumour vessels are derived from vasculogenesis, but given that recurrence occurs within 2 cm of the irradiated volume (4,5) it is critical to assess perfusion parameters in both the CEL and NEL after radiotherapy.
None of the imaging measurements made in the CEL before surgery showed a significant correlation with OS. This could be because total resection of the tumour (mostly CEL) is a stronger predictor of OS. Over 60% of patients in this study underwent total resection and the extent of resection showed a significant association with OS. Prediction of survival using pre-surgery CT perfusion parameters in the CEL may be more appropriate for patients who are not candidates for total resection. For example, pre-surgery tumour BV is a predictor of survival in a study with a mixture of patients that received biopsy, subtotal resection, and total resection (12). However, pre-surgery measurement of BF in the NEL proved to be useful in predicting OS in this study. This result points to the role of tumour burden in the T2 hyperintense lesion that is not typically removed by surgery.

Although a larger sample size is required to show consistent associations between OS and CT perfusion parameters across all time points, our results are consistent with previous reports that higher BV and PS are associated with poor outcomes (12,13,26,27). It is also noteworthy that while we showed significant hazards of death associated with both volumetric and CT perfusion parameters, only CT perfusion parameters resulted in sensitivities and specificities ≥ 70% in predicting OS. CT perfusion parameters can provide complementary information to volumetric MR measurements in predicting survival in high-grade glioma patients. Volume of the CEL may not be a reliable predictor of outcome because the volume of contrast-enhancement may be affected by many nontumoural processes including inflammation, postsurgical changes, pseudoprogression, and treatment-induced necrosis (30-33). Similarly, the volume of the NEL encompasses many causes of T2 hyperintensity such as vasogenic edema, gliosis, cystic changes, inflammation, and tumour infiltration (34-36). It is evident from Figure 6-4 that tumours can have regions of high BF, BV, and PS that are bigger than the CEL. These regions can potentially lead to future sites of recurrence. Although this is hypothesis-generating, there is preliminary evidence to suggest that there could be better spatial concordance between CT perfusion parameters with the site of future recurrence than the CEL with the site of future recurrence (23).
Some limitations must be considered. Our sample size was relatively small and five patients had anaplastic oligodendrogliomas, which are known to have a higher BV than astrocytic gliomas despite better survival (37,38). This can hamper the ability to stratify OS based on BV. In addition, we did not have information regarding other known biologic biomarkers like MGMT methylation status that are associated with OS and thus we could not correct for those effects in our regression models. Likewise, the variable use of salvage therapies like second surgery and chemotherapy may have influenced OS although in glioblastoma patients these effects could be expected to be modest (39). Another limitation was the use of a one-phase CT perfusion protocol in one third of the patients. The duration of the CT perfusion protocol can affect the measurements of CT perfusion parameters, in particularly PS (24). Although we did not find a statistical difference in these parameters in the CEL and NEL at baseline between the two protocols (data not shown), it is important to use a two-phase CT perfusion protocol in future studies. We did not consider the impact of change in each of the imaging parameters over time on OS by treating the serial measurements as time-dependent covariates in a joint model of survival and time-dependent covariates. This is because we first want to evaluate the predictive value of these imaging parameters as independent predictors of survival in order to limit the number of CT perfusion follow-ups in future studies. Finally, a perfusion imaging scan at the time point of pre-radiotherapy but post-surgery could be a better baseline scan than a pre-surgery perfusion imaging scan. This may have helped extract the relative contribution of perfusion imaging parameters versus the extent of surgical resection in predicting survival.

6.5 Conclusions

BF, BV, PS are potential biomarkers of OS in patients with high-grade gliomas treated with multi-modality therapy (surgery, radiation, chemotherapy) even after adjustments for age, WHO grade, Karnofsky Performance Status, and the extent of resection. The results of this study, if verified in a larger cohort of patients, could establish CT perfusion imaging as a reliable predictor of survival.
6.6 References


Chapter 7

7 Conclusion and Future Work

7.1 Summary of Findings

This thesis demonstrated 1) the importance of mitigating some of the uncertainties associated with CT perfusion imaging and 2) the possibilities of using CT perfusion imaging to stratify outcomes in brain tumour patients and in an experimental model of brain tumour. In this chapter, major findings of the five studies in this thesis are summarized, and future investigations are discussed.

7.1.1 Mitigating Uncertainties in CT Perfusion

Although much research has been done in the field of CT perfusion imaging, interpretation of these results can be confounded by variations in image acquisition protocols affecting the measurements of different CT perfusion parameters (e.g. blood flow, BF). The absence of a standardized protocol has led to the procedure variability observed amongst published studies. One imaging acquisition parameter that varied widely in the literature is the scan duration. Chapter 2 addressed the role of scan duration in the measurements of BF, blood volume (BV), and permeability-surface area product (PS). Systematic and random errors in BF, BV, and PS measurements increased with shorter scan duration. Tumour rim PS values computed from shorter (60 s) scans were significantly different from the corresponding values computed from the longer (150 s) scans ($P < 0.01$). As a result of these analyses, a minimum scan duration of 90 s is recommended.

CT image noise not only affects the visualization of anatomical structures; it affects the calculated BF, BV, and PS values. Chapter 3 evaluated the improvements in the measurements of these parameters after filtering CT perfusion images using principal component analysis (PCA). From the simulation, PCA filtering reduced the measurement errors of BF, BV, and PS. Similarly, the noise of BF, BV, and PS measurements also decreased after PCA filtering. From experiments, we showed that PCA improved the
contrast-to-noise ratio of CT perfusion images. At a noise level of 17 HU, a minimum of 4 principal components was recommended for filtering CT perfusion images.

While other aspects of CT perfusion imaging remain to be optimized, the development of recommended minimum scan duration and an optimized image noise filtering technique are important components of developing standardized approaches to perfusion imaging.

7.1.2 CT Perfusion as a Biomarker of Treatment Outcomes

Clinical outcomes of patients with malignant gliomas vary widely with some patients surviving longer than others despite standard treatments. Thus, a biomarker that can stratify patients by survival can potentially personalize treatments for these patients. To contribute to this goal, we examined the ability of CT perfusion in identifying “long-term survivors” and “short-term survivors” in both malignant glioma patients and a preclinical animal model.

Stereotactic radiosurgery (SRS) has garnered clinical interests over the years for the treatment of malignant gliomas, but clinical trials of SRS have not demonstrated clinically meaningful improvements in survival over conventional fractionated radiotherapy. Using the C6 glioma model for rats (Chapter 4), we investigated the efficacy of CT perfusion as a potential early imaging biomarker of response to SRS. Our results showed that response to SRS was heterogeneous. Stratification of treated animals based on 15 day survival showed that responders (surviving > 15 days) had lower relative BV and PS on day 7 post-SRS when compared to controls and non-responders \((P < 0.05)\). In addition, relative BV and PS on day 7 post-SRS were predictive of survival with 92% accuracy while tumour volume was not predictive of survival. These findings point to the potential role of CT perfusion as an early biomarker of response to SRS.

Identifying active tumour regions that are likely to persist after treatment can help tailor radiotherapy to target these regions. Chapter 5 investigated whether multiparametric imaging with CT perfusion and 18F-Fluorodeoxyglucose positron
emission tomography (FDG-PET) can identify tumour sites that are likely to correlate with the eventual location of tumour progression. We developed a method to generate probability maps of tumour progression based on CT perfusion, FDG-PET, and anatomical MR imaging data. Our results showed that PS had the highest area under the receiver operating characteristic curve for identifying tumour regions that are likely to coincide with future sites of progression (AUC = 0.72 ± 0.12). Although the sensitivity and specificity were modest for identifying tumour regions that were likely to progress, this study demonstrated the use of voxel-based analysis of multi-parametric imaging data in relation to future sites of progression.

The final study of this thesis (Chapter 6) examined the serial changes in tumour volumetric and CT perfusion parameters and evaluated the predictive values of these data in stratifying malignant glioma patients by overall survival. Patients were imaged with conventional MR and CT perfusion before surgery and regularly after radiotherapy for up to a year. A trend towards higher BF, BV, and PS in the contrast-enhancing lesion (CEL) and the non-enhancing lesion (NEL) were found in patients with overall survival less than 18 and 24 months, and these values were significant at some time points ($P < 0.05$). Pre-surgery BF in the NEL and BV in the CEL three months after radiotherapy had the highest combination of sensitivities and specificities of $\geq 80\%$ in predicting 24 months overall survival. These results suggest using BF, BV, and PS as early predictors of survival.

### 7.2 Clinical Translational Potential

The findings of this thesis contributed important information for the clinical translation of CT perfusion in brain tumour imaging. Here, we describe how this research is clinically relevant.

Decision making based CT perfusion information relies on accurate and precise measurements of BF, BV, and PS. This thesis proposed two ways to improve the accuracy and precision of CT perfusion parameter measurements. Our investigation of
the effect of scan duration demonstrated that protocol standardization is a simple first step in reducing the uncertainties associated with CT perfusion parameters. This work is important and two more studies investigating the effect of CT perfusion scan duration have cited our work since our study was published in January, 2013 (1,2). Image filtering using PCA is another way to mitigate some of the uncertainties in the measurements of BF, BV, and PS. PCA filtering of CT perfusion images has important clinical relevance in terms of improving image quality and reducing radiation dose. Radiation dose is of concern when performing serial CT perfusion studies. Thus, dose reduction will facilitate the use of serial CT perfusion follow-ups in the clinic. Reducing the image acquisition frequency has been proposed as a method to reduce radiation dose (3-5). This method is simple to implement and reduces radiation dose effectively. However, the lesser number of acquired images translates into a reduction in the amount of data available for estimating BF, BV, and PS. As a result, it is recommended that the frequency of image acquisition be less than 4 s per image. Our method can be more effective in reducing image noise because PCA filtering is a post-image acquisition technique. Future investigation should examine the ability of PCA in maintaining image quality while reducing radiation dose.

One of the challenges in the treatment of malignant gliomas is the heterogeneity in clinical outcomes. Here we propose several roles that CT perfusion imaging can play to improve the care of these patients in terms of spatial targeting and temporal monitoring of these tumours.

Image-guidance has improved the precision of surgical resection of brain tumours and spatial targeting in radiotherapy. Image-guidance has largely been limited to post-gadolinium T1-weighted and T2-weighted or fluid attenuated inversion recovery (FLAIR) MR. These techniques predominately assess the structural abnormalities of tumours. The results described in chapters 5 and 6 point to a possible spatial mismatch between the CEL on MR and tumour regions with high CT perfusion parameter values. In radiotherapy, the CEL is called the gross tumour volume. Biologic imaging modalities, such as CT perfusion, have been proposed to help delineate a “biologic target volume” in radiotherapy (6). The spatial mismatch between the gross tumour volume (i.e. CEL) and
the biologically active tumour volume has been studied in a few PET imaging studies (7-10). The spatial mismatch suggested in this thesis could serve for improving the delineation of targets for radiotherapy dose escalation. CT perfusion is of particular importance in this respect because CT scanners/simulators are readily available in radiotherapy centers and an integral part of the radiation treatment planning workflow. The use of CT perfusion imaging facilitates the registration of treatment planning CT images with CT perfusion parameter maps. It is also inexpensive compared with other imaging techniques such as MR perfusion, and can acquire data for generating maps of BF, BV, and PS within a few minutes. Therefore, CT perfusion is currently the easiest modality to implement as a biologic imaging modality in radiation therapy.

Chapters 4 and 6 point to the potential role of CT perfusion in the follow-up of patients post-treatment. Results from the pre-clinical study (Chapter 4) are consistent with the results of the clinical study (Chapter 6). Both studies showed that higher BF, BV, and PS after radiation treatments are associated with worse survival. These findings are clinically important because they indicate that tumours with higher BF, BV, and PS are more aggressive and less likely to respond to radiotherapy. These patients might benefit from additional treatments. Currently, salvage treatments for recurrent glioblastomas are not standardized. Treatments options include second surgery, repeat irradiation, chemotherapy, and anti-angiogenic therapies (11). Therefore, early selection of patients with aggressive tumours based on CT perfusion parameters may facilitate earlier administration of salvage therapies.

7.3 Future Work

This thesis addressed many important questions regarding CT perfusion imaging of malignant gliomas. As with any research, this thesis generated a number of new and important questions. The following section outlines possible future projects.
7.3.1 A Framework for Quality Assurance (QA) in CT Perfusion Imaging

As alluded to earlier, quality assurance (QA) is important for widespread implementation of CT perfusion imaging in oncology trials and practice. Consensus guidelines for the use of CT perfusion were published in 2012 (12). However, a QA framework is needed to establish tolerance limits and best practices guidelines. Figure 7-1 proposes a QA framework for CT perfusion imaging so that tolerance limits and best practices guidelines can be established in the future. This framework proposes four areas of QA: (i) protocol QA, (ii) machine QA, (iii) user QA, and (iv) software QA. Protocol QA should include a checklist to ensure that a standardized CT perfusion protocol is followed. Machine QA involves the use of a physical phantom to check image quality and the variability in time concentration curves obtained from different scanning conditions (13). At present, flow phantoms are available to check the variability in time concentration curves (13,14). User education is needed to ensure proper analysis of CT perfusion datasets and minimize interobserver variability. Digital phantoms like the one developed in this thesis and other studies (15-17) can be used to assess the variability in CT perfusion parameter measurements computed from different software. It can also be used to assess the quality of image filtering. A physiological flow phantom that mimics tissue hemodynamics (flow, volume, and permeability) can potentially replace the physical phantom and digital phantom by evaluating measurements of CT perfusion parameters. However, research is needed to develop a physiological flow phantom that mimics tissue hemodynamics. Such a phantom can be used for accreditation of CT perfusion imaging across sites (13). By establishing this QA framework, we hypothesize that tolerance limits and best practices guidelines can be established.
7.3.2 Delineating a Biologic Target Volume (BTV) in Radiotherapy

Our results point to a mismatch between regions of contrast enhancement and regions of high BF, BV, and PS in some patients with malignant gliomas. The potential application of using BF, BV, and PS maps for radiotherapy treatment planning warrants further investigations. Two important research questions need to be answered:

a. Will maps of BF, BV, and PS affect radiation oncologists’ decision in defining a target volume for radiotherapy?

b. Will targeting a biological target volume based on these CT perfusion maps improve treatment outcomes when compared to conventional targeting of the gross tumour volume?
The above questions can potentially change clinical practice and the care of patients with malignant gliomas.

7.3.3 CT Perfusion Imaging to Monitor Response to Combined Anti-angiogenic Therapy, Radiotherapy, and Chemotherapy

Bevacizumab is an anti-angiogenic agent that is under active investigation for the treatment of newly diagnosed glioblastomas. Results from a randomized placebo-controlled trial showed that Bevacizumab did not prolong overall survival compared to conventional treatments (18). Bevacizumab treatments in this trial started during week four of radiotherapy. However, preclinical evidence showed that judicious timing of anti-angiogenic agent before radiotherapy could exert a synergistic effect on tumour control suggesting further optimization of radiotherapy and bevacizumab combinations may be possible (19). Further work could examine the combined effects of radiotherapy and Bevacizumab on tumour perfusion in pre-clinical models of glioma to further optimize the use of this agent. In doing so, the C6 glioma model may not be the optimal tumour model for this investigation because the efficacy of binding of Bevacizumab to rodent vascular endothelial growth factor (VEGF) is controversial (20-22). A xenograft model such as the human glioblastoma cell line U87MG model is a more appropriate tumour model to use in this investigation (23).

The ultimate goal remains to use functional imaging to tailor the appropriate treatments of cancer patients. It is hoped that the publications from this PhD dissertation will raise community awareness to the potential benefits of CT perfusion imaging – offering a readily accessible functional imaging modality that might personalize cancer treatments for patients affected by this disease.
7.3.4 References


Appendix

Appendix A: Animal Ethics Approval for the Work Contained Within Chapter 4

January 20, 2010

*This is the Original Approval for this protocol*
*A Full Protocol submission will be required in 2014*

Dear Dr. Lee,

Your Animal Use Protocol form entitled:
Monitoring the radiation therapy treatment effect on the growth of C6 glioma brain tumors using clinical CT high resolution imaging
Funding Agency: Internal

has been approved by the University Council on Animal Care. This approval is valid from January 20, 2010 to January 31, 2011. The protocol number for this project is #2010-009 which replaces #2004-063.

1. This number must be indicated when ordering animals for this project.
2. Animals for other projects may not be ordered under this number.
3. If no number appears please contact this office when grant approval is received.
   If the application for funding is not successful and you wish to proceed with the project, request that an internal scientific peer review be performed by the Animal Use Subcommittee office.
4. Purchases of animals other than through this system must be cleared through the ACVS office. Health certificates will be required.

ANIMALS APPROVED FOR 4 Years

<table>
<thead>
<tr>
<th>Species</th>
<th>4 Year Total Numbers Estimated as Required</th>
<th>List All Strain(s)</th>
<th>Age / Weight</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rat</td>
<td>88</td>
<td>Wistar</td>
<td>200 - 250g</td>
</tr>
</tbody>
</table>

REQUIREMENTS/COMMENTS
Please ensure that individual(s) performing procedures on live animals, as described in this protocol, are familiar with the contents of this document.

The holder of this Animal Use Protocol is responsible to ensure that all associated safety components (biosafety, radiation safety, general laboratory safety) comply with Institutional safety standards and have received all necessary approvals. Please consult directly with your institutional safety officers.

Approval Letter - T. Lee, J. Hadway, W. Lagenwerf
Appendix B: Human Ethics Approval for the Work Contained within Chapter 5

Use of Human Participants - Ethics Approval Notice

Principal Investigator: Dr. Glenn Bauman
File Number: 4117
Review Level: Full Board
Protocol Title: Development of Radiation Treatment Planning Using Biologic and Anatomic Imaging for Malignant Glioma
Department & Institution: Schulich School of Medicine and Dentistry/Oncology, London Regional Cancer Program
Sponsor: Brain Tumour Foundation of Canada

Ethics Approval Date: December 03, 2013
Ethics Expiry Date: December 31, 2017

Documents Reviewed & Approved & Documents Received for Information:

<table>
<thead>
<tr>
<th>Document Name</th>
<th>Comments</th>
<th>Version Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Updated Approval</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

This is to notify you that the University of Western Ontario Health Sciences Research Ethics Board (HSREB) which is organized and operates according to the Tri-Council Policy Statement: Ethical Conduct of Research Involving Humans and the Health Canada/ICH Good Clinical Practice Practices: Consolidated Guidelines; and the applicable laws and regulations of Ontario has reviewed and granted approval to the above referenced study on the approval date noted above. The membership of this HSREB also complies with the membership requirements for REB’s as defined in Division 5 of the Food and Drug Regulations.

The ethics approval for this study shall remain valid until the expiry date noted above assuming timely and acceptable responses to the HSREB’s periodic requests for surveillance and monitoring information. If you require an updated approval notice prior to that time you must request it using the University of Western Ontario Updated Approval Request form.

Member of the HSREB that are named as investigators in research studies, or declare a conflict of interest, do not participate in discussions related to, nor vote on, such studies when they are presented to the HSREB.

The Chair of the HSREB is Dr. Joseph Gilbert. The HSREB is registered with the U.S. Department of Health & Human Services under the IRB registration number IRB 0000940.
Appendix C: Human Ethics Approval for the Work Contained Within Chapter 6

"A primary brain tumours registry as a framework for promoting clinical research in Neuro-Oncology: Project of Emilia-Romagna region on Neuro-Oncology (PERNO). Valutazione delle capacità diagnostiche e prognostiche della tomografia computerizzata di perfusione."


Ditta/sponsor: Programma di ricerca Regione-Università 2007-2009 (Area 1® - Innovative Research)

Codice identificativo del piano clinico generale: Perno

Specialità medicinale (nome o sigla): / /

Principio/i attivo/i: / /

Codice CAS (ove disponibile): / /

Classe farmacologica di appartenenza: / /

Codice ATC proposto (secondo codifica OMS): / /

Codice ICD: / /

Fase della sperimentazione clinica: /
COMITATO ETICO DELLA PROVINCIA DI FERRARA

Indicazione proposta: si tratta di uno studio volto alla valutazione delle capacità diagnostiche della Tomografia Computerizzata (TC) e a verificare se la TC di Perfusione (TCP) può essere utile per distinguere i tumori primitivi cerebrali da altri tipi di lesione, per guidare la biopsia stereotassica e la resezione chirurgica, per distinguere fra la recidiva tumorale e il tessuto reso non più vitale dalla radioterapia, per predire la evoluzione del tumore, per monitorare la risposta alla terapia radiante e alla chemioterapia. La ricerca è anche orientata a chiarire se la TCP può essere di aiuto nella programmazione pre- e post operatoria, nel caso in cui corrieli con i dati clinici e, quando possibile, con i reperti Risonanza Magnetica Perfusionale (MR-PWI).

Forma farmaceutica: //
Via di somministrazione: //
Durata dello studio: 3 anni.

Schema dello studio e posologia: il disegno dello studio prevede due fasi:

1) la fase pre-operatoria riguarderà i pazienti con lesione espansiva sopratentoriale isolata, indicativa di tumore cerebrale intra-assiale: in questa prima fase saranno inclusi tutti pazienti con masse solitarie cerebrali sopratentoriali ammessi nel centro di Ferrara con indagini TC e/o MRI convenzionali che suggeriscano la diagnosi di sospetto tumore primitivo cerebrale. Tutti i pazienti inclusi in questa parte della ricerca verranno sottoposti ad uno studio TCP e ad un’indagine MR-PWI subito dopo l’ingresso. In tutti pazienti sottoposti a rimozione chirurgica del tumore verrà eseguito uno studio TC standard con un somministrazione endovenosa di mezzo di contrasto iodato entro 48 ore dall’operazione, per verificare la presenza di eventuali residui tumorali.

2) La fase post-operatoria interesserà i pazienti con glioma a basso ed alto grado a sede sovratentoriale, confermato istologicamente dopo resezione chirurgica o biopsia stereotassica. In tutti pazienti ammessi alla seconda parte dello studio, il deterioramento clinico o l’aumento della dimensione della lesione riscontrato con risonanza magnetica, saranno ritenuti indicatori di recidiva tumorale.

Tutti i pazienti saranno sottoposti a controlli TCP e/o MR-PWI sequenziali nel tempo, programmati:

a) ogni 3 mesi dall’intervento chirurgico per il primo anno;
b) ogni 6 mesi nel due anni successivi.
COMITATO ETICO DELLA PROVINCIA DI FERRARA

In tutti i pazienti con glioma ad alto grado sottoposti a radioterapia e/o chemioterapia post-operatoria verranno effettuati controlli con TCP e/o MR-PWI longitudinali nel tempo programmati: a) a 1 e a 3 mesi dal termine del trattamento; b) ogni 3-6 mesi successivamente.

In fase sia pre-operatoria che post-operatoria la performance verrà valutata in tutti i pazienti selezionati per lo studio utilizzando le scale di valutazione clinica correntemente accettate e, in particolare, il Karnofsky performance status.

Gli esami TC e MRI standard saranno valutati da due medici neuroradiologi che non saranno a conoscenza dei risultati della TCP e della MR-PWI, mentre le mappe di TCP e di MR-PWI saranno generate da medici che non saranno a conoscenza dei dati clinici e del quadro radiologico dei pazienti. Al termine dello studio tutti i risultati emersi dalle indagini TCP verranno confrontati e correlati con i dati provenienti dagli esami PWI e con quelli clinico-epidemiologici, molecolari e neurofisiologici acquisiti nelle altre unità. Le indagini TCP e MR-PWI saranno eseguite in accordo con protocolli precedentemente convalidati nella letteratura scientifica specifica.

In tutti i pazienti reclutati nei diversi stadi della ricerca gli studi di TCP saranno realizzati secondo il metodo di “first pass bolus-tracking”, che analizza l’effetto prodotto dal primo passaggio di un bolus di mezzo di contatto attraverso il letto vascolare cerebrale, utilizzando un apparecchio TC a scansione singola o multipla equipaggiato con un software dedicato per TCP. Per ogni paziente, in ciascuno degli intervalli temporali stabiliti in fase pre- e/o post-operatoria, verranno generate mappe perfusionali di flusso ematico cerebrale (CBF) di CBV, di tempo di transito medio (MTT) e di flusso di permeabilità di superficie (PSF) per misurare la permeabilità microvascolare.

Studi MR-PWI - in tutti i pazienti inclusi nelle varie fasi del progetto gli studi di MR-PWI verranno eseguiti secondo la metodologia del “Dynamic Susceptibility Contrast” (DSC), che misura ancora una volta l’effetto determinato dal primo passaggio di un bolus di mezzo di contrasto attraverso il letto vascolare cerebrale, impiegando una unità di risonanza magnetica da 1.5 Tesla equipaggiata con un software dedicato per la PWI. Per ogni paziente, in ciascuno degli intervalli temporali stabiliti in fase pre- e/o post-operatoria, verranno generate mappe perfusionali di CBV. Se possibile, negli stessi pazienti e nelle medesime fasi dello studio, verranno anche create mappe di “volume transfer constant” (Ktrans), utili per la valutazione della permeabilità microvascolare, usando il metodo del “Dynamic Contrast-Enhanced (DCE)”

In ogni sezione in cui il tessuto tumorale senza o con accentuazione contrastografica sarà visibile, i parametri TCP e MR-PWI saranno misurati in due differenti regioni di interesse disegnate a mano libera sulla singola sezione della TC o MRI di base: 1) il tessuto tumorale con o senza accentuazione contrastografica; 2) un’area di tessuto nervoso apparentemente sano situata nell’emisfero controlaterale, disposta simetricamente alla neoplasia e corrispondente alla zona lesionale.

Eventuale terapia concomitante: //
AIC in Italia: //
all’estero: //
Indicazioni all’AIC, posologia, vie di somministrazione e forme farmaceutiche autorizzate: //
COMITATO ETICO DELLA PROVINCIA DI FERRARA

Precedenti approvazioni/autorizzazioni alla sperimentazione per la stessa indicazione proposta: /
/

Obiettivo/i dello degli studio/i:
Primari:
- verificare se l'approccio multiparametrico con TCP può servire per:
  1. distinguere i tumori primitivi cerebrali da altri tipi di lesione che simulano il tumore, quali le infezioni, le lesioni demielizzanti tumescenti e le lesioni ischemiche;
  2. discriminare i gliomi da altre lesioni neoplastiche solitarie intra-assiali cerebrali come i linfomi e le metastasi;
  3. differenziare i gliomi ad alto grado da quelli a basso grado;
  4. guidare la biopsia stereotassica e la resezione chirurgica verso la porzione più aggressiva del tumore;
  5. diversificare fra la recidiva tumorale e la necrosi da radiazioni;
  6. predire l'evoluzione del tumore;
  7. monitorare la risposta alla terapia radiante e alla chemioterapia.

Secondari:
1. chiarire se la tecnologia TCP può essere di aiuto nella programmazione pre-chirurgica e nella pianificazione post-operatoria;
2. comprendere se esistano correlazioni fra i dati TCP e quelli clinici, molecolari e MR-PWI.

Tipologia dei soggetti da arruolare (specificare se pazienti o volontari sani): saranno arruolati pazienti di entrambi i sessi, maggiorenni. Nella prima fase pre-operatoria dello studio saranno inclusi tutti i pazienti con masse solitarie cerebrali sopratenziali ammesse nel nostro centro con indagini TC e/o la MRI convenzionali che suggeriscono la diagnosi di sospetto tumore primitivo cerebrale. Nella seconda fase post-operatoria dello studio verranno inclusi tutti i pazienti con glioma a basso ed alto grado confermato istologicamente dopo resezione chirurgica o biopsia stereotassica.

Numero dei soggetti da arruolare: lo studio prevede l'inclusione di almeno 100 pazienti nella prima fase pre-operatoria e di almeno 50 pazienti con gliomi ad alto grado di malignità e di almeno 30 pazienti con gliomi ad alto grado di aggressività sovraposto a radioterapia in quella post-operatoria.
COMITATO ETICO DELLA PROVINCIA DI FERRARA

Informazione al candidato: mediante scheda informativa, nella quale si riportano notizie sulla natura, durata e scopo dello studio, nonché il rapporto rischio/beneficio.

L’informazione del paziente, in virtù della propedeuticità di tale fase, dovrà essere fornita in un momento formalmente distinto dal recepimento del consenso. Si raccomanda che l’avvenuta informazione venga formalizzata su cartella clinica o su scheda personale del paziente (in alternativa su modulo che ne faccia parte integrante), riportando contestualmente data e firma del medico sperimentatore e dell’arruolando stesso.

Recepimento del consenso: mediante apposito modulo. Si raccomanda che il recepimento del consenso/dissenso avvenga in un momento formalmente distinto dalla fase informativa e ad essa successivo e venga formalizzato su cartella clinica o su scheda personale del paziente (oppure su modulo che ne faccia parte integrante).

Criteri di inclusione/esclusione:

criteri di inclusione:
Fase pre-operatoria: in questa prima fase verranno arruolati nello studio tutti i pazienti che soddisferanno i seguenti criteri di inclusione:
- età maggiore o uguale a 18 anni;
- assenza di instabilità dei parametri clinici (agitazione, disorientamento, coma ed altri segni di grave ipertensione endocranica);
- assenza di segni riferibili a gravidanza in atto;
- assenza di controindicazioni alla TC ed alla MRI comprese quelle riguardanti la somministrazione intravenosa di contrasto iodato o di Gadolinio chelato;
- disponibilità dei dati clinici, compresa una valutazione della severità della malattia mediante il Karnofsky performance status.
Fase post-operatoria: in questa seconda fase verranno inclusi:
- tutti i pazienti con glioma a basso ed alto grado confermato istologicamente dopo resezione chirurgica o biopsia stereotassica.

criteri di esclusione:
Fase pre-operatoria: in questa prima fase verranno esclusi dallo studio tutti i pazienti con le seguenti caratteristiche:
- età minore di 18 anni;
- presenza di instabilità dei parametri clinici (agitazione, disorientamento, coma ed altri segni di grave ipertensione endocranica);
- presenza di segni riferibili a gravidanza in atto;
- presenza di controindicazioni alla TC ed alla MRI comprese quelle riguardanti la somministrazione intravenosa di contrasto iodato o di Gadolinio chelato;
- mancata disponibilità dei dati clinici, compresa una valutazione della severità della malattia mediante il Karnofsky performance status.
COMITATO ETICO DELLA PROVINCIA DI FERRARA

Fase post-operatoria: in questa seconda fase verranno inclusi:
- tutti i pazienti con glioma a basso ed alto grado confermato istologicamente dopo resezione chirurgica o biopsia stereotassica.

Sorveglianza clinica: / /

Modalità di sospensione:
è prevista l’interruzione dello studio qualora si verifichino eventi avversi, su decisione del medico sperimentatore e, comunque, per libera scelta e disposizione dell’arruolato.

Il Comitato Etico esprime parere favorevole allo studio proposto, ove siano soddisfatti i prerequisiti etici nei termini innanzi richiesti.
Si ricorda al proponente responsabile la necessità di comunicare alla Segreteria Tecnico-Scientifica del Comitato Etico la fine dello studio, nonché di trasmettere copia di eventuale/i pubblicazione/i ovvero del report finale.

Si dà atto che il Comitato Etico ha preso visione della seguente documentazione:
- n. 1 copia di lettera d’intenti;
- n. 1 copia di protocollo di studio;
- n. 1 copia di sinossi del protocollo di studio;
- n. 1 copia di foglio informativo per il paziente;
- n. 1 copia di modulo di consenso;
- n. 1 copia di lettera per il medico d base;
- n. 1 copia di approvazione definitiva del progetto di ricerca da parte dell’Agenzia Sanitaria Regionale;
- n. 1 copia di elenco dei centri partecipanti.

Il Presidente del Comitato Etico
(Prof. Adalberto Ciaccia)
Appendix D: Permission to Reproduce Previously Published Materials

June 23, 2014

Timothy Yeung

Dear Timothy Yeung:

This is to grant you permission to reproduce the following figure in your thesis entitled “Functional Imaging of Malignant Gliomas with CT Perfusion” for the University of Western Ontario:

Figure 1 from Brian T. Hawkins and Thomas P. Davis, The Blood-Brain Barrier/Neurovascular Unit in Health and Disease, Pharmacol Rev June 2003 57:173-185

Permission to reproduce the figure is granted for worldwide use in all languages, translations, and editions, and in any format or medium including print and electronic. The authors and the source of the materials must be cited in full, including the article title, journal title, volume, year, and page numbers.

Sincerely yours,

Richard Dodenhoff
Journal Director
This is a License Agreement between Timothy Pok Chi Yeung ("You") and American Society of Clinical Oncology ("American Society of Clinical Oncology") provided by Copyright Clearance Center ("CCC"). The license consists of your order details, the terms and conditions provided by American Society of Clinical Oncology, and the payment terms and conditions.

All payments must be made in full to CCC. For payment instructions, please see information listed at the bottom of this form.

<table>
<thead>
<tr>
<th>License Number</th>
<th>3413910641083</th>
</tr>
</thead>
<tbody>
<tr>
<td>License date</td>
<td>Jun 21, 2014</td>
</tr>
<tr>
<td>Licensed content publisher</td>
<td>American Society of Clinical Oncology</td>
</tr>
<tr>
<td>Licensed content publication</td>
<td>The Journal of Clinical Oncology</td>
</tr>
<tr>
<td>Licensed content title</td>
<td>Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group</td>
</tr>
<tr>
<td>Licensed content date</td>
<td>Apr 10, 2010</td>
</tr>
<tr>
<td>Type of Use</td>
<td>Dissertation/Thesis</td>
</tr>
<tr>
<td>Geographic Rights</td>
<td>North American</td>
</tr>
<tr>
<td>Will you be translating?</td>
<td>No</td>
</tr>
<tr>
<td>Title of your thesis / dissertation</td>
<td>Functional Imaging of Malignant Gliomas with CT Perfusion</td>
</tr>
<tr>
<td>Expected completion date</td>
<td>Aug 2014</td>
</tr>
<tr>
<td>Estimated size (pages)</td>
<td>300</td>
</tr>
<tr>
<td>Billing Type</td>
<td>Invoice</td>
</tr>
</tbody>
</table>

Total: 0.00 USD

Terms and Conditions

Permission is granted upon the requester's compliance with the following terms and conditions.

https://10.100.10.10/copyright.com/AccessDispatch/Login
conditions:

1. A credit line will be prominently placed in your product(s) and include: for books-the author, book title, editor, copyright holder, year of publication; for journals-the author, title of article, title of journal, volume number, issue number, and the inclusive pages. The credit line must include the following wording: "Reprinted with permission. © (Year of publication being used) American Society of Clinical Oncology. All rights reserved." The citation format must be as follows: Author last name, first initial et al: J Clin Oncol (or substitute appropriate title) Vol. (Issue), Year: Page-Page.

2. The requester warrants that the material shall not be used in any manner that may be derogatory to the title, content, or authors of the material or to ASCO, including but not limited to an association with/unrelated to ASCO, including but not limited to an association with conducts that are fraudulent or otherwise illegal, or (a) the use of or abuse of alcohol, cigarette, or illegal drugs.

3. Permission is granted for the term (or Books/CDs-Shelf Life, for Internet/Intranet-In perpetuity, for all other forms of print).life of the title and use of it and purpose specified in your request. Once permission has expired, permission to renew must be made in writing.

4. Permission granted is nonexclusive, and is valid throughout the world in English and the languages specified in your original request. A new permission must be requested for revisions of the publication under current consideration.

5. ASCO cannot supply the requester with the original artwork or a "clean copy."

6. If the ASCO material is to be translated, the following lines must be included: The authors, editors, and ASCO are not responsible for errors or omissions in translations.

If you would like to pay for this license now, please remit this license along with your payment made payable to "COPYRIGHT CLEARANCE CENTER" otherwise you will be invoiced within 48 hours of the license date. Payment should be in the form of a check or money order referencing your account number and this invoice number. 5013334662. Once you receive your invoice for this order, you may pay your invoice by credit card. Please follow instructions provided at that time.

Make Payment To:

Gratis licenses (referencing $0 in the Total field) are free. Please retain this printable license for your reference. No payment is required.
This is a License Agreement between Timothy Pok Chi Yeung ("You") and Elsevier ("Elsevier") provided by Copyright Clearance Center ("CCC"). The license consists of your order details, the terms and conditions provided by Elsevier, and the payment terms and conditions.

All payments must be made in full to CCC. For payment instructions, please see information listed at the bottom of this form.

<table>
<thead>
<tr>
<th>Supplier</th>
<th>Elsevier Limited</th>
</tr>
</thead>
<tbody>
<tr>
<td>Registered Company Number</td>
<td>1982084</td>
</tr>
<tr>
<td>Customer name</td>
<td>Timothy Pok Chi Yeung</td>
</tr>
<tr>
<td>Customer address</td>
<td></td>
</tr>
<tr>
<td>License number</td>
<td>3413910957754</td>
</tr>
<tr>
<td>License date</td>
<td>Jun 21, 2014</td>
</tr>
<tr>
<td>Licensed content publisher</td>
<td>Elsevier</td>
</tr>
<tr>
<td>Licensed content publication</td>
<td>Academic Radiology</td>
</tr>
<tr>
<td>Licensed content title</td>
<td>The Effect of Scan Duration on the Measurement of Perfusion Parameters in CT Perfusion Studies of Brain Tumors</td>
</tr>
<tr>
<td>Licensed content author</td>
<td>Timothy Pok Chi Yeung, Slav Yartsev, Glenn Bauman, Wenqing He, Enrico Fainardi, Ting-Yim Lee</td>
</tr>
<tr>
<td>Licensed content date</td>
<td>January 2013</td>
</tr>
<tr>
<td>Licensed content volume number</td>
<td>20</td>
</tr>
<tr>
<td>Licensed content issue number</td>
<td>1</td>
</tr>
<tr>
<td>Number of pages</td>
<td>7</td>
</tr>
<tr>
<td>Start Page</td>
<td>59</td>
</tr>
<tr>
<td>End Page</td>
<td>65</td>
</tr>
<tr>
<td>Type of Use</td>
<td>reuse in a thesis/dissertation</td>
</tr>
<tr>
<td>Intended publisher of new work</td>
<td>other</td>
</tr>
<tr>
<td>Portion</td>
<td>full article</td>
</tr>
<tr>
<td>Format</td>
<td>both print and electronic</td>
</tr>
<tr>
<td>Are you the author of this</td>
<td>Yes</td>
</tr>
</tbody>
</table>

https://s100.license.com/AppDispatchServlet
INTRODUCTION

1. The publisher for this copyrighted material is Elsevier. By clicking "accept" in connection with completing this licensing transaction, you agree that the following terms and conditions apply to this transaction (along with the Billing and Payment terms and conditions established by Copyright Clearance Center, Inc. ("CCC"), at the time that you opened your Rightslink account and that are available at any time at http://myaccount.copyright.com).

GENERAL TERMS

2. Elsevier hereby grants you permission to reproduce the aforementioned material subject to the terms and conditions indicated.

3. Acknowledgement: If any part of the material to be used (for example, figures) has appeared in our publication with credit or acknowledgement to another source, permission must also be sought from that source. If such permission is not obtained then that material may not be included in your publication/copies. Suitable acknowledgement to the source must be made, either as a footnote or in a reference list at the end of your publication, as follows:

"Reprinted from Publication title, Vol./edition number, Author(s), Title of article / title of chapter, Pages No., Copyright (Year), with permission from Elsevier [OR APPLICABLE SOCIETY COPYRIGHT OWNER]." Also Lancet special credit - "Reprinted from The Lancet, Vol. number, Author(s), Title of article, Pages No., Copyright (Year), with permission from Elsevier."

4. Reproduction of this material is confined to the purpose and/or media for which permission is hereby given.

5. Altering/Modifying Material Not Permitted. However figures and illustrations may be altered/adapted minimally to serve your work. Any other abbreviations, additions, deletions and/or any other alterations shall be made only with prior written authorization of Elsevier Ltd.

6. If the permission fee for the requested use of our material is waived in this instance, please be advised that your future requests for Elsevier materials may attract a fee.
7. Reservation of Rights: Publisher reserves all rights not specifically granted in the combination of (i) the license details provided by you and accepted in the course of this licensing transaction, (ii) these terms and conditions and (iii) CCC’s Billing and Payment terms and conditions.

8. License Contingent Upon Payment: While you may exercise the rights licensed immediately upon issuance of the license at the end of the licensing process for the transaction, provided that you have disclosed complete and accurate details of your proposed use, no license is finally effective unless and until full payment is received from you (either by publisher or by CCC) as provided in CCC’s Billing and Payment terms and conditions. If full payment is not received on a timely basis, then any license preliminarily granted shall be deemed automatically revoked and shall be void as if never granted. Further, in the event that you breach any of these terms and conditions or any of CCC’s Billing and Payment terms and conditions, the license is automatically revoked and shall be void as if never granted. Use of materials as described in a revoked license, as well as any use of the materials beyond the scope of an unrevoked license, may constitute copyright infringement and publisher reserves the right to take any and all action to protect its copyright in the materials.

9. Warranties: Publisher makes no representations or warranties with respect to the licensed material.

10. Indemnity: You hereby indemnify and agree to hold harmless publisher and CCC, and their respective officers, directors, employees and agents, from and against any and all claims arising out of your use of the licensed material other than as specifically authorized pursuant to this license.

11. No Transfer of License: This license is personal to you and may not be sublicensed, assigned, or transferred by you to any other person without publisher’s written permission.

12. No Amendment Except in Writing: This license may not be amended except in a writing signed by both parties (or, in the case of publisher, by CCC on publisher’s behalf).

13. Objection to Contrary Terms: Publisher hereby objects to any terms contained in any purchase order, acknowledgment, check endorsement or other writing prepared by you, which terms are inconsistent with these terms and conditions or CCC’s Billing and Payment terms and conditions. These terms and conditions, together with CCC’s Billing and Payment terms and conditions (which are incorporated herein), comprise the entire agreement between you and publisher (and CCC) concerning this licensing transaction. In the event of any conflict between your obligations established by these terms and conditions and those established by CCC’s Billing and Payment terms and conditions, these terms and conditions shall control.

14. Revocation: Elsevier or Copyright Clearance Center may deny the permissions described in this License at their sole discretion, for any reason or no reason, with a full refund payable to you. Notice of such denial will be made using the contact information provided by you. Failure to receive such notice will not alter or invalidate the denial. In no event will Elsevier or Copyright Clearance Center be responsible or liable for any costs, expenses or damage incurred by you as a result of a denial of your permission request, other than a refund of the amount(s) paid by you to Elsevier and/or Copyright Clearance Center for denied permissions.

LIMITED LICENSE
The following terms and conditions apply only to specific license types:

15. Translation. This permission is granted for non-exclusive world English rights only unless your license was granted for translation rights. If you licensed translation rights you may only translate this content into the languages you requested. A professional translator must perform all translations and reproduce the content word for word preserving the integrity of the article. If this license is to re-use 1 or 2 figures then permission is granted for non-exclusive world rights in all languages.

16. Posting licensed content on any Website. The following terms and conditions apply as follows. Licensing material from an Elsevier journal. All content posted to the website must maintain the copyright information line on the bottom of each image. A hyper-text must be included to the Home page of the journal from which you are licensing at http://www.sciencedirect.com/science/journal/xxxxxx or the Elsevier homepage for books at http://www.elsevier.com. Central Storage. This license does not include permission for a scanned version of the material to be stored in a central repository such as that provided by HeronXanEdu.

Licensing material from an Elsevier book. A hyper-text link must be included to the Elsevier homepage at http://www.elsevier.com. All content posted to the website must maintain the copyright information line on the bottom of each image.

Posting licensed content on Electronic reserve: In addition to the above the following clauses are applicable: The website must be password-protected and made available only to bona fide students registered on a relevant course. This permission is granted for 1 year only. You may obtain a new license for future web posting.

For journal authors: the following clauses are applicable in addition to the above. Permission granted is limited to the author accepted manuscript version* of your paper.

*Accepted Author Manuscript (AAM) Definition: An accepted author manuscript (AAM) is the author’s version of the manuscript of an article that has been accepted for publication and which may include any author-incorporated changes suggested through the processes of submission, processing, peer review, and editor-author communications. AAMs do not include other publisher value-added contributions such as copy-editing, formatting, technical enhancements and (if relevant) pagination.

You are not allowed to download and post the published journal article (whether PDF or HTML proof or final version), nor may you scan the printed edition to create an electronic version. A hyper-text must be included to the Home page of the journal from which you are licensing at http://www.sciencedirect.com/science/journal/xxxxxx. As part of our normal production process, you will receive an e-mail notice when your article appears on Elsevier’s online service ScienceDirect (www.sciencedirect.com). That e-mail will include the article’s Digital Object Identifier (DOI). This number provides the electronic link to the published article and should be included in the posting of your personal version. We ask that you wait until you receive this e-mail and have the DOI to do any posting.

Posting to a repository: Authors may post their AAM immediately to their employer’s
institutional repository for internal use only and may make their manuscript publicly available after the journal-specific embargo period has ended.

Please also refer to Elsevier’s Article Posting Policy for further information.

18. For book authors the following clauses are applicable in addition to the above: Authors are permitted to place a brief summary of their work online only. You are not allowed to download and post the published electronic version of your chapter, nor may you scan the printed edition to create an electronic version. Posting to a repository: Authors are permitted to post a summary of their chapter only in their institution’s repository.

20. Thesis/Dissertation: If your license is for use in a thesis/dissertation your thesis may be submitted to your institution in either print or electronic form. Should your thesis be published commercially, please reapply for permission. These requirements include permission for the Library and Archives of Canada to supply single copies, on demand, of the complete thesis and include permission for UMI to supply single copies, on demand, of the complete thesis. Should your thesis be published commercially, please reapply for permission.

Elsevier Open Access Terms and Conditions

Elsevier publishes Open Access articles in both its Open Access journals and via its Open Access articles option in subscription journals.

Authors publishing in an Open Access journal or who choose to make their article Open Access in an Elsevier subscription journal select one of the following Creative Commons user licenses, which define how a reader may reuse their work: Creative Commons Attribution License (CC BY), Creative Commons Attribution – Non Commercial – ShareAlike (CC BY NC SA) and Creative Commons Attribution – Non Commercial – No Derivatives (CC BY NC ND)

Terms & Conditions applicable to all Elsevier Open Access articles:

Any reuse of the article must not represent the author as endorsing the adaptation of the article nor should the article be modified in such a way as to damage the author’s honour or reputation.

The author(s) must be appropriately credited.

If any part of the material to be used (for example, figures) has appeared in our publication with credit or acknowledgement to another source it is the responsibility of the user to ensure their reuse complies with the terms and conditions determined by the rights holder.

Additional Terms & Conditions applicable to each Creative Commons user license:

CC BY: You may distribute and copy the article, create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, including for commercial purposes without permission from Elsevier
CC BY NC SA: For non-commercial purposes you may distribute and copy the article, create extracts, abstracts and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text and data mine the article and license new adaptations or creations under identical terms without permission from Elsevier.

CC BY NC ND: For non-commercial purposes you may distribute and copy the article and include it in a collective work (such as an anthology), provided you do not alter or modify the article, without permission from Elsevier.

Any commercial reuse of Open Access articles published with a CC BY NC SA or CC BY NC ND license requires permission from Elsevier and will be subject to a fee.

Commercial reuse includes:

- Promotional purposes (advertising or marketing)
- Commercial exploitation (e.g., a product for sale or loan)
- Systematic distribution (for a fee or free of charge)

Please refer to Elsevier's Open Access Policy for further information.

21. Other Conditions:

v1.7

If you would like to pay for this license now, please remit this license along with your payment made payable to "COPYRIGHT CLEARANCE CENTER" otherwise you will be invoiced within 48 hours of the license date. Payment should be in the form of a check or money order referencing your account number and this invoice number 501333664. Once you receive your invoice for this order, you may pay your invoice by credit card. Please follow instructions provided at that time.

Make Payment To:

Gratis licenses (referencing $0 in the Total field) are free. Please retain this printable license for your reference. No payment is required.

https://s100.copyright.com/AppDispatchServlet
This is a License Agreement between Timothy Pok Chi Yeung ("You") and Elsevier ("Elsevier") provided by Copyright Clearance Center ("CCC"). The license consists of your order details, the terms and conditions provided by Elsevier, and the payment terms and conditions.

All payments must be made in full to CCC. For payment instructions, please see information listed at the bottom of this form.

<table>
<thead>
<tr>
<th>Supplier</th>
<th>Elsevier Limited</th>
</tr>
</thead>
<tbody>
<tr>
<td>Registered Company Number</td>
<td>1982084</td>
</tr>
<tr>
<td>Customer name</td>
<td>Timothy Pok Chi Yeung</td>
</tr>
<tr>
<td>Customer address</td>
<td></td>
</tr>
</tbody>
</table>

| License number     | 3413910870699   |
| License date       | Jun 21, 2014    |
| Licensed content publisher | Elsevier       |
| Licensed content publication | Academic Radiology |
| Licensed content title | Improving Quantitative CT Perfusion Parameter Measurements Using Principal Component Analysis |
| Licensed content author | Timothy Pok Chi Yeung, Mark Dekaban, Nathan De Haan, Laura Morrison, Lisa Hoffman, Yves Bureau, Xiaogang Chen, Slav Yartsev, Glenn Baumh, Tino-Yim Lee |
| Licensed content date | May 2014 |
| Licensed content volume number | 21        |
| Licensed content issue number | 5         |
| Number of pages    | 9               |
| Start Page         | 624             |
| End Page           | 632             |
| Type of Use        | reuse in a thesis/dissertation |
| Intended publisher of new work | other |
| Portion            | full article    |
| Format             | both print and electronic |

https://ccc.copyright.com/AppDispatchServlet
INTRODUCTION

1. The publisher for this copyrighted material is Elsevier. By clicking "accept" in connection with completing this licensing transaction, you agree that the following terms and conditions apply to this transaction (along with the Billing and Payment terms and conditions established by Copyright Clearance Center, Inc. ("CCC"), at the time that you opened your Rightslink account and that are available at any time at http://myaccount.copyright.com).

GENERAL TERMS

2. Elsevier hereby grants you permission to reproduce the aforementioned material subject to the terms and conditions indicated.

3. Acknowledgement: If any part of the material to be used (for example, figures) has appeared in our publication with credit or acknowledgement to another source, permission must also be sought from that source. If such permission is not obtained then that material may not be included in your publication/copies. Suitable acknowledgement to the source must be made, either as a footnote or in a reference list at the end of your publication, as follows:

"Reprinted from Publication title, Vol./edition number, Author(s). Title of article / title of chapter, Pages No., Copyright (Year), with permission from Elsevier [OR APPLICABLE SOCIETY COPYRIGHT OWNER]." Also Lancet special credit - "Reprinted from The Lancet, Vol number, Author(s). Title of article, Pages No., Copyright (Year), with permission from Elsevier."

4. Reproduction of this material is confined to the purpose and/or media for which permission is hereby given.

5. Altering/Modifying Material: Not Permitted. However figures and illustrations may be altered/adapted minimally to serve your work. Any other abbreviations, additions, deletions and/or any other alterations shall be made only with prior written authorization of Elsevier Ltd.

6. If the permission fee for the requested use of our material is waived in this instance, please be
advised that your future requests for Elsevier materials may attract a fee.

7. Reservation of Rights: Publisher reserves all rights not specifically granted in the combination of (i) the license details provided by you and accepted in the course of this licensing transaction. (ii) these terms and conditions, and (iii) CCC’s Billing and Payment terms and conditions.

8. License Contingent Upon Payment: While you may exercise the rights licensed immediately upon issuance of the license at the end of the licensing process for the transaction, provided that you have disclosed complete and accurate details of your proposed use, no license is finally effective unless and until full payment is received from you (either by publisher or by CCC) as provided in CCC’s Billing and Payment terms and conditions. If full payment is not received on a timely basis, then any license preliminarily granted shall be deemed automatically revoked and shall be void as if never granted. Further, in the event that you breach any of these terms and conditions or any of CCC’s Billing and Payment terms and conditions, the license is automatically revoked and shall be void as if never granted. Use of materials as described in a revoked license, as well as any use of the materials extending beyond the scope of an unrevoked license, may constitute copyright infringement and publisher reserves the right to take any and all action to protect its copyright in the materials.

9. Warranties: Publisher makes no representations or warranties with respect to the licensed material.

10. Indemnity: You hereby indemnify and agree to hold harmless publisher and CCC, and their respective officers, directors, employees and agents, from and against any and all claims arising out of your use of the licensed material other than as specifically authorized pursuant to this license.

11. No Transfer of License: This license is personal to you and may not be sublicensed, assigned, or transferred by you to any other person without publisher’s written permission.

12. No Amendment Except in Writing: This license may not be amended except in a writing signed by both parties (or, in the case of publisher, by CCC on publisher’s behalf).

13. Objection to Contrary Terms: Publisher hereby objects to any terms contained in any purchase order, acknowledgment, check endorsement or other writing prepared by you, which terms are inconsistent with these terms and conditions or CCC’s Billing and Payment terms and conditions. These terms and conditions, together with CCC’s Billing and Payment terms and conditions (which are incorporated herein), comprise the entire agreement between you and publisher (and CCC) concerning this licensing transaction. In the event of any conflict between your obligations established by these terms and conditions and those established by CCC’s Billing and Payment terms and conditions, these terms and conditions shall control.

14. Revocation: Elsevier or Copyright Clearance Center may deny the permissions described in this License at their sole discretion, for any reason or no reason, with a full refund payable to you. Notice of such denial will be made using the contact information provided by you. Failure to receive such notice will not alter or invalidate the denial. In no event will Elsevier or Copyright Clearance Center be responsible or liable for any costs, expenses or damage incurred by you as a result of a denial of your permission request, other than a refund of the amount(s) paid by you to Elsevier and/or Copyright Clearance Center for denied permissions.
LIMITED LICENSE

The following terms and conditions apply only to specific license types:

15. Translation: This permission is granted for non-exclusive world English rights only unless your license was granted for translation rights. If you licensed translation rights you may only translate this content into the languages you requested. A professional translator must perform all translations and reproduce the content word for word preserving the integrity of the article. If this license is to re-use 1 or 2 figures then permission is granted for non-exclusive world rights in all languages.

16. Posting licensed content on any Website. The following terms and conditions apply as follows: Licensing material from an Elsevier journal: All content posted to the web site must maintain the copyright information line on the bottom of each image: A hyper-text must be included to the Homepage of the journal from which you are licensing at http://www.sciencedirect.com/science/journal/xxxxx or the Elsevier homepage for books at http://www.elsevier.com. Central Storage: This license does not include permission for a scanned version of the material to be stored in a central repository such as that provided by Heron/XanEdu.

Licensing material from an Elsevier book: A hyper-text link must be included to the Elsevier homepage at http://www.elsevier.com. All content posted to the web site must maintain the copyright information line on the bottom of each image.

Posting licensed content on Electronic reserve: In addition to the above the following clauses are applicable: The web site must be password-protected and made available only to bona fide students registered on a relevant course. This permission is granted for 1 year only. You may obtain a new license for future website posting.

For journal authors: the following clauses are applicable in addition to the above: Permission granted is limited to the author accepted manuscript version* of your paper.

*Accepted Author Manuscript (AAM) Definition: An accepted author manuscript (AAM) is the author’s version of the manuscript of an article that has been accepted for publication and which may include any author-incorporated changes suggested through the processes of submission processing, peer review, and editor-author communications. AAMs do not include other publisher value-added contributions such as copy-editing, formatting, technical enhancements and (if relevant) pagination.

You are not allowed to download and post the published journal article (whether PDF or HTML, proof or final version), nor may you scan the printed edition to create an electronic version. A hyper-text must be included to the Homepage of the journal from which you are licensing at http://www.sciencedirect.com/science/journal/xxxxx. As part of our normal production process, you will receive an e-mail notice when your article appears on Elsevier’s online service ScienceDirect (www.sciencedirect.com). That e-mail will include the article’s Digital Object Identifier (DOI). This number provides the electronic link to the published article and should be included in the posting of your personal version. We ask that you wait until you receive this e-mail and have the DOI to do any posting.
Posting to a repository: Authors may post their AAM immediately to their employer’s institutional repository for internal use only and may make their manuscript publically available after the journal-specific embargo period has ended.

Please also refer to Elsevier's Article Posting Policy for further information.

18. For book authors the following clauses are applicable in addition to the above: Authors are permitted to place a brief summary of their work online only. You are not allowed to download and post the published electronic version of your chapter, nor may you scan the printed edition to create an electronic version. Posting to a repository: Authors are permitted to post a summary of their chapter only in their institution’s repository.

20. Thesis/Dissertation: If your license is for use in a thesis/dissertation your thesis may be submitted to your institution in either print or electronic form. Should your thesis be published commercially, please reapply for permission. These requirements include permission for the Library and Archives of Canada to supply single copies, on demand, of the complete thesis and include permission for UMI to supply single copies, on demand, of the complete thesis. Should your thesis be published commercially, please reapply for permission.

Elsevier Open Access Terms and Conditions

Elsevier publishes Open Access articles in both its Open Access journals and via its Open Access articles option in subscription journals.

Authors publishing in an Open Access journal or who choose to make their article Open Access in an Elsevier subscription journal select one of the following Creative Commons user licenses, which define how a reader may reuse their work: Creative Commons Attribution License (CC BY), Creative Commons Attribution – Non Commercial - ShareAlike (CC BY NC SA) and Creative Commons Attribution – Non Commercial – No Derivatives (CC BY NC ND)

Terms & Conditions applicable to all Elsevier Open Access articles:

Any reuse of the article must not represent the author as endorsing the adaptation of the article nor should the article be modified in such a way as to damage the author’s honour or reputation.

The author(s) must be appropriately credited.

If any part of the material to be used (for example, figures) has appeared in our publication with credit or acknowledgement to another source it is the responsibility of the user to ensure their reuse complies with the terms and conditions determined by the rights holder.

Additional Terms & Conditions applicable to each Creative Commons user license:

CC BY: You may distribute and copy the article, create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, including for commercial
purposes without permission from Elsevier

CC BY NC SA: For non-commercial purposes you may distribute and copy the article, create extracts, abstracts and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text and data mine the article and license new adaptations or creations under identical terms without permission from Elsevier.

CC BY NC ND: For non-commercial purposes you may distribute and copy the article and include it in a collective work (such as an anthology), provided you do not alter or modify the article, without permission from Elsevier.

Any commercial reuse of Open Access articles published with a CC BY NC SA or CC BY NC ND license requires permission from Elsevier and will be subject to a fee.

Commercial reuse includes:

- Promotional purposes (advertising or marketing)
- Commercial exploitation (e.g. a product for sale or loan)
- Systematic distribution (for a fee or free of charge)

Please refer to Elsevier's Open Access Policy for further information.

21. Other Conditions:

v1.7

If you would like to pay for this license now, please remit this license along with your payment made payable to "COPYRIGHT CLEARANCE CENTER" otherwise you will be invoiced within 48 hours of the license date. Payment should be in the form of a check or money order referencing your account number and this invoice number 501333663.

Once you receive your invoice for this order, you may pay your invoice by credit card. Please follow instructions provided at that time.

Make Payment To:

Gratis licenses (referencing $0 in the Total field) are free. Please retain this printable license for your reference. No payment is required.
Title: Relationship of computed tomography perfusion and positron emission tomography to tumour progression in malignant glioma

Author: Timothy P. C. Yeung, Slav Yartsev, Ting-Yim Lee, Eugene Wong, Wenqing He, Barbara Fisher, Lauren L. VanderSpek, David Macdonald, Glenn Bauman

Publication: Journal of Medical Radiation Sciences

Publisher: John Wiley and Sons

Date: Jan 16, 2014

© 2014 The Authors. Journal of Medical Radiation Sciences published by Wiley Publishing Asia Pty Ltd on behalf of Australian Institute of Radiography and New Zealand Institute of Medical Radiation Technology.

Open Access Article

This article is available under the terms of the Creative Commons Attribution Non-Commercial License (CC BY-NC), which permits non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.

Permission is not required for non-commercial reuse. For commercial reuse, please hit the "back" button below and select the most appropriate commercial requestor type before completing your order.

Copyright © 2014 Copyright Clearance Center, Inc. All Rights Reserved. Privacy statement.

Comments? We would like to hear from you.
Appendix E: Membership of the PERNO Study Group

Steering Committee

Baruzzi A. (Chair), Albani F., Calbucci F., D'Alessandro R., Michelucci R. (IRCCS Institute of Neurological Sciences, Bologna, Italy), Brandes A. (Department of Medical Oncology, Bellaria-Maggiore Hospitals, Bologna, Italy), Eusebi V. (Department of Hematology and Oncological Sciences “L. & A. Seràgnoli”, Section of Anatomic Pathology at Bellaria Hospital, Bologna, Italy), Ceruti S., Fainardi E., Tamarozzi R. (Neuroradiology Unit, Department of Neurosciences and Rehabilitation, S. Anna Hospital, Ferrara, Italy), Emiliani E. (Istituto Oncologico Romagnolo, Department of Medical Oncology, Santa Maria delle Croci Hospital, Ravenna, Italy), Cavallo M. (Division of Neurosurgery, Department of Neurosciences and Rehabilitation, S. Anna Hospital, Ferrara, Italy).

Executive Committee

Franceschi E., Tosoni A. (Department of Medical Oncology, Bellaria-Maggiore Hospitals, Bologna, Italy), Cavallo M. (Division of Neurosurgery, Department of Neurosciences and Rehabilitation, S. Anna Hospital, Ferrara, Italy), Fiorica F. (Department of Radiation Oncology, S. Anna Hospital, Ferrara, Italy), Valentini A. (Division of Neurosurgery, Nuovo Ospedale Civile S. Agostino-Estense, Baggiovara, Modena, Italy), Depenni R. (Department of Oncology, Policlinico di Modena, Italy), Mucciariini C. (Department of Oncology, Ramazzini Hospital, Carpi, Modena, Italy), Crisi G. (Department of Neuroradiology, Maggiore Hospital, Parma, Modena, Italy), Biasini C., Cavanna L. (Department of Oncology and Hematology, Guglielmo da Saliceto Hospital, Piacenza, Italy), Guidetti D. (Department of Neurology, Guglielmo da Saliceto Hospital, Piacenza, Italy), Marcello N., Pisanello A. (Department of Neurology, Istituto in tecnologie avanzate e modelli assistenziali in oncologia, IRCCS, S. Maria Nuova
Registry Coordination Office: de Pasqua S., Testoni S. (IRCCS Institute of Neurological Sciences, Bologna, Italy).

Participants

Curriculum Vitae of Timothy Pok Chi Yeung

Name: Timothy Pok Chi Yeung

Post-secondary Education and Degrees:
The University of Western Ontario
London, Ontario, Canada
2009 - 2014 PhD

University of Toronto
Toronto, Ontario, Canada
2003 - 2008 BSc (Med. Rad. Sci)

The Michener Institute for Applied Health Sciences
Toronto, Ontario, Canada
2003-2008 Diploma of Health Sciences

Honours and Awards:
Canadian Cancer Society “Celebrating Impact in Community Outreach” Award
2014

The 11th Annual Oncology Research & Education Day Poster Award
2014

CIHR Doctoral Research Award
2011-2014

Third Prize, Poster Competition, 10th Imaging Network Ontario Symposium
2012

Ontario Graduate Scholarship (Declined)
2011

CIHR Institute of Cancer Research Travel Award Competition
2010

CIHR Master’s Award: Frederick Banting and Charles Best Canada Graduate Scholarship
2010-2011

Western Graduate Scholarship
2010-2014
CIHR Strategic Training Program in Cancer Research and Technology Transfer Program (CIHR-STP) 2009-2014

Schulich Graduate Scholarship 2009-2010

**Related Work Experience**

Research Assistant
Princess Margaret Hospital & Spatio-Temporal Targeting and Amplification of Radiation Response (STTARR) Program 2008-2009

Undergraduate Thesis Project
London Regional Cancer Program, London Health Sciences Centre 2007-2008

Radiation Therapy Student
London Regional Cancer Program, London Health Sciences Centre 2007-2008

Summer Student Research Assistant
The Michener Institute for Applied Health Sciences 2006

**Publications:**

**Published or Accepted Refereed Papers**


**Completed Manuscripts**


Book Chapter


Refereed Abstracts


Newspaper and Media